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ABSTRACT 
 
 Opioids are amongst the most effective and widely prescribed medications for 
the treatment of pain following spinal cord injury (SCI). Spinally-injured patients 
receive opioids shortly upon arrival at the emergency room, and prolonged opioid 
regimens are often employed for the management of post-SCI chronic pain. However, 
despite their utility, questions remain regarding the safety of these analgesics in the 
clinical setting.  Indeed, previous studies in our laboratory suggest that the effects of 
opioids, such as morphine, may be altered in the pathophysiological context of 
neurotrauma. Specifically, our studies suggest that morphine use is contraindicated in the 
early phase of SCI. In our rodent model of SCI, acute morphine treatment increases 
tissue loss at the injury site, increases mortality, undermines weight gain and reduces 
recovery of motor and sensory function even weeks after treatment. The literature also 
suggests that opioids may exacerbate secondary injury mechanisms following SCI, 
increasing neurotoxicity at the lesion site. Based on these data, it would be tempting to 
suggest that morphine be eliminated as an analgesic after SCI. However, as pain is one 
of the most debilitating consequences of SCI, we cannot afford to simply remove a 
potential analgesic therapy. To address this, the experiments presented here examined 
the molecular mechanisms underlying the adverse effects of morphine. The first set of 
experiments evaluated classic opioid receptor signaling and showed that the κ-opioid 
receptor (KOR) system significantly contributes to the morphine-induced attenuation of 
function following SCI. The second set of experiments showed that, while non-classic 
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opioid receptor signaling is not sufficient, glial activation is critical to morphine’s 
adverse effects. The last set of experiments investigated the effects of acute morphine 
treatment on the cellular environment of the lesion site. The findings suggest that opioid-
immune interactions following SCI – mediated by the KOR system – may exacerbate 
secondary injury mechanisms, leading to increased cell death and attenuated recovery of 
function. Together, the results presented here underscore the need to improve the safety 
and efficacy of opioids in the clinical setting. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Pain following spinal cord injury 
 Pain is one of the most debilitating consequences of spinal cord injury (SCI). 
Approximately two-thirds of spinally-injured patients develop chronic pain within 5 
years of their injury (Gorp et al., 2015; Siddall & Loeser, 2001; Siddall et al., 2003).  
Along with recovery of motor, bladder/bowel, and sexual function, patients often rate 
pain management as one of their top priorities following SCI (Anderson, 2004; Simpson 
et al., 2012). Importantly, chronic pain has been associated with diminished physical and 
psychological health, disrupted sleep patterns, impaired social interactions and 
community involvement, and an overall decrease in vitality and well-being (Attal et al., 
2011; Gormsen et al., 2010; Jensen et al., 2007; McDermott et al., 2006; Smith et al., 
2007). Clearly, effective pain management is imperative to improve quality of life for 
patients suffering from a spinal cord injury.  
 Treatment of post-SCI chronic pain, however, has been complicated by its 
complex etiology and heterogeneity. Although a number of anatomical and 
neurochemical alterations have been identified as contributing to chronic pain following 
SCI (Finnerup & Jensen, 2004; Hassler et al., 2014; Lee-Kubli et al., 2016; Lerch et al., 
2014; Q. Yang et al., 2014), the precise mechanisms underlying its initiation and 
maintenance remain to be elucidated. Clinically, spinally-injured patients often describe 
a wide range of chronic pain symptoms, including dull, aching, sharp, shooting, 
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stabbing, electric, or even burning sensations (Siddall et al., 2003). Variations in 
intensity (mild to severe pain), duration (persistent versus intermittent), and 
responsiveness to stimulation (spontaneous versus evoked) further complicate 
management of chronic pain. In addition,  exacerbating  the frustration of patients and 
health-care professionals, chronic pain often shows resistance to conventional 
therapeutic strategies (Warms et al., 2002). Consequently, treatment of chronic pain 
following SCI has been based on a trial-and-error approach.  
Opioids are among the most potent analgesics currently available, and have 
shown efficacy in the management of chronic pain conditions (Eisenberg et al., 2006; 
Gilron et al., 2005; Gimbel et al., 2003; Raja et al., 2002; Warms et al., 2002; Watson et 
al., 2003). However, due to concerns about unwanted side effects, opioids are no longer 
recommended as a first-line medication for the treatment of chronic pain (Attal et al., 
2010; Eisenberg et al., 2005; Furlan et al., 2006; Kalso et al., 2004; O'Connor & 
Dworkin, 2009). Indeed, many unwanted effects associated with opioid administration 
have been well documented (Buenaventura et al., 2008; McNicol et al., 2003). Some of 
the side effects that can result from acute opioid treatment include nausea, itching, 
vomiting, dizziness, drowsiness, and constipation. Respiratory depression can also occur 
at high doses. Opioids can also interact with the endocrine system, resulting in hormone 
suppression, hypogonadism, and altered sexual function (Abs et al., 2000; Daniell, 2002; 
N. Katz & Mazer, 2009). Additionally, with prolonged use, opioid tolerance, 
dependence, and addiction can develop (Chu et al., 2006; Højsted & Sjøgren, 2007; 
Martell et al., 2007). Paradoxically, long term administration of opioids has also been 
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linked to the development of abnormal pain sensitivity, an effect known as opioid-
induced hyperalgesia (Angst & Clark, 2006; Chu et al., 2008; Chu et al., 2006). 
 Alarmingly, evidence also suggests that opioids may be contraindicated 
following injury to the spinal cord (Hook et al., 2007; Hook et al., 2009; Hook et al., 
2011; Woller et al., 2014; Woller et al., 2012). Using a rodent model of SCI, our 
previous studies have shown that regardless of the route of administration 
(intraperitoneal, intrathecal, or intravenous), morphine given in the acute phase of SCI 
increases tissue loss at the injury site, increases mortality, undermines weight gain, 
reduces recovery of motor and sensory function, and increases pain reactivity, even 
weeks after treatment (Hook et al., 2007; Hook et al., 2009; Hook et al., 2011; Woller et 
al., 2014; Woller et al., 2012). Based on these data, it may be tempting to eliminate 
opioids from the list of treatments currently used for post-SCI pain. However, for 
patients facing a lifetime of intractable pain, simply removing these powerful drugs from 
clinical use is not an option. Instead, further understanding of the interactions between 
opioids and injury is necessary to improve the safety and efficacy of these drugs.  
Mechanisms of opioid-induced cell death 
Elucidating the molecular mechanisms underlying the adverse effects of opioids 
is necessary to improve the safety and efficacy of these drugs. The dramatic 
consequences of morphine administration following SCI (discussed above) suggest that 
opioids may induce cell death. Indeed, in a study from our laboratory investigating the 
neurobiological effects of morphine following SCI, Hook et al. (2016) showed that acute 
treatment with this analgesic negatively impacts the survival of key cell types at the 
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lesion site. Subjects were administered incremental doses of intravenous morphine for 7 
days following SCI, and tissue was collected 24 hours after the last dose for 
immunohistochemical analyses. The results showed that virtually no neurons or 
astrocytes remained across the rostral-caudal extent of the lesion in contused subjects 
treated with morphine (Hook et al., 2016). Furthermore, although not significant, these 
subjects also showed decreased expression of microglia/macrophages and increased 
expression of markers for neurodegeneration than their saline-treated counterparts.  
Supporting our findings, other studies have also shown that morphine displays 
toxic properties. For example, morphine-induced death has been observed in a study of 
human neurons and microglia in vitro (Hu et al., 2002). Increased cell death has also 
been observed in the brains of rodent subjects undergoing chronic morphine 
administration (Atici et al., 2004; Bekheet et al., 2010; Emeterio et al., 2006; L.-W. Liu 
et al., 2013). Additionally, morphine also promotes monocyte and lymphocyte death 
(Bhat et al., 2004; Singhal et al., 1999; Singhal et al., 1998; Yin et al., 2006), an 
observation that may explain immune suppression in heroin addicts (Govitrapong et al., 
1998). Although still under investigation, research suggests that opioids may induce cell 
death by promoting excitotoxicity, apoptosis, and inflammation.  
Excitotoxicity 
 Evidence suggests that opioid-induced cell death may be a result of 
excitotoxicity. Prolonged opioid administration often results in the development of 
dependence, tolerance, and paradoxical pain (Bekhit, 2010; Ueda & Ueda, 2008). 
Opioid-induced alterations in N-methyl-D-aspartate receptor (NMDA receptor) signaling 
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have been strongly implicated in these effects (Mao et al., 1994; Marek et al., 1991; 
Trujillo & Akil, 1991). For example, co-administration of the noncompetitive NMDA 
receptor antagonist MK-801 attenuates the development of tolerance and dependence to 
chronic morphine, without affecting the analgesic efficacy of the drug (Mao et al., 1994; 
Marek et al., 1991; Trujillo & Akil, 1991). Repeated morphine administration has also 
been shown to increase protein kinase C (PKC) expression, activation, and translocation 
to the cell membrane (Mao et al., 1995; Mayer et al., 1995). Importantly, PKC can 
increase calcium influx by removing the magnesium blockade from the NMDA 
receptor/calcium channel (L. Chen & Huang, 1992). Furthermore, chronic morphine 
exposure is also associated with downregulation of glutamate transporters (Mao et al., 
2002a; L. Yang et al., 2008) and enhanced excitatory neurotransmitter release from 
primary afferents (Gardell et al., 2002). Altogether, the evidence suggests that opioids 
directly and indirectly contribute to heightened excitation in the spinal cord, which may 
potentiate the central sensitization and excitotoxic cell death inherent to the injury 
process.  
Apoptosis 
 Opioid-induced cell death has been linked with increased expression of a variety 
of apoptosis-related proteins (Boronat et al., 2001; Emeterio et al., 2006; Hu et al., 2002; 
L.-W. Liu et al., 2013; Singhal et al., 1999; Willner et al., 2014; Yin et al., 1999; Yin et 
al., 2006). In vitro, morphine promotes apoptosis of neural progenitor cells, neurons, and 
microglia via a Caspase-3 mechanism, and this effect is blocked by naloxone (Hu et al., 
2002; Willner et al., 2014). In vivo, addiction studies have found significantly increased 
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expression of pro-apoptotic Fas and Caspase-3, accompanied by decreased expression of 
anti-apoptotic Bcl-2, in the brains of rats undergoing prolonged morphine administration 
(L.-W. Liu et al., 2013). Similarly, chronic morphine-treated mice exhibit neuron and 
astrocyte death throughout the brain, as well as upregulated FasL, Fas, Bad, and the 
active fragments of caspases 3 and 8 (Emeterio et al., 2006). In Jurkat cells and human T 
lymphocytes, morphine-induced cell death appears to depend on the generation of 
reactive oxygen species, activation of the Fas/p53 pro-apoptotic pathway, and inhibition 
of the phosphatidylinositol 3-kinase (PI3K)/Akt anti-apoptotic pathway (Singhal et al., 
1999; Yin et al., 2006). Decreased levels of the pro-survival phosphorylated protein 
kinase Akt, however, have also been shown in the brain under chronic morphine 
conditions (Muller & Unterwald, 2004).  
Inflammation 
 Indirectly, morphine may also induce cell death by activating immune-competent 
cells and increasing the release of pro-inflammatory cytokines. Opioid-induced glial 
activation has been associated with decreased analgesic efficacy, dependence, tolerance, 
and paradoxical pain (Hutchinson et al., 2007; Raghavendra et al., 2002; Raghavendra et 
al., 2004; Watkins et al., 2009). In vitro, lumbar dorsal spinal cord sections show 
significant increases in the release of IL-1β, IL-6, fractalkine, GRO/KC, MIP-1α, MCP-1 
and TNF-α following 180 minutes of incubation with 100 µM morphine compared to 
media alone (Hutchinson et al., 2008a). In vivo, increases in IL-1α, IL-1β, IL-6 and 
TNF-α have also been demonstrated after 7 days of intrathecal morphine (Hutchinson et 
al., 2008a). Importantly, pro-inflammatory cytokines can affect cell health and viability 
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(Buntinx et al., 2004; Hermann et al., 2001; Lee et al., 2000; van Kralingen et al., 2013; 
Ye et al., 2013). For example, astrocyte cultures treated with IL-1β and TNFα show 
compromised function (such as decreased cell adhesion and ATP production) as early as 
24 hours post-treatment and significant cell death by 96 hours. Similarly, in 
oligodendrocyte cell lines cultured in the presence of TNFα and IFN-γ, cell death is 
evidenced as early as 24 hours post-treatment in a dose dependent fashion (Buntinx et 
al., 2004). 
Synergistic effects of opioids and spinal cord injury 
 Importantly, opioids may act synergistically with processes innate to SCI to 
increase cell death and attenuate recovery of function  (Woller & Hook, 2013). The 
extent of damage during SCI is determined by the primary injury, and the secondary 
injury processes that immediately follow. It is during this secondary phase of injury that 
damage spreads from the epicenter of the lesion, to the rostral and caudal segments of 
the spinal cord. As opposed to the primary injury, medical intervention is possible during 
the secondary phase of injury to minimize the extent of the damage to surviving spinal 
tissue. On the other hand, opioid administration during this phase of SCI may exacerbate 
secondary injury, increasing cell death, and leading to decreased recovery of function. 
For example, following SCI, there is a significant increase in the release of glutamate 
and other excitatory amino acids (D. Liu et al., 1991). This contributes to increased 
NMDA, AMPA, and kainate receptor activity and the activation of voltage-gated ion 
channels (Dumont et al., 2001; Kwon et al., 2004). Subsequently, calcium and sodium 
influx increase to lethal levels, resulting in excitotoxicity. Combined with opioid-
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induced increases in NMDA receptor activation and downregulation of glutamate 
transporters, this could significantly increase damage at the lesion site.   
 Furthermore, vascular disruption following SCI results in hemorrhage and 
ischemia (Mautes et al., 2000; Tator & Koyanagi, 1997). During ischemia, reactive 
oxygen species are generated, including superoxide, hydroxyl radicals, and nitric oxide, 
leading to oxidative stress (Jia et al., 2012). These toxic factors contribute to secondary 
damage during reperfusion of the spinal cord through oxidation of proteins, lipids, and 
nucleic acids. Morphine treatment also promotes the production of reactive oxygen 
species, such as nitric oxide (Chandel et al., 2012; Singhal et al., 1998). Reactive oxygen 
species can compromise key mitochondrial functions, resulting in metabolic distress and 
triggering apoptosis via cytochrome c release and caspase activation (Dumont et al., 
2001; Kwon et al., 2004). As discussed above, prolonged morphine administration can 
also activate pro-apoptotic pathways in a variety of cells, decreasing tissue sparing at the 
injury site. 
 Lastly, inflammation is innate to SCI; however, an unchecked immune response 
can also increase collateral damage at the lesion site (Donnelly & Popovich, 2008; 
Fleming et al., 2006; Popovich et al., 1997). After SCI, the first response to the site of 
damage is by neutrophils, which secrete lytic enzymes and cytokines (Taoka et al., 
1997). Then, circulating macrophages are recruited to the lesion site and resident 
microglia become activated (Popovich et al., 1997). The role of these phagocytes is 
crucial to the resolution of injury, since they are necessary of the clearance of dead cells 
and debris (Kigerl et al., 2009). On the other hand, the pro-inflammatory products 
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released by these cells also increase glial activation, chemotaxis, and cell proliferation. 
As previously mentioned, opioid administration also results in glial activation and the 
release of pro-inflammatory cytokines (Hutchinson et al., 2007; Hutchinson et al., 
2008a; Hutchinson et al., 2011; Watkins et al., 2009). In the pathophysiological context 
of a SCI, opioids may trigger a positive feedback loop of pro-inflammatory cytokine 
production that can exacerbate the neurotoxic environment and result in further tissue 
damage. Paradoxically, opioid treatment following SCI may also result in aberrant glial 
activation, promoting the development of chronic pain (Christensen & Hulsebosch, 
1997; Crown et al., 2006; Detloff et al., 2008; Gwak et al., 2012; Hulsebosch, 2008; 
Hutchinson et al., 2011; Watkins et al., 2009).  
 Overall, the extant literature suggests that opioids should not be used following 
SCI. As previously mentioned, however, simply abstaining from using these potent 
analgesics for the treatment of post-SCI pain is not an option. Instead, the mechanisms 
underlying morphine’s adverse effects need to be elucidated to ensure that this drug can 
be safely used in the clinical setting.  I propose that the beneficial (analgesia) versus 
adverse (undermined recovery) effects of opioids may be mediated by different opioid 
receptor subtypes. Next, I will discuss classic and non-classic opioid receptor signaling.  
The opioid receptors 
Classic opioid receptors 
 The term “classic” refers to three major opioid receptor subtypes: the mu (µ or 
MOR), delta (δ or DOR), and kappa (κ or KOR) opioid receptors (Y. Chen et al., 1993; 
Evans et al., 1992; Kieffer et al., 1992; Meng et al., 1993). The classic opioid receptors 
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belong to the class A (Rhodopsin) group of receptors, and form part of the G-protein 
coupled receptor (GPCR) superfamily (HUGO Gene Nomenclature Committee, n.d.). In 
humans, these receptors are encoded in the OPRM1, OPRD1, and OPRK1 genes, 
localized in chromosomes 6, 1, and 8, respectively (HUGO Gene Nomenclature 
Committee, n.d.). These genes are highly conserved; indeed, the classic opioid receptors 
are identical in approximately 60% of their amino acid sequence (Sobczak et al., 2014). 
The classic opioid receptors also share many structural similarities. These receptors are 
formed by seven transmembrane helical domains connected by three extracellular and 
three intracellular loops, with an extracellular N-terminus and an intracellular C-
terminus (Filizola & Laakkonen, 1999; Law et al., 1999). While the  transmembrane 
domains and intracellular loops are comparable across all three opioid receptor subtypes, 
the N-terminus, C-terminus, and extracellular loops can differ to varying degrees (Law 
& Loh, 2006). This divergence results in differences in ligand binding profiles and 
intracellular signaling.  
 In the absence of exogenous opioid compounds, opioid receptor activity occurs 
through binding of endogenous ligands produced under physiological conditions. Three 
main precursor proteins, pro-opiomelanocortin (POMC), proenkephalin, and 
prodynorphin, give rise to multiple active opioid peptides upon cleavage (Akil et al., 
1984; Khachaturian et al., 1985). Their products- endormorphins, enkephalins, and 
dynorphins- show high affinity for the MOR, DOR, and KOR respectively. The major 
site of endogenous opioid production is the pituitary; however, opioid peptides have also 
been identified areas of the hypothalamus, the nucleus of the solitary tract, the nucleus 
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commissuralis, the spinal cord, and regions outside of the nervous system such as the 
adrenal medulla and along the gastrointestinal tract. Furthermore, immune cells also 
release opioid peptides, and play an important role in peripheral mechanisms of intrinsic 
opioid antinociception (Rittner et al., 2001; Schäfer et al., 1994; Stein et al., 1990). For 
example, in response to peripheral inflammation, opioid-containing immune cells can 
migrate to inflamed tissue and release opioid peptides (Schäfer et al., 1994). Stress can 
also trigger opioid release from immune cells by a mechanism involving corticotropin-
releasing hormone (Schäfer et al., 1994).  
 Similar to the widespread production of endogenous opioid peptides, early 
autoradiography binding studies provided evidence that all three of the classic opioid 
receptors are widely distributed throughout the nervous system (Atweh & Kuhar, 1977a, 
1977b, 1977c; Gouardères et al., 1985; Mansour et al., 1987; Tempel & Zukin, 1987). 
More recently, with the use of in situ hybridization and immunohistochemical 
techniques, localization of these receptors has been achieved with better resolution and 
higher specificity (Ding et al., 1996; Mansour et al., 1996; Mansour et al., 1995a; 
Mansour et al., 1995b; Mansour et al., 1994).  
 The differential expression of the classic opioid receptors across the nervous 
system has been linked with a variety of important physiological and psychological 
functions. For instance, opioid receptor mRNA has been localized to various nuclei of 
the hypothalamus and the pituitary, suggesting a role for opioid modulation of hormonal 
responses. In fact, altered endocrine function has been observed in patients receiving 
long-term treatment with opioids. These patients usually exhibit sex hormone 
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suppression, a condition also known as “opioid-induced hypogonadism”, which can 
result in severe erectile dysfunction and decreased libido, among other symptoms (Abs 
et al., 2000; Daniell, 2002; N. Katz & Mazer, 2009).  Additionally, mRNA in the 
nucleus accumbens, ventral tegmental area (VTA), substantia nigra, and striatum 
underscore the role of opioid receptor activation in mechanisms of drug abuse and 
addiction (Lutz & Kieffer, 2013a). Localization to mesolimbic areas like the amygdala 
and hippocampus, coupled with modulation of dopamine centers, also supports a role of 
the opioid receptor systems in emotional processing and affect (Filliol et al., 2000; Kang 
et al., 2000; König et al., 1996; Lutz & Kieffer, 2013b; Ragnauth et al., 2001). 
 The localization of opioid receptors throughout the pain circuits of the nervous 
system is particularly important in the context of SCI. For instance, opioid receptor 
mRNA has been localized in dorsal root ganglia (DRG), the spinal cord, the spinal 
trigeminal nuclei, reticular nuclei, raphe nuclei, the periaqueductal gray (PAG), and the 
thalamus- areas involved in ascending and descending pain modulation (Mansour et al., 
1995a; Mansour et al., 1994). At the supraspinal level, opioid receptors modulate pain by 
acting on neurons of the ventromedial medulla, which project to the spinal dorsal horn 
inhibiting pain transmission.  This is an example of “descending” pain control. Opioid 
receptors also play an important role in the regulation of “ascending” pain signals. In 
primary sensory neurons, for example, opioid receptors are synthesized and transported 
to central and peripheral terminals. Centrally, they can act presynaptically to inhibit 
neurotransmitter release to the spinal cord. Peripherally, opioid receptors on cutaneous 
tissue can regulate pain and itch, and may also play a role in skin disorders and wound 
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healing (Bigliardi et al., 2009; Rook et al., 2008; Salemi et al., 2005; Taneda et al., 
2011).  
 Aside from modulating the activity of these different neuronal populations 
throughout the PNS and CNS, opioid compounds can also act on a variety of other cell 
types that also express opioid receptors under normal physiological conditions. For 
example, opioid receptors have been detected on skin cells such as keratinocytes, 
fibroblasts, and epidermal melanocytes (Bigliardi-Qi et al., 2003; Cheng et al., 2008; 
Kauser et al., 2003).With the use of RT-PCR, opioid receptor expression has also been 
quantified in other human tissues, including lung, spleen, kidney, heart, skeletal muscle, 
liver, thymus, small intestine, pancreas, and adrenal gland (Peng et al., 2012).  Further 
supporting an interaction between the immune and opioid systems, studies have 
demonstrated that cells involved in host defense, including circulating monocytes and 
peritoneal macrophages, also express opioid receptor mRNA (Bidlack et al., 2006; 
Chuang et al., 1995; Sharp, 2006). Even within the nervous system, opioid receptor 
expression is not restricted to neurons. Astrocytes, oligodendrocytes, and microglia also 
express opioid receptors (Chao et al., 1996; Chao et al., 1997; Ruzicka et al., 1995; 
Stiene-Martin et al., 1998; Tryoen‐Toth et al., 2000).  
 Opioid receptor signal transduction mechanisms resulting in antinociception have 
been well characterized (Law, 2011; Law & Loh, 2006; Law et al., 2000). Like other 
GPCRs, opioid receptors signal trough intracellular G (guanine nucleotide-binding) 
proteins. G proteins are heterotrimers composed of α-, β-, and γ-subunits. Following the 
binding of the ligand to the opioid receptor, GDP bound to the α-subunit is released, 
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allowing the binding of GTP. This results in the dissociation of the G protein into two 
different signaling units: Gα and Gβγ. These subunits then interact with other effectors 
and intracellular proteins to decrease neuronal activity.  For instance, Gα subunits have 
been shown to inhibit adenylyl cyclase, resulting in decreased cAMP and PKA 
production. Gα subunits can also activate G protein-coupled inwardly rectifying 
potassium (KIR) channels at the postsynaptic membrane, hyperpolarizing the cell. 
Furthermore, Gβγ subunits can inhibit pre- and postsynaptic voltage-gated calcium 
(Ca
2+
) channels, blocking Ca
2+ 
influx into the cell, and reducing neurotransmitter release.  
 Aside from these well-known signal transduction pathways involved in the 
inhibitory effects of opioids, the classic opioid receptors may also play a role in other 
important signaling cascades. For example, activation of the classic opioid receptors has 
also been shown to modulate the MAP kinase pathways, composed of three protein 
kinase cascades: the extracellular-signal regulated kinases (Erks), the Jun N-terminal 
kinases (JNKs), and the p38 kinases (Law, 2011; Law & Loh, 2006; Law et al., 2000). 
Although not fully understood, potential mechanisms through which opioids activate 
these important signaling pathways are beginning to emerge. For example, selective 
agonists for the MOR and KOR can active the ERK/MAPK cascade via secondary 
messengers like PKC (Belcheva et al., 2005). Additionally, intracellular proteins 
regularly recruited during opioid receptor activation, like the β-arrestins, may not only 
play a role in receptor trafficking and endocytosis, but may also activate MAPKs 
through the formation of complexes with other effector proteins (Bruchas et al., 2006). 
Overall, activation of MAPK signaling suggests that, aside from their well-known 
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analgesic effects, opioids and opioid receptors may also play a role in regulating 
numerous important cellular processes, including differentiation, survival, and apoptosis 
(Tegeder & Geisslinger, 2004).  
Non-classic opioid receptors 
 One property of opioids that has facilitated the study of non-classic binding sites 
is stereoselectivity. The classic opioid receptors bind to conventional opioid drugs in a 
stereoselective fashion, meaning that they can bind to [-]-, but not [+]- isomers. These 
[+]- enantiomers, also known as unnatural opioids, have been widely used to investigate 
non-classic opioid binding in the nervous system. For example, in one of the earliest 
studies in opioid binding,  Goldstein et al. (1971) used the morphine congener 
levorphanol and its enantiomer, dextrorphan, in the mouse brain. Among their most 
noteworthy results, Goldstein and colleagues showed that nonspecific binding sites are 
widely spread throughout the mouse brain. Furthermore, nonspecific sites greatly 
outnumbered stereospecific sites, constituting approximately 50% and 2% of overall 
binding respectively. Unfortunately, this non-stereospecific binding was not fully 
characterized in the original study, and was not pursued further in any subsequent work. 
Therefore, many questions remain as to the nature of these non-stereoselective sites. 
Recent findings, however, suggest these sites may represent opioids binding to non-
classic receptors on glia, such as toll-like receptors (TLRs), resulting in 
immunomodulatory and anti-analgesic effects. 
 Many experiments published in recent years are helping to elucidate the role of 
the toll-like receptors (TLRs) in opioid-induced glial activation, decreased analgesic 
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efficacy, and the development and maintenance of pain (Hutchinson et al., 2011; Nicotra 
et al., 2012). The toll-like receptors are important components of the innate immune 
system (Kawasaki & Kawai, 2014). To date, over thirteen TLRs have been identified: 
TLR 1-10 in humans; TLR1-9, and TLR11-13 in mice. Together, they form part of a 
wide class of pattern recognition receptors (PRRs) that detect danger signals in the 
cellular environment. These signals include pathogen-associated microbial patterns 
(PAMPs) typically expressed by microbial pathogens and danger-associated molecular 
patterns (DAMPs) released from dying cells. Structurally, TLRs are type I 
transmembrane proteins, consisting of extracellular leucine-rich repeats (LRRs) and a 
cytoplasmic Toll/IL-1 receptor domain (Stirling et al., 2004). Upon recognition of 
PAMPs or DAMPs, individual TLRs can induce different signaling cascades by 
recruitment of adaptor proteins. Five of these proteins have been identified, including 
MyD88, Mal (MyD88 adaptor-like protein), TRIF (TIR domain-containing adaptor 
protein-inducing IFN-β), TRAM (TRIF-related adaptor molecule), and SARM (sterile α- 
and armadillo-motif-containing protein). Signaling is achieved by coupling of the 
adaptor proteins to downstream kinases that activate a variety of transcription factors, 
such as NF-κB, ultimately leading to the production of pro-inflammatory cytokines and 
chemokines.   
 TLR4, the receptor that recognizes lipopolysaccharide (LPS), appears to play a 
particularly important role in opioid-glia interactions. For instance, research suggests 
that opioid ligands can bind to TLR4 and its accessory molecules in a non-
stereoselective manner,  activating glia, and initiating the inflammatory response 
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(Hutchinson et al., 2010a; Hutchinson et al., 2010b; Lewis et al., 2010; Wang et al., 
2012). As mentioned previously, the release of pro-inflammatory substances can 
undermine opioid analgesia and potentiate pain. These effects, however, can be blocked 
with LPS-specific antagonists like LPS-RS, and non-stereoselectively by the use of 
unnatural opioid antagonists like [+]- naloxone (Hutchinson et al., 2008b; Hutchinson et 
al., 2010b). Genetic studies further support the role of TLR4 in opioid-induced 
inflammation. TLR4 knockout mice show a three-fold increase in morphine analgesia 
when compared to their wildtype counterparts (Hutchinson et al., 2010b). Importantly, in 
a model of sciatic nerve chronic constriction injury, non-stereoselective inhibition of 
TLR4 by intrathecal [+]- naloxone and [+]- naltrexone suppressed microglial activation 
and successfully reversed symptoms of neuropathic pain (Hutchinson et al., 2008b). 
These findings suggest that TLR4 could be targeted pharmacologically to improve the 
safety and efficacy of clinically-employed opioid analgesics.  
Specific aims 
 Morphine can bind stereoselectively to the classic opioid receptors (MOR, DOR, 
and KOR), but it can also activate non-classic receptors in a non-stereoselective fashion 
(Kristensen et al., 1994; Wang et al., 2012). Despite the traditional categorization of 
morphine as a selective MOR agonist, research shows that morphine also binds to the 
DOR and KOR, although with approximately 70 and 40 less affinity than MOR 
(Kristensen et al., 1994). Therefore, morphine may exert its adverse effects through any 
of the opioid-receptor systems, alone or in combination. The aim of the experiments 
reported in Chapters 3-5 (outlined in Figure 1) was to identify the critical receptor 
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subtypes involved in the morphine-induced attenuation of locomotor recovery after SCI. 
Based on the extant literature, three primary mechanisms were identified that may result 
in morphine-induced attenuation of function following SCI. 
 First, repeated MOR activation may contribute to neurotoxicity and the 
development of paradoxical pain observed with morphine administration. Whereas 
activation of the MOR is typically associated with analgesia, Mao et al. (1995) proposed 
that repeated activation of this receptor system leads to a PKC-mediated decoupling of 
the receptor from its associated G-protein and decreased morphine-induced 
antinociception. Binding of morphine to the MOR is also thought to initiate G-protein 
mediated protein kinase C (PKC) translocation and activation, promoting the removal of 
the NMDA receptor Mg
+
 plug (L. Chen & Huang, 1992) and allowing Ca
2+
 influx. An 
increase in intracellular Ca
2+
 leads to activation of additional PKC, production of nitric 
oxide (NO), and regulation of gene expression. NO may act as a retrograde messenger to 
enhance glutamate release from the presynaptic neuron, which would further potentiate 
activity in the postsynaptic neuron. Mao and colleagues have also shown that chronic 
morphine exposure is associated with downregulation of glutamate transporters, directly 
contributing to the heightened activity of NMDA receptors (Mao et al., 2002a; L. Yang 
et al., 2008). Overall, sustained potentiation of the NMDA receptor maintains central 
sensitization and hyperalgesia in the neural system, and may lead to excitotoxic cell 
death (Mao et al., 2002b; Woolf & Thompson, 1991). 
 Morphine may also undermine recovery of function after SCI by activating the 
KOR system. Behaviorally, Faden and colleagues have demonstrated that intrathecal 
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administration of dynorphin (an endogenous KOR ligand) causes hindlimb paralysis in 
neurologically intact rats, and blocking the KOR improves neurological outcomes after a 
contusion SCI (Faden & Jacobs, 1983; Faden et al., 1987). KOR activation may also 
increase glial activation, leading to decreased recovery of function. For example, Xu and 
colleagues (2007) explored the cellular consequences of KOR activation in a model of 
partial sciatic nerve ligation. This injury normally results in increased astrocyte 
proliferation in the spinal dorsal horn. However, the same manipulation failed to show 
astrocyte proliferation in dynorphin knock-out mice, mice with a homozygous KOR 
deletion, or mice treated with the specific KOR antagonist norBNI. Importantly, in the 
same study, blocking downstream KOR targets in vivo for 7 days following partial 
sciatic nerve ligation resulted in reduced spinal astrocyte proliferation, an effect that 
correlated with decreased signs of neuropathic pain, such as allodynia and hyperalgesia. 
 Morphine may also exert its negative effects through activation of non-classic 
opioid receptors that play an important role in immunity (Hutchinson et al., 2007; 2008b; 
Tawfik et al., 2005; Watkins et al., 2009).  For example, research suggests that opioid 
ligands can bind to TLR4 and its accessory molecules in a non-stereoselective manner, 
leading to glial activation and initiating the inflammatory response (Hutchinson et al., 
2010a; Hutchinson et al., 2010b; Lewis et al., 2010; Wang et al., 2012). The subsequent 
release of pro-inflammatory cytokines in the spinal cord has been shown to oppose 
opioid analgesia and facilitate pain (Hutchinson et al., 2008a; Johnston et al., 2004). In 
the SCI model, we have also shown that morphine administration results in increased 
pro-inflammatory cytokine expression (IL-1β and IL-6) at the injury site, and that 
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blocking the IL-1 receptor during morphine administration prevents morphine-induced 
attenuated recovery (Hook et al., 2011). These data suggest that non-classic opioid 
receptor signaling may be key mechanism contributing to the morphine-induced 
attenuation of function. 
 To address these hypotheses, in the first set of experiments (Chapter 3), I 
evaluated the contribution of MOR and KOR activation to the morphine-induced 
attenuation of function observed following experimental SCI using selective opioid 
receptor agonists and antagonists. In the second set of experiments (Chapter 4), I 
assessed the contribution of TRL4 using a selective agonist and antagonist. I also 
assessed overall non-classic signaling and glial activation using [+]- morphine and 
minocycline, respectively. In the last set of experiments (Chapter 5), I assessed the 
effects of morphine at the lesion site by quantifying key cell populations using 
immunohistochemistry. Since I posited that opioid-immune interactions may 
significantly contribute to morphine’s adverse effects, I also investigated the immune 
response and classic opioid receptor co-localization on microglia and macrophages using 
flow cytometry. The aim of the experiments reported here was to further our 
understanding of opioid receptor signaling within the pathophysiological context (spinal 
cord injury) in which they are prescribed. This avenue of research has been largely 
overlooked, but merits further investigation in order to improve the safety and efficacy 
of current pain medications for the spinally-injured population. 
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Figure 1: Specific aims.  This is an outline of the experiments presented here. Aims 1, 2, 
and 3 correspond to Chapters 3, 4, and 5 respectively. 
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CHAPTER II  
GENERAL METHODOLOGY 
 
Subjects 
 The subjects were male Sprague-Dawley rats obtained from Harlan (Houston, 
TX, USA).  They were approximately 90-110 days old (300-350 g) and were 
individually housed in Plexiglas bins [45.7 (length) x 23.5 (width) x 20.3 (height) cm] 
with food and water continuously available.  Following surgery, subjects were manually 
expressed in the morning (7:00-8:30 a.m.) and in the evening (4:30-6:00 p.m.) until they 
regained full bladder control (operationally defined as three consecutive days with an 
empty bladder at the time of expression). Subjects were checked daily for signs of 
autophagia and spastic hypertonia.  A subject was classified as having spastic hypertonia 
if the limb was in an extended, fixed position and was resistant to movement.  The 
subjects were maintained on a 12 hour light/dark cycle and all behavioral testing was 
conducted during the light cycle.  
 All of the experiments reported here were reviewed and approved by the 
Institutional Animal Care Committee at Texas A&M University and all NIH guidelines 
for the care and use of animal subjects were followed. 
Surgery 
 Subjects received a moderate contusion injury using the Infinite Horizon spinal 
cord impactor (PSI, Fairfax Station, VA, USA). Briefly, subjects were anesthetized with 
isoflurane (5%, gas), and after a stable level of anesthesia was reached, the concentration 
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of isoflurane was lowered to 2-3%.  The subject’s back was shaved and disinfected with 
iodine and a 5.0 cm incision was made over the spinal cord. Two incisions were made 
along the vertebral column, on each side of the dorsal spinous processes, extending 
about 2 cm rostral and caudal to the T12 segment. Muscle and connective tissue were 
then dissected to expose the underlying vertebral segments. Musculature around the 
transverse processes was cleared to allow for clamping of the vertebral spinal column. 
Next, the dorsal spinous process at T12 was removed (laminectomy), and the spinal 
tissue exposed (approximately L1-L3). The dura remained intact. The vertebral column 
was fixed within the IH device using two pairs of Adson forceps. A moderate injury was 
produced using an impact force of 150 kdynes and a 1 s dwell time.  
 After injury, a 15-cm-long polyethylene (PE-10) cannula, fitted with a stainless 
steel guiding wire (P01008, Ernie Ball Inc., Coachella, CA, USA), was threaded 2 cm 
under the vertebrae immediately caudal to the injury site. The tubing was inserted into 
the subarachnoid space. To prevent cannula movement, the exposed end of the tubing 
was secured to the vertebrae rostral to the injury using tissue adhesive (3M Vetbond 
Tissue Adhesive, 3M Animal Care Products, St Paul, MN, USA). The wire was then 
pulled from the tubing and the wound was closed using Michel clips. To help prevent 
infection, subjects were treated with 100 000 units/kg Pfizerpen (penicillin G potassium) 
immediately after surgery and again 2 days later. For the first 24 h after surgery, rats 
were placed in a recovery room maintained at 26.6 °C. To compensate for fluid loss, 
subjects were given 3 ml of saline after surgery. Michel clips were removed 14 d after 
surgery. 
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Drug administration 
 Drug administration took place on the day after surgery, following baseline tests 
of locomotion and thermal reactivity. Baseline BBB scores were balanced across all 
groups. Drugs were administered via an intrathecal route. The following drugs were 
used: [-]- Morphine (NIDA Drug Supply Program), DAMGO ([D-Ala
2
, NMe-Phe
4
, Gly-
ol
5
]-enkephalin; Tocris Bioscience, Bristol, UK), CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-
Thr-Pen-Thr-NH2; Tocris Bioscience, Bristol, UK), GR89696 (4-[(3,4-
Dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-1-piperazinecarboxylic acid methyl 
ester fumarate salt; Sigma-Aldrich, St. Louis, MO, USA), NorBNI (nor-
Binaltorphimine; Tocris Bioscience, Bristol, UK), LPS (Lipopolysaccharide from 
Escherichia coli; Sigma-Aldrich, St. Louis, MO, USA), LPS-RS Lipopolysaccharide 
from Rhodobacter sphaeroides; InvivoGen, San Diego, CA, USA), [+]- morphine 
(NIDA Drug Supply Program), minocycline (minocycline hydrochloride; Sigma-
Aldrich, St. Louis, MO, USA). Filtered saline (0.9%) was used to flush catheters 
following the injection of a drug at a volume of 10 μL. 
Assessment of sensory reactivity 
Thermal reactivity 
 To assess acute drug efficacy, the tail-flick test (D'amour & Smith, 1941; Jeffrey 
et al., 2001; Šedý et al., 2008) of thermal reactivity was used immediately before and 
after treatment. Subjects were placed in restraining tubes and allowed to acclimate to the 
tail-flick apparatus (IITC Life Science Inc., Woodland Hills, CA, USA) and testing room 
(maintained at 26.5˚C) for 15 min. Prior to testing, the temperature of the light, focused 
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on the tail, was set to elicit a baseline tail-flick response in approximately 4 s in an intact 
rat.  This pre-set temperature was then maintained across the SCI subjects.  In testing, 
the latency to flick the tail away from the radiant heat source (light) was recorded.  If a 
subject failed to respond, the test trial was automatically terminated after 8 s of heat 
exposure. Two tests occurred at 2-minute intervals, and the last tail-flick latency was 
recorded.  
Tactile reactivity 
 To evaluate the long-term recovery of sensory function, reactivity thresholds 
were also assessed after day 21 post-injury. Thermal reactivity was evaluated using the 
tail-flick test, as described above. Mechanical reactivity was tested by applying von Frey 
filaments (Semmes-Weinstein Anesthesiometer, Stoelting Co., Chicago, IL, USA) to the 
plantar surface of the hindpaws, in a manner previously described by others (Chaplan et 
al., 1994; Jeffrey et al., 2001; Šedý et al., 2008). Briefly, stimuli were presented every 2 
seconds until rats exhibited a motor (hindpaw withdrawal) and vocal response. The 
intensity of the stimuli that produced a response was reported using the formula provided 
by Semmes-Weinstein: Intensity=log10 (10,000 * g force). If one or both responses 
(motor and vocal) were not observed, testing was terminated at a force of 300 g. Each rat 
was tested twice on each hindpaw in a counterbalanced ABBA order (A= left paw, B= 
right paw). 
Girdle reactivity 
 Tactile reactivity was also assessed at the level of injury using the girdle test 
(Christensen & Hulsebosch, 1997). To ensure that the rats remained calm for testing, 
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they were handled for 5 minutes immediately prior to beginning the girdle test. For this 
test, the girdle region was shaved and a von Frey filament with bending force of 204.14 
mN (26 g force) was applied across a grid covering the girdle region. The filament was 
applied to 44 points (4 across the back of the subject and 11 down), and vocalization 
responses were recorded and mapped onto a grid map of that animal. Since animals do 
not normally vocalize to this stimulus, a vocalization response indicated that a noxious 
stimulus was experienced. In mapping the area of response, the number of vocalizations 
are recorded (Nv) and normalized by the following formula: (Nv × 100)/total number of 
applications (44), indicating the percent vocalizations out of the total number of 
applications.   
Assessment of locomotor recovery 
BBB scoring  
 Locomotor behavior was assessed for 21 days post-injury, using the Basso, 
Beattie and Bresnahan (BBB) scale (Basso et al., 1995; Šedý et al., 2008) in an open 
enclosure (a blue children’s wading pool, 99 cm in diameter, 23 cm deep). Baseline 
motor function was assessed on the day following injury and prior to drug treatment. 
Locomotor behavior was then scored once per day for 1 week (days 2–7). Subjects were 
scored every other day from day 9 to day 15 and every third day on days 18 and 21. 
Because rodents often remain motionless (freeze) when first introduced to a new 
apparatus, subjects were acclimated to the observation fields for 5 min per day for 3 days 
prior to surgery. Each subject was placed in the open field and observed for 4 min. Care 
was taken to ensure that all investigators’ scoring behavior had high intra- and inter- 
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observer reliability (all r’s > 0.89) and that they were blind to the subject’s experimental 
treatment. 
Tapered beam and ladder walk tests 
 Additional measures of motor recovery were obtained at the end of the 21-day 
recovery period using tapered beam and ladder walk tasks (Šedý et al., 2008). Prior to 
testing, subjects were habituated to the experimental context for 3 days (8 min per day). 
During this period of familiarization, they were trained to traverse a wide beam (48.3 
cm) and enter a black box positioned at the end of the beam runway. The beginning of 
the runway was brightly lit, motivating subjects to move toward the dark box. They were 
left in the box for 2 min after they had traversed the beam. Subjects were then tested on 
the tapered beam and ladder. 
 The beam walk test (Schallert, 2002; Schallert & Woodlee, 2005) provides a 
comparative index of the postural stability of the rats, as well as a gross measure of paw 
placement abilities. The ledged, tapered beam was 6.75 in (17.15 cm) wide at the start, 
and 0.375 in (0.95 cm) wide at the end. The width at which each hindpaw failed to 
plantar place on the beam was recorded. The average width across the two legs was used 
as an index of beam walk performance. 
 The ladder task (Metz & Whishaw, 2002; Šedý et al., 2008) provides a measure 
of the extent to which experimental manipulations affect the fine motor abilities of the 
hindpaws. The rats were required to cross a horizontal ladder (20 cm wide; 37 rungs at 
2.5 cm spacing) in order to reach the black box. The number of times that the rats did not 
successfully place their hindpaws (their paws slipped between the rungs) was assessed 
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using post hoc frame-by-frame video analyses. Each hindpaw was scored according to 
the number of errors made, with lower scores indicating better ladder walk performance 
(a maximum of 11 errors was recorded if no plantar placement was observed per 
hindpaw).  
Histology 
 At the end of behavioral testing, subjects were deeply anesthetized (100 mg/kg of 
beuthanasia, i.p.) and perfused intracardially with 4% paraformaldehyde. A 1-cm-long 
segment of the spinal cord, that included the lesion center, was taken and prepared for 
cryostat sectioning. The tissue was sectioned coronally (20 µm) and every 10
th
 slice was 
preserved for staining. All sections were stained with cresyl violet for Nissl substance 
and luxol fast blue for myelin (Beattie, 1992; Behrmann et al., 1992). 
 The total cross-sectional area of the cord and spared tissue was assessed at the 
lesion center using Neurolucida software (MFB Bioscience, Williston, VT, USA). 
Sections ± 600, 1200, 1800, and 2400 µm from the lesion center (rostral and caudal) 
were also traced and analyzed. Four indices of lesion magnitude were derived: lesion, 
residual gray matter, residual white matter, and width. To determine the area of lesion, 
an observer who was blind to the experimental treatments, traced around the boundaries 
of cystic formations and areas of dense gliosis (Basso et al., 1995). Nissl-stained areas 
that contained neurons and glia of approximately normal densities denoted residual gray 
matter. White matter was judged spared in myelin-stained areas lacking dense gliosis 
and swollen fibers. The total area of each cross-section was derived by summing the 
areas of damage, and gray and white matter. Width was determined from the most lateral 
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points across the transverse plane. These analyses yielded six parameters for each 
section: white matter area, gray matter area, spared tissue (white + gray), damaged tissue 
area, net area (white + gray + damage), and section width. 
 To control for variability in section area across subjects, a correction factor was 
applied derived from standard undamaged cord sections taken from age-matched 
controls. This correction factor is based on section widths and is multiplied by all area 
measurements to standardize area across analyses (Grau et al., 2004). By standardizing 
area across sections, it is possible to estimate the degree to which tissue is ‘missing’ (i.e., 
tissue loss from atrophy, necrosis, or apoptosis). An accurate assessment of the degree to 
which a treatment has impacted, or lesioned, the cord includes both the remaining 
damaged tissue as well as resolved lesioned areas. By adding the amount of missing 
tissue and the measured damaged area, an index of the relative lesion (% relative lesion) 
can be derived in each section that is comparable across sections. Similarly, this allows 
an estimation of the relative percent of gray and white matter remaining in each section, 
relative to intact controls. These measures are highly correlated with various measures of 
behavioral performance including BBB locomotor scores and recovery of bladder 
function (Grau et al., 2004). 
Immunohistochemistry 
 For immunohistochemical analyses, spinal cord sections mounted on Superfrost 
Plus slides were washed (3 × 10 min) in phosphate-buffered saline (1X PBS), then 
incubated in blocking solution (3% normal goat serum, 0.1% Triton X-100 in 1X PBS) 
for 1 hour at room temperature. A total of three sets of slides were used (see Table 1) 
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Primary antibodies were diluted in blocking solution, applied to the slides, and allowed 
to incubate overnight at room temperature on an orbital at gentle speed. The following 
day, all slides were washed (3 × 10 min) in cold 1X PBS, and incubated in the 
appropriate Alexa fluor-conjugated secondary antibodies prepared in blocking solution 
for 2 hours at room temperature. After another series of washes in 1X PBS (3 × 10 min), 
the slides were mounted in Prolong Gold + DAPI antifading mounting medium (Life 
Technologies, NY, USA) and coverslipped.  
 To quantify immunofluorescence, images of spinal sections ± 600, 1200, 1800, 
and 2400 µm from the lesion center (rostral and caudal)  were captured using a Virtual 
Tissue 2D system in Stereo Investigator (MFB Bioscience, Williston, VT) at 4X 
magnification. The Virtual Tissue 2D program aligns, stitches, and blends the section 
together into a montage, providing a complete image of the total spinal section. Digital 
image analyses were performed using ImageJ Software (U. S. National Institutes of 
Health, Bethesda, Maryland, USA). Basic cell counting in ImageJ was used to quantify 
neurons. Fluorescence thresholds were set and background was subtracted from all 
images. The size and circularity of the target particles were defined and the counts 
generated by the program were recorded. Astrocyte and microglia/macrophage 
fluorescence was quantified using densiometric features in ImageJ. First, the perimeter 
of each section was digitally outlined. A threshold value was obtained for each image 
ensuring that all labeled cells were selected (i.e., target area). The magnitude of 
fluorescent expression was reported as integrated density, obtained by multiplying the 
“Integrated Density” by “Counts” generated by the program. 
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Table 1. List of antibodies used for immunohistochemistry. 
 
 
 
Table 2. List of antibodies used for flow cytometry. 
 
Primary Manufacturer Dilution Secondary Manufacturer Dilution Set 
NeuN (chicken) Abcam (Cambridge, UK) 1:500 Alexa Fluor 633 Abcam (Cambridge, UK) 1:500 1 
GFAP (chicken) Abcam (Cambridge, UK) 1:500 Alexa Fluor 633 Abcam (Cambridge, UK) 1:500 2 
OX-42 (mouse) Abcam (Cambridge, UK) 1:500 Alexa Fluor 633 Abcam (Cambridge, UK) 1:500 3 
Target Antibody Manufacturer Conj. Dye Dilution** Plate 
CD11b Anti-CD11b  Abcam (Cambridge, UK) Phycoerythrin 1:100 1, 2 
 Anti-Rat CD11/b/c eBioscience (San Diego, CA, USA) eFluor 660 1:100 3 
IBA1 Anti-Iba1  Abcam (Cambridge, UK) Alexa Fluor 647 1:100 1, 2 
 Anti-Iba1 Abcam (Cambridge, UK) FITC 1:200 3 
CD45 Anti-Rat CD45  eBioscience (San Diego, CA, USA) eFluor 450 3:100 1, 3 
CD86 Biotin anti-rat CD86 BioLegend (San Diego, CA, USA) * 2:100 1 
CD68 Anti-CD68 LifeSpan Biosciences (Seattle, WA, USA) FITC 9:400 1 
CD206 Macrophage Mannose Receptor 1 Antibodies-Online (Atlanta, GA, USA) * 2:100 2 
MOR Anti-μ-Opioid Receptor Alomone Labs (Jerusalem, Israel) ATTO-488 1:100 2 
KOR Anti-kappa Opioid Receptor Abcore (Ramona, CA, USA) Cy3 1:100 3 
      
*  Biotinylated antibody conjugated to PE/Cy7 Steptavidin (BioLegend, San Diego, CA, USA)       ** Per 150,000 cells in 200 μL of solution 
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Flow cytometry 
 Subjects were deeply anesthetized (100 mg/kg of beuthanasia, i.p.) and perfused 
intracardially with 100 ml of cold 1X PBS. A 1-cm-long segment of the spinal cord 
including the lesion center was collected, mechanically dissociated using a blade, 
washed in X-VIVO 15 (Lonza, Basel, Switzerland), and retrieved by centrifugation (300 
X G, 5 min, 4 degrees Celsius). The tissue was then enzymatically (Neural Dissociation 
Kit P, Miltenyi Biotec, Bergisch Gladbach, Germany) and mechanically dissociated. The 
cell suspension was washed in X-VIVO 15 and pelleted by centrifugation (300 X G, 10 
min, 4 degrees Celsius). The cell pellet was resuspended in 6 ml of X-VIVO 15, and 
applied to an Opti-Prep gradient. The gradient was composed of four 1-ml layers of 
Opti-prep diluted in X-VIVO 15, arranged in the following order (from bottom to top): 
35%, 25%, 20%, and 15%.  The 10 ml tube containing the cell suspension and gradient 
was centrifuged at 726 X G for 15 minutes at 20 degrees Celsius with low acceleration 
and no brake. Following centrifugation, the top 7 ml of solution, containing myelin and 
debris, was aspirated and discarded. The remaining 3 ml, containing a heterogeneous 
mixture of cells (including inflammatory cells, neurons, astrocytes, etc.), were filtered 
through a 30 μm strainer, washed twice in X-VIVO 15, and counted (Countess, Life 
Technologies, Carlsbad, CA, USA). The single-cell suspension was then pipetted into 
three 96-well plates and incubated with antibodies for the following markers: CD11b, 
IBA1, CD45, CD86, CD68, CD206, MOR, and KOR (see Table 2).  
 For each subject, 2 technical replicates were prepared and phenotyped using a 
FACSFortessa flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed with 
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FlowJo software (FlowJo, LLC, Ashland, OR, USA). 100,000 events were read per 
sample. The following gating strategy was used to identify cells of interest. “Live” cells 
were selected using forward and side scatter, which enabled the removal of dead cells 
and debris. To control for cellular autofluorescence, unstained samples were prepared. 
To be considered positive (+), cell populations were selected using a gate that contained 
<1% unstained cells. Microglia/macrophages were identified by selecting cells that were 
positive for both, CD11b and IBA1 markers. To differentiate between infiltrating 
macrophages and resident microglia, a CD45 marker was used. CD45+ cells were 
selected and further separated into discrete populations of high and low based on 
fluorescence intensity. For all further analysis (i.e. CD86/CD86, MOR/CD206, 
KOR/CD206), a quadrant system was created to determine phenotype and receptor 
expression.     
Statistical analysis 
The results were analyzed using analysis of variance (ANOVA). When main 
effects were found to be significant, the Bonferroni test was used for post-hoc analyses. 
Planned comparisons were also included in our assessment of the data when more than 
one drug treatment was used. These were performed in anticipation of dose-dependent 
effects of adjuvants on morphine’s efficacy, even in the absence of overall main effects. 
This also allowed for independent comparisons between morphine and vehicle-treated 
groups, regardless of the adjuvant or dose used. Lastly, in experiments with a continuous 
independent variable (e.g., recovery of locomotor function across days and histology), 
mixed-design ANOVAs were used.  
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Locomotor scores using the BBB scale were transformed, as previously 
described by our lab (Ferguson et al., 2004) to help assure that the data were amendable 
to parametric analyses. Briefly, this transformation removes a discontinuity in the scale, 
which justifies the use of parametric statistical analyses, and increases statistical power. 
Additional statistical power was also achieved by obtaining a measure of locomotor 
performance 24 h after injury, prior to drug treatment. Using day 1 as a covariate in an 
analysis of covariance (ANCOVA) substantially reduces unexplained variance and 
thereby increases statistical power. 
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CHAPTER III  
EVALUATION OF THE CLASSIC OPIOID RECEPTORS
*
 
 
Introduction 
As previously discussed in Chapter I, despite its clinical utility, morphine 
administered following SCI has been shown to produce a variety of unwanted side 
effects, including reduced functional recovery and increased paradoxical pain (Hook et 
al., 2007; Hook et al., 2009; Hook et al., 2011; Woller et al., 2014; Woller et al., 2012). 
These findings are alarming and suggest that morphine may be contraindicated in the 
days following trauma. However, without a viable alternative to opioids, simply 
abstaining from use of these potent analgesics is unfeasible. Instead, elucidating the 
mechanisms underlying the adverse effects of morphine and similar medications is 
imperative in order to ensure their safety and efficacy in the clinical setting. 
 Investigation of the molecular pathways underlying the effects of opioids must 
begin with the primary targets of these drugs- the classic opioid receptors. The  (mu)-
opioid receptor (MOR),  (delta)-opioid receptor (DOR), and  (kappa)-opioid receptor 
(KOR) are the key binding sites for endogenous and exogenous opioids, and are 
collectively known as the “classic opioid receptors.” Opioids differentially engage these 
                                                 
*
 Part of the data reported in this chapter is reprinted from Aceves, M., Mathai, B.B., & 
Hook, M.A. (2016). Evaluation of the effects of specific opioid receptor agonists in a 
rodent model of spinal cord injury. Spinal Cord, 54(10), 767-777 (Copyright 2016 by the 
authors) and Aceves, M., Bancroft, E.A., Aceves, A.R., & Hook, M.A. (2017). Nor-
Binaltorphimine blocks the adverse effects of morphine after spinal cord injury. Journal 
of Neurotrauma, 34(6), 1164-1174 (Copyright 2017 by Mary Ann Liebert, Inc.). 
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receptors, resulting in varied positive and negative effects. Although the mechanism(s) 
of action of morphine and other opioids at these classic receptors has been well 
described, there is a lack of research looking at the effects of these drugs in the 
pathophysiological context of an injury. Indeed, the research outlined below suggests 
that the adverse effects of morphine following SCI may depend on classic opioid 
receptor signaling. 
 Morphine binds to the MOR with high affinity, but also binds with lower affinity 
to the DOR and KOR (Kristensen et al., 1994). Morphine may exert its adverse effects 
through any of these receptor systems. For example, whereas activation of the MOR is 
typically associated with analgesia, binding of morphine to the MOR is also thought to 
initiate G-protein mediated protein kinase C (PKC) translocation and activation, 
promoting the removal of the NMDA receptor Mg
+
 plug and allowing Ca
2+
 influx (L. 
Chen & Huang, 1992; L. Chen & Marine, 1991). Chronic morphine exposure is also 
associated with down regulation of glutamate transporters, directly contributing to the 
heightened activity of NMDA receptors (Mao et al., 2002a; L. Yang et al., 2008). In this 
way, morphine may act through the MOR to potentiate NMDA receptor activation, 
maintaining central sensitization and hyperalgesia in the neural system, and leading to 
excitotoxic cell death (Mao et al., 2002b; Woolf & Thompson, 1991).  
 The KOR system has also been implicated in detrimental effects following 
trauma. For example, Faden and colleagues showed that dynorphin, the endogenous 
ligand of the KOR, and dynorphin-related peptides induce paraplegia even when 
administered to the intact spinal cord (Faden & Jacobs, 1983; Herman & Goldstein, 
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1985). Prodynorphin mRNA expression and dynorphin immunoreactivity are also 
significantly elevated in the spinal cord following trauma, and correlate with injury 
severity and neurological dysfunction (Cox et al., 1985; Faden et al., 1985a; Faden et al., 
1985b; Przewłocki et al., 1988; Tachibana et al., 1998). Importantly, administration of 
intrathecal dynorphin exacerbates functional deficits after SCI, whereas treatment with 
dynorphin antiserum improves outcome after trauma (Faden, 1990). These data strongly 
suggest that the adverse effects of morphine following SCI may be mediated by the 
KOR system. 
 Based on the extant literature, the following experiments evaluated the 
contribution of MOR and KOR activation to the morphine-induced attenuation of 
function observed following experimental SCI (due to a lack of evidence supporting a 
detrimental role of DOR activation, this receptor system was not assessed). In order to 
more clearly dissociate the beneficial (analgesic) and deleterious consequences of 
morphine treatment, these opioid receptor systems were probed using selective opioid 
receptor agonists and antagonists. The data presented here support a role for the KOR, 
but not the MOR, in the adverse effects of morphine administration following SCI.  The 
results indicate increased involvement of the spinal KOR system in attenuated functional 
recovery, increased paradoxical pain, and decreased tissue sparing at the lesion site 
following injury.  
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Methods and results 
The μ-opioid receptor system 
Exp. 1A Sufficiency of MOR activation 
 In this experiment I used the highly selective MOR agonist DAMGO to assess 
the contribution of the MOR system to the morphine-induced attenuation of function 
after SCI. To test whether selective activation of MORs is sufficient to reproduce the 
adverse effects of morphine following spinal injury, DAMGO was dissolved in distilled 
water (filtered 0.9% saline was used as the vehicle control) and administered via an 
intrathecal route, as described in Chapter II General Methodology. Three DAMGO doses 
were tested (0, 0.04, and 0.32 μmol). With an n=8 per group, this experimental design 
used a total of 24 rats. 
Analgesic efficacy of DAMGO 
 Sensory function was evaluated, using the tail-flick test, to establish baseline 
thermal reactivity thresholds. Prior to treatment, tail-flick scores (± S.E.M.) ranged from 
4.43 ± 0.26 s to 4.73 ± 0.52 s. There were no significant differences between the groups 
at this time point (F (2, 21) = 0.10, p > 0.05; data not shown). An ANOVA on post-
treatment scores, however, revealed a significant main effect of DAMGO on tail-flick 
latency (F (2, 21) = 44.30, p < 0.05). As shown in Figure 2, both groups receiving 
DAMGO had increased tail-flick latencies relative to vehicle-treated controls. At the 
highest dose (0.32 μmol), subjects displayed maximal tail-flick latencies (the test was 
automatically terminated at 8 seconds to prevent tissue injury). 
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Figure 2: Analgesic efficacy of DAMGO.  The results of the tail-flick test of thermal 
reactivity are depicted. DAMGO administration significantly increased tail-flick 
latencies relative to vehicle-treated controls. Results are shown as Mean ± S.E.M. *p < 
0.05 for post-hoc tests. 
 
 
Effects of DAMGO on locomotor recovery 
As can be seen in Figure 3, administration of DAMGO did not significantly 
affect recovery of locomotor function at any of the doses tested. Mean converted BBB 
scores (± S.E.M.) on day 1 ranged from 2.13 ± 0.36 to 2.25 ± 0.39. Statistical analyses 
showed that locomotor scores did not differ across groups prior to drug treatment (F (2, 
21) = 0.03, p > 0.05). A mixed-design ANOVA also showed that there were no 
significant group differences across the recovery period (F (2, 21) = 1.17, p > 0.05). 
Motor recovery was further evaluated at the end of the 21-day recovery period using the 
tapered beam and ladder walk tests (Figure 4). Treatment with DAMGO did not have a 
significant effect on either beam (F (2, 21) = 0.60, p > 0.05) or ladder performance (F (2, 
21) = 1.56, p > 0.05). 
  
 
40 
 
 
Figure 3: Effects of DAMGO on locomotor recovery.  Subjects were monitored for 21 
days following a moderate contusion SCI. Intrathecal administration of DAMGO, on day 
1 post-injury, did not affect locomotor recovery. Results shown as Mean ± S.E.M.  
 
 
 
 
 
 
 
Figure 4: Effects of DAMGO on beam and ladder walk performance.  At the end of the 
21-day recovery period, locomotor recovery was further assessed using the tapered beam 
(A) and ladder walk (B) tests. DAMGO had no effect on the performance of these tests. 
Results shown as Mean ± S.E.M.  
 
  
 
41 
 
Figure 5: Effects of DAMGO on sensory reactivity.  At the end of the 21-day recovery 
period, sensory reactivity was assessed using the tail-flick (A), girdle (B), and von Frey 
(C, D) tests. A single dose of DAMGO did not affect long-term pain reactivity. Results 
shown as Mean ± S.E.M.  
 
 
 
Effects of DAMGO on sensory reactivity 
Sensory function was assessed at the end of the 21-day recovery period using the 
tail-flick, von Frey, and girdle tests (Figure 5). DAMGO did not have a significant effect 
on thermal reactivity (F (2, 21) = 0.57, p > 0.05) assessed with the tail-flick test. 
Furthermore, there were no effects of DAMGO on motor (F (2, 21) = 2.51, p > 0.05) or 
vocal reactivity (F (2, 21) = 1.87, p > 0.05) to a mechanical stimulus applied to the 
hindpaws. An ANOVA, however, revealed a main effect of drug dose on the girdle test 
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(F (2, 21) = 4.20, p < 0.05), with vehicle controls showing more reactivity to at-level 
stimulation than either the 0.04 μmol or 0.32 μmol groups. This difference, however, 
was based on a comparison of 1.7% vocalizations by the vehicle controls, to zero 
vocalizations by the 0.04 and 0.32 μmol groups, and thus may not be functionally 
significant. 
Effects of DAMGO on general health 
Weight was monitored as an index of general health. Immediately before injury, 
weight did not differ across groups (F (2, 21) = 2.49, p > 0.05; data not shown). To 
assess changes in weight across recovery, the daily % weight loss was calculated by 
subtracting the starting weight (weight at the day of surgery) from daily weight. A 
repeated-measures ANOVA on daily % weight loss values showed that there was no 
significant effect of DAMGO (F (2, 21) = 0.30, p > 0.05). As shown in Figure 6, all 
groups lost weight following SCI, and slowly regained it throughout the recovery period.  
 In addition to weight, mortalities, autophagia, spastic hypertonia, and recovery of 
bladder control were also recorded to assess general health. There were no mortalities or 
cases of spastic hypertonia observed in any of the treatment groups. Only one subject 
(treated with 0.32 μmol DAMGO) showed signs of autophagia, and only one completely 
recovered bladder function (treated with vehicle). 
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Figure 6: Effects of DAMGO on weight change across recovery.  This graph depicts the 
daily % weight loss across the 21-day recovery period, calculated by subtracting starting 
weight from daily weight. DAMGO did not affect weight loss, or other signs of general 
health, following SCI. Results shown as Mean ± S.E.M.  
 
 
 
Exp. 1B Necessity of MOR activation 
In this experiment I used the highly selective MOR antagonist CTOP to assess 
the necessity of MOR activation in the morphine-induced attenuation of function after 
SCI. To test whether inactivation of MORs blocks the adverse effects of morphine 
following SCI, subjects were pretreated with intrathecal CTOP (0 or 10 μg dissolved in 
distilled water). One hour later, half of the subjects in each dose group were treated with 
90 μg of morphine and the remaining subjects were treated with vehicle (0.09% saline). 
The 1 hr waiting period between CTOP and morphine administration was chosen based 
on previous studies that demonstrate that CTOP binding in rat brain tissue reaches a 
steady state 30 to 90 minutes post-administration (Hawkins et al., 1989). This 2 X 2 
experimental design (4 groups) used a total of 40 rats (n=10). 
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Effects of CTOP on the analgesic efficacy of morphine 
Sensory function was evaluated using the tail-flick test to establish baseline 
thermal reactivity thresholds. Prior to treatment, tail-flick scores (± S.E.M.) ranged from 
3.06 ±0.31 s to 4.00 ±0.34 s. Statistical analyses showed that there were no significant 
differences between the groups at this time point (F (3, 35) = 2.16, p > 0.05; data not 
shown). Post-treatment, a two-factor ANOVA revealed significant main effects of 
morphine (F (1, 35) = 73.36, p < 0.05) and CTOP treatment (F (1, 35) = 6.51, p < 0.05), 
as well as a significant morphine X CTOP interaction (F (1, 35) = 4.97, p < 0.05) on tail-
flick latency. As shown in Figure 7, both groups receiving morphine showed 
significantly increased tail-flick latencies compared to saline controls. Pre-treatment 
with 10 μg CTOP significantly decreased the analgesic effects of morphine (p < 0.05).  
Effects of CTOP on locomotor recovery 
 In addition to the effects on analgesia, I wanted to assess whether MOR 
activation was necessary to induce the morphine-induced attenuation of locomotor 
recovery. To address this, CTOP was administered as an adjuvant to morphine treatment 
24 hours following SCI, and locomotor recovery was monitored for a 21-day period. 
Locomotor scores collected before treatment on day 1 did not differ significantly across 
groups (F (3, 36) = 0.32, p > 0.05). Mean converted BBB scores (± S.E.M.) on day 1 
ranged from 1.75 ± 0.26 to 2.20 ± 0.49. 
  
 
45 
  
 
Figure 7: Effects of CTOP on the analgesic efficacy of morphine.  The analgesic efficacy 
of morphine challenged with CTOP pre-treatment is depicted for the test of thermal 
reactivity. At both doses (0 and 10 μg), subjects that received morphine had significantly 
increased tail-flick latencies relative to saline controls. However, morphine’s analgesic 
effects decreased with CTOP pre-treatment. Results shown as Mean ± S.E.M. * p < 0.05 
for post-hoc tests; # p < 0.05 for planned comparisons; M = significant main effect of 
morphine. 
 
 
 
Converted BBB scores across recovery were analyzed using a mixed-design 
ANCOVA (with day 1 scores as a covariate). There was a significant main effect of 
morphine treatment on locomotor recovery (F (1, 35) = 12.71, p < 0.05), but no effect of 
CTOP (F (1, 35) = 0.31, p > 0.05) and no significant interaction between morphine and 
CTOP (F (1, 35) = 1.13, p > 0.05). As shown in Figure 8, subjects that received 
morphine had lower converted BBB scores throughout recovery irrespective of CTOP 
treatment. Planned comparisons confirmed that control subjects (0 μg CTOP) treated 
with morphine showed significantly reduced locomotor recovery when compared to their 
saline-treated counterparts (p < 0.05), replicating our previous studies (Hook et al., 2009; 
Hook et al., 2011). At the 10 μg dose, the difference between morphine and saline 
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treatment only approached significance (p = 0.07). The 10 μg CTOP + morphine group, 
however, showed significantly lower locomotor scores across recovery when compared 
to the control subjects not treated with CTOP (p < 0.05).  
 
 
Figure 8: Effects of CTOP on locomotor recovery.  Morphine significantly undermined 
locomotor recovery following SCI across doses. Planned comparisons revealed 
significant differences between morphine and saline-treated subjects at the 0 μg dose of 
CTOP (A), but this effect did not reach significance with the 10 μg dose (B). Results 
shown as Mean ± S.E.M.  # p < 0.05 for planned comparisons; M = significant main 
effect of morphine. 
 
 
Motor recovery was further evaluated at the end of the 21-day recovery period 
using the tapered beam and ladder walk tests (Figure 9). Commensurate with the BBB 
assessments, I found a significant main effect of morphine on beam performance (F (1, 
36) = 5.88, p < 0.05), but no effect of CTOP (F (1, 36) = 1.94, p > 0.05) and no 
morphine X CTOP interaction (F (1, 36) = 1.25, p > 0.05). Interestingly, on this task, 
saline-treated subjects at the 10 μg dose of CTOP performed almost as poorly as 
morphine-treated animals. In the ladder walk test, morphine also significantly increased 
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the number of possible errors, indicating decreased locomotor function (F (1, 36) = 5.59, 
p < 0.05). As in the beam test, CTOP did not have a significant effect (F (1, 36) = 0.22, p 
> 0.05) and no interaction between the drug treatments was observed (F (1, 36) = 0.33, p 
> 0.05).  
 
 
Figure 9: Effects of CTOP on beam and ladder walk performance.  At the end of the 21-
day recovery period, locomotor recovery was further assessed using the tapered beam 
(A) and ladder walk (B) tests. Morphine significantly undermined performance in both 
tests. There was no effect of CTOP on the performance of either task. Results shown as 
Mean ± S.E.M. # p < 0.05 for planned comparisons; M = significant main effect of 
morphine. 
 
 
 
Effects of CTOP on sensory reactivity 
Long-term effects on sensory function were assessed at the end of the 21-day 
recovery period using the tail-flick, von Frey, and girdle tests (Figure 10). There was no 
effect of morphine (F (1, 36) = 1.54, p > 0.05), CTOP (F (1, 36) = 0.09, p > 0.05), or a 
morphine CTOP interaction (F (1, 36) = 0.13, p > 0.05) on the test of thermal reactivity.  
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Figure 10: Effects of CTOP on sensory reactivity.  Drug treatment had no effect on the 
development of thermal hyperalgesia (A) or at-level allodynia (B). Mechanical reactivity 
of the hindpaws appeared to be affected by drug treatment, although this effect was only 
observed in vocal (D), but not motor (C), responses. Results shown as Mean ± S.E.M. *p 
< 0.05 for post-hoc tests; # p < 0.05 for planned comparisons; M = significant main 
effect of morphine. 
 
 
 
Similarly, I did not find any significant differences across the groups in our 
assessment of motor responses to von Frey stimulation. Analysis showed that there were 
no effects of morphine (F (1, 36) = 1.75, p > 0.05) or CTOP (F (1, 36) = 0.01, p > 0.05) 
treatment, and no interaction (F (1, 36) = 1.75, p > 0.05). On the other hand, drug 
treatment appeared to affect vocal responses to tactile stimulation of the hindpaws. A 
two-factor ANOVA on vocal responses revealed a significant main effect of morphine 
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treatment (F (1, 36) = 5.27, p < 0.05) and a significant interaction between morphine and 
CTOP (F (1, 36) = 5.00, p < 0.05), but no main effect of CTOP administration (F (1, 36) 
= 2.24, p > 0.05). Unexpectedly, as shown in Figure 10, saline controls showed lower 
vocal thresholds in comparison to the other three treatment groups at 21 days post injury 
and treatment.  
Lastly, in the girdle test of at-level allodynia, I found no effect of morphine (F (1, 
36) = 1.75, p > 0.05) or CTOP (F (1, 36) = 0.01, p > 0.05), and no interaction effect with 
the two drug treatments (F (1, 36) = 1.75, p > 0.05).  
Effects of CTOP on general health 
Weight immediately before injury did not differ across groups (F (3, 36) = 0.57, 
p > 0.05; data not shown). However, a repeated-measures ANOVA on daily % weight 
loss values revealed a significant main effect of morphine treatment (F (1, 36) = 7.41, p 
< 0.05) and a significant morphine X CTOP interaction (F (1, 36) = 5.20, p < 0.05), with 
no effect of CTOP alone (F (1, 36) = 0.80, p > 0.05).  As shown in Figure 11, morphine-
treated subjects lost more weight than their saline-treated counterparts. Interestingly, 
CTOP administration appeared to augment weight loss in saline-treated animals, which 
lost significantly more weight across recovery than saline-treated animals not pre-treated 
with CTOP (p < 0.05).  
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Figure 11: Effects of CTOP on weight change across recovery.  The average daily % 
weight loss is depicted across the 21-day recovery period. Morphine significantly 
decreased weight across recovery. Results shown as Mean ± S.E.M. *p < 0.05 for post-
hoc tests; # p < 0.05 for planned comparisons; M = significant main effect of morphine. 
 
 
 In addition to weight, mortalities, autophagia, spastic hypertonia, and recovery of 
bladder control were also recorded to assess general health. There were no mortalities 
and no cases of autophagia. Furthermore, only one subject (in the 0 μg CTOP + 
morphine group) showed signs of spastic hypertonia. Recovery of bladder control was 
observed in 55% of our subjects, as early as 7 days post-injury. To assess the effect of 
drug treatment on bladder function, I compared the latency to recovery (days) across 
conditions. A two-factor ANOVA showed that there were no effects of morphine (F (1, 
36) = 0.02, p > 0.05), CTOP (F (1, 36) = 1.54, p > 0.05), or an interaction (F (1, 36) = 
0.38, p > 0.05) on the duration of neurogenic bladder symptoms.   
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The κ-opioid receptor system 
Exp. 2A Sufficiency of KOR activation 
In this experiment I used the highly selective KOR agonist GR89696 to assess 
the contribution of the KOR system to the morphine-induced attenuation of function 
after SCI. To test whether selective activation of KORs in the spinal cord following 
injury is sufficient to attenuate recovery, GR89696 was dissolved in 34% DMSO 
solution (34% DMSO solution was also used as the vehicle control) and administered via 
an intrathecal route, as described in Chapter II General Methodology. Four doses of 
GR89696 were tested (0, 0.01, 0.04, and 0.32 μmol). With an n=8 per group, this 
experimental design used a total of 32 rats.  
Analgesic efficacy of GR89696 
 Sensory function was evaluated using the tail-flick test to establish baseline 
thermal reactivity thresholds. Prior to treatment on day 1, tail-flick scores (± S.E.M.) 
ranged from 3.56 ± 0.27 s to 4.58 ± 0.17 s. Statistical analyses showed that there were no 
significant differences between the groups at this time point (F (3, 28) = 2.83, p > 0.05; 
data not shown). An ANOVA on post-treatment scores, however, revealed a significant 
main effect of GR89696 on tail-flick latency (F (3, 28) = 12.60, p < 0.05). As shown in 
Figure 12, groups receiving GR89696 had increased tail-flick latencies relative to 
vehicle-treated controls. There was a dose-dependent effect of GR89696 on the tail-flick 
response; at the highest dose of GR89696 (0.32 μmol) subjects displayed maximal 
latencies (8 seconds), an effect commensurate with morphine administration. 
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Figure 12: Analgesic efficacy of GR89696.  The results of the tail-flick test of thermal 
reactivity are depicted. GR89696 administration significantly increased tail-flick 
latencies relative to vehicle-treated controls. Results shown as Mean ± S.E.M. *p < 0.05 
for post-hoc tests. 
 
 
Effects of GR89696 on locomotor recovery 
 In contrast to DAMGO, administration of GR89696 in the acute phase of SCI 
undermined recovery of locomotor function at all doses tested (Figure 13). Locomotor 
scores collected before treatment on day 1 did not differ across groups (F (2, 21) = 0.40, 
p > 0.05). Mean converted BBB scores (± S.E.M.) ranged from 1.38 ± 0.25 to 1.94 ± 
0.53. There was no main effect of drug treatment (F (3, 27) = 2.00, p > 0.05) on 
locomotor recovery. However, using day 1 scores as a covariate, an ANCOVA revealed 
that there was a significant interaction between drug dose and BBB scores across the 21 
day recovery period (F (33, 297) = 1.86, p <0. 05). An ANOVA comparing locomotor 
function from Days 13-21, when locomotor performances had stabilized, revealed a 
main effect of dose on locomotor function (F (3, 28) = 3.01, p <0. 05). As can be seen in 
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Figure 13, subjects treated with GR89696, irrespective of dose, displayed significantly 
lower levels of locomotor recovery relative to vehicle-treated controls (p < 0.05).  
Vehicle-treated controls also performed better than GR89696-treated subjects on 
additional tests of motor recovery. As shown in Figure 14, vehicle-treated controls 
walked across the narrow edge of the tapered beam with more success than experimental 
subjects and made fewer errors when traversing a ladder. These differences, however, 
did not reach statistical significance on either the beam (F (3, 28) = 2.10, p > 0.05) or 
ladder walk tests (F (3, 28) = 1.83, p > 0.05).  
 
  
Figure 13: Effects of GR89696 on locomotor recovery.  Subjects were assessed for 21 
days following a moderate contusion SCI. Intrathecal administration of GR89696, on 
day 1 post-injury, undermined recovery of locomotor function at all doses tested (A). 
Results shown as Mean ± S.E.M. *p < 0.05 for post-hoc tests. 
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Figure 14: Effects of GR89696 on beam and ladder walk performance.  At the end of the 
21-day recovery period, motor recovery was further assessed using the tapered beam (A) 
and ladder walk (B) tests. Although administration of GR89696 appeared to worsen 
performance in these tasks, the effect did not reach statistical significance (p < 0.05). 
Results shown as Mean ± S.E.M.  
 
 
 
Effects of GR89696 on sensory reactivity 
At 21 days post injury and treatment, there was no effect of GR89696 on thermal 
reactivity (F (3, 28) = 2.77, p > 0.05), motor reactivity to tactile stimulation (F (3, 28) = 
2.49, p > 0.05) or at-level allodynia assessed with the girdle test (F (3, 28) = 0.29, p > 
0.05). However, as shown in Figure 15, ANOVAs uncovered significant differences for 
vocal reactivity to tactile stimulation of the hindpaws across doses (F (3, 28) = 2.95, p < 
0.05), with subjects in the 0.01 μmol group showing decreased reactivity thresholds 
when compared with subjects in the 0.32 μmol and control groups. 
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Figure 15: Effects of GR89696 on sensory reactivity.  At the end of the 21-day recovery 
period, no effect of GR89696 on sensory reactivity was observed using the tail-flick (A), 
girdle (B), and von Frey test for motor responses (C). However, vocal responses to 
tactile stimulation were affected by dose (D). Results shown as Mean ± S.E.M. *p < 0.05 
for post-hoc tests. 
 
 
Effects of GR89696 on general health 
As in previous experiments, weight was monitored as an index of general health. 
Weight immediately before injury did not differ across groups (F (3, 28) = 0.32, p > 
0.05; data not shown). All subjects showed decreased weight early after injury, which 
was slowly regained over time (Figure 16). A repeated-measures ANOVA on daily % 
weight loss values revealed no significant effect of GR89696 treatment on weight loss (F 
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(3, 28) = 1.17, p > 0.05). Furthermore, there were no significant effects of drug treatment 
on recovery of bladder control F (3, 28) = 0.43, p > 0.05; data not shown). Mortality was 
also unaffected, with only one death recorded in the vehicle group, and one in the 0.32 
μmol group. Only one case of spastic hypertonia was observed (0.01 μmol group) for the 
entire experiment. Finally, although I observed a dose-dependent increase in autophagia, 
this was not a statistically significant effect (χ2= 7.38, p > 0.05; data not shown). 
 
 
Figure 16: Effects of GR89696 on weight change across recovery.  This graph depicts 
the daily % weight loss across the 21-day recovery period, calculated by subtracting 
starting weight from daily weight. GR89696 did not affect weight change, or other signs 
of general health, following SCI. Results shown as Mean ± S.E.M.  
 
 
Effects of GR89696 on tissue sparing at the site of injury 
 Since GR89696 administration had a significant impact on locomotor recovery, I 
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lowest (0.01 μmol) and the highest (0.32 μmol) dose groups were further assessed using 
histology.  Spinal tissue was subdivided into rostral (1800 – 600 μm), center (0 μm), and 
caudal (-1800 – -2400 μm) segments. Four measures were analyzed: residual white 
matter, residual gray matter, tissue damage, and relative lesion (damage + missing 
tissue). There were no effects of drug dose on any of the histological measures at the 
center of the lesion (Figure 17). Similarly, there were no significant effects rostral to the 
lesion, although a main effect of drug dose on residual gray matter approached 
significance (F (2, 17) = 2.99, p = 0.077). Caudally, however, I found a significant main 
effect of dose on residual gray matter (F (2, 15) = 5.74, p < 0.05). Post-hoc analyses 
revealed that subjects in the 0.01 μmol group had significantly less spared gray matter 
than subjects treated with vehicle. A main effect of drug dose also approached, but did 
not reach, significance for the measure of tissue damage caudal to the injury site (F (2, 
15) = 2.98, p = 0.08). There were no significant effects on residual white matter at this 
level of the spinal cord. 
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Figure 17: Effects of GR89696 on tissue sparing at the site of injury.  At the end of the 
experiment, subjects were perfused and tissue was collected for histological analyses. 
The dose-dependent effects of GR89696 on lesion size (relative lesion), damage, 
residual gray matter and residual white matter are depicted. A single 0.01 μmol dose of 
GR89696, administered in the acute phase of SCI, significantly decreased the amount of 
spared gray matter caudal to the injury center in comparison with vehicle-treated 
controls. Results shown as Mean ± S.E.M. *p < 0.05 for post-hoc tests. 
 
 
Exp. 2B Necessity of KOR activation 
In this experiment I used the highly selective KOR antagonist nor-
Binaltorphimine (norBNI) to assess the necessity of KOR activation to the morphine-
induced attenuation of function after SCI. To test whether antagonism of KORs blocks 
the adverse effects of morphine, subjects were pretreated with intrathecal norBNI (0, 
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subjects in each dose group were treated with 90 μg of morphine and the remaining 
subjects were treated with vehicle (0.09% saline). The 2 hr waiting period between 
norBNI and morphine administration was chosen to account for the slow-onset of 
norBNI antagonistic action at the KOR, which reaches a plateau at 2 hr in vivo (Endoh et 
al., 1991). This 4 X 2 experimental design (8 groups) used a total of 100 rats (n=12 for 
doses 0.02, 0.08, 0.32 μmol norBNI; n=14 for dose 0 μmol norBNI).  
Effects of norBNI on the analgesic efficacy of morphine 
Sensory function was evaluated using the tail-flick test to establish baseline 
thermal reactivity thresholds. Prior to treatment, tail-flick scores (± S.E.M.) on day 1 
ranged from 3.79 ±0.21 s to 4.31 ±0.20 s. Statistical analyses showed that there were no 
significant differences between the groups at this time point (F (7, 91) = 1.04, p > 0.05; 
data not shown). A two-factor ANOVA on post-treatment scores, however, revealed 
significant main effects of morphine (F (1, 91) = 193.97, p < 0.05) and norBNI treatment 
(F (3, 91) = 5.52, p < 0.05), and a significant interaction (F (3, 91) = 6.57, p < 0.05) on 
tail-flick latency. As shown in Figure 18, all groups that received morphine had 
increased tail-flick latencies relative to controls. NorBNI, however, decreased the 
analgesic effects of morphine, with a significant linear reduction in efficacy across 
increasing doses (F (1, 46) = 21.03, p < 0.05). Whereas rats that received morphine 
alone displayed maximal latencies (the test was automatically terminated at 8 seconds to 
prevent tissue injury), those pretreated with the highest dose of norBNI (0.32 μmol) had 
a mean tail-flick latency of 5.83 ± 0.40 seconds.  
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Figure 18: Effects of norBNI on the analgesic efficacy of morphine.  The analgesic 
efficacy of morphine challenged with norBNI pre-treatment is depicted for the test of 
thermal reactivity. All groups that received morphine had significantly increased tail-
flick latencies relative to vehicle-treated controls. However, morphine’s analgesic effects 
decreased with increasing doses of norBNI. Results shown as Mean ± S.E.M. *p < 0.05 
for post-hoc tests; # p < 0.05 for planned comparisons; M = significant main effect of 
morphine. 
 
 
 
Effects of norBNI on locomotor recovery 
In addition to the effects on analgesia, I wanted to assess whether KOR 
activation was necessary to induce the morphine-induced attenuation of locomotor 
recovery (Hook et al., 2007; Hook et al., 2009; Hook et al., 2011; Woller et al., 2014; 
Woller et al., 2012). To address this, norBNI was administered as an adjuvant to 
morphine treatment 24 hours following SCI, and locomotor recovery was monitored for 
a 21-day period. Locomotor scores collected before treatment on day 1 did not differ 
significantly across groups (F (7, 92) = 0.01, p > 0.05). Mean converted BBB scores (± 
S.E.M.) on day 1 ranged from 1.61 ± 0.26 to 1.88 ± 0.33. A mixed-design ANCOVA 
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using day 1 scores as a covariate did not find significant main effects of morphine (F (1, 
91) = 1.85, p < 0.05) or norBNI treatment (F (3, 91) = 1.83, p > 0.05). An interaction 
approached, but did not reach, significance (F (3, 91) = 2.30, p = 0.083). However, as 
shown in Figure 19, planned comparisons revealed that control rats (0 μmol of norBNI) 
treated with morphine showed significantly reduced locomotor recovery when compared 
to their vehicle-treated counterparts (F (1, 25) = 4.96, p < 0.05), replicating our previous 
studies (Hook et al., 2009; Hook et al., 2011). Morphine and vehicle groups also differed 
significantly at the lowest dose (0.02 μmol) of norBNI (F (1, 21) = 5.78, p < 0.05). In 
contrast, there were no differences between morphine- and vehicle-treated rats at the 
0.08 μmol (F (1, 21) = 0.46, p > 0.05) or 0.32 μmol (F (1, 21) = 0.17, p > 0.05) doses of 
norBNI. This suggests that- although morphine and vehicle groups recovered equally 
when higher doses (0.08 and 0.32 μmol) of norBNI were used- lower doses of norBNI 
were not able to block the morphine-induced attenuation of locomotor recovery.  
Motor recovery was further evaluated at the end of the 21-day recovery period 
using the tapered beam and ladder walk tests. Although we observed that morphine-
treated rats at the higher doses of norBNI showed better performance on the tapered 
beam test than those receiving the lower doses (Figure 20), statistical analysis did not 
confirm significant main effects of norBNI (F (3, 92) = 1.17, p > 0.05) or morphine (F 
(1, 92) = 1.62, p > 0.05) treatment, and no interaction (F (3, 92) = 1.31, p > 0.05). In the 
ladder walk test, I found a significant main effect of norBNI (F (3, 92) = 3.39, p < 0.05). 
Post-hoc analysis showed that rats in the 0.08 μmol dose performed better than rats not 
  
 
62 
treated with norBNI. However, I did not find an effect of morphine treatment (F (1, 92) 
= 0.60, p > 0.05) or a significant interaction (F (3, 92) = 1.11, p > 0.05).  
 
 
Figure 19: Effects of norBNI on locomotor recovery.  NorBNI pretreatment blocked the 
adverse effects of morphine on long-term recovery of locomotor function. Morphine 
undermined recovery of locomotor function in the absence of norBNI (A) and at a dose 
of 0.02 μmol norBNI (B). Pretreatment with 0.08 (C) or 0.32 (D) μmol norBNI, 
however, prevented the morphine-induced attenuation of locomotor recovery. Results 
shown as Mean ± S.E.M.  # p < 0.05 for planned comparisons. 
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Figure 20: Effects of norBNI on beam and ladder walk performance.  NorBNI improved 
motor performance on the ladder walk test conducted 21-days after injury. While there 
were no significant effects of morphine or norBNI on the tapered beam test (A), norBNI 
significantly improved performance on the ladder walk test (B). Results shown as Mean 
± S.E.M. *p < 0.05 for post-hoc tests. 
 
 
 
Effects of norBNI on sensory reactivity 
Long-term effects on sensory function were assessed at the end of the 21-day 
recovery period using the tail-flick, von Frey, and girdle tests. In the tail-flick test, mean 
latencies (± S.E.M.) ranged from 3.41 ± 0.26 to 4.68 ± 0.26 seconds. Although I did not 
find an effect of morphine (F (1, 92) = 0.95, p > 0.05) or an interaction (F (3, 92) = 2.05, 
p > 0.05), statistical analyses revealed a significant main effect of norBNI treatment (F 
(3, 91) = 2.95, p < 0.05) on thermal reactivity after day 21. As shown in Figure 21, 
norBNI improved tail-flick latency. In effect, post-hoc tests showed that rats treated with 
the highest dose of norBNI (0.32 μmol) had significantly higher reactivity thresholds 
than those that did not receive norBNI treatment (0.00 μmol).  
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Figure 21: Effects of norBNI on sensory reactivity.  There were significant effects of 
norBNI pre-treatment on the long-term recovery of sensory function. At the end of the 
21-day recovery period, there was a significant main effect of norBNI on thermal 
reactivity (A). NorBNI decreased thermal reactivity relative to subjects that were not 
given norBNI. By contrast, on the girdle test of at-level allodynia, there was a significant 
interaction between norBNI and morphine treatment (B); norBNI appeared to increase 
reactivity in subjects that were not treated with morphine. As found on the test of 
thermal reactivity, both morphine and norBNI decreased motor (C) and vocal responses 
(D) responses to tactile stimulation at day 21 post-injury. Results shown as Mean ± 
S.E.M. *p < 0.05 for post-hoc tests; # p < 0.05 for planned comparisons; M = significant 
main effect of morphine. 
 
 
Mechanical reactivity of the hindpaws tested at the end of the recovery period 
appeared to decrease with higher doses of norBNI. A two-factor ANOVA on motor 
thresholds uncovered significant main effects of morphine (F (1, 91) = 14.82, p < 0.05) 
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and norBNI (F (3, 91) = 8.58, p < 0.05), but an interaction only approached significance 
(F (3, 91) = 2.47, p = 0.067). Across norBNI groups, rats treated with higher doses of 
norBNI showed increased mechanical thresholds. Rats that did not receive norBNI 
showed the most reactivity to tactile stimulation, and significantly differed from those in 
the 0.02 μmol and 0.32 μmol groups. On the other hand, rats treated with the highest 
dose of norBNI (0.32 μmol) showed the least reactivity in this test. Surprisingly, overall, 
vehicle-treated rats had significantly lower motor thresholds than morphine-treated 
animals (p < 0.05). Similarly, a significant main effect of morphine treatment on vocal 
thresholds to von Frey stimulation (F (1, 91) = 6.10, p < 0.05) supported the observation 
that vehicle-treated rats exhibited more symptoms of mechanical hyperalgesia in the 
long term. An effect of norBNI treatment approached but did not reach significance (F 
(3, 92) = 2.55, p = 0.06), and no interaction was observed (F (3, 92) = 0.88, p > 0.05). 
Together, the motor and vocal responses obtained in the von Frey test of mechanical 
reactivity suggest that morphine treatment in combination with norBNI, may reduce pain 
and prevent the development of allodynia following SCI.  
Lastly, in the girdle test of at-level allodynia, I did not find main effects of 
norBNI (F (3, 92) = 2.48, p > 0.05) or morphine (F (1, 92) = 2.15, p > 0.05), but there 
was a significant interaction between the two treatments (F (3, 91) = 4.37, p < 0.05). As 
depicted in Figure 21, vocal responses to at-level stimulation decreased with escalating 
norBNI doses for morphine-treated rats. On the other hand, higher doses of norBNI 
appeared to exacerbate allodynia in vehicle-treated controls, shown by a steady increase 
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in vocalization. At the highest dose tested (0.32 μmol), vehicle-treated rats vocalized 
approximately 24% of the time, compared to 3% in morphine-treated rats. 
Effects of norBNI on general health 
As in the previous experiments, weight was monitored throughout recovery as an 
index of general health. Weight immediately before injury differed across groups (F (7, 
90) = 2.96, p < 0.05; data not shown). Starting weight (± S.E.M.) across dose groups 
were the following: for 0 μmol norBNI, 358.14±7.95 g for saline-treated subjects and 
348.79 ±5.99 g for those treated with morphine; for 0.02 μmol norBNI, 348.25±4.25 g 
for saline and 336.36±3.88 g for morphine; for 0.08 μmol norBNI, 329.58±5.04 g for 
saline and 342.00±4.74 g for morphine; and for 0.32 μmol norBNI, 331.60±3.93 g for 
saline and 341.58±3.53 g for morphine. To assess changes in weight across recovery 
taking into account initial differences, the daily % weight loss was calculated by 
subtracting the starting weight (weight on the day of surgery) from daily weight. A 
repeated-measures ANOVA on daily % weight loss values revealed that weight across 
recovery was unaffected by morphine (F (1, 90) = 0.48, p > 0.05) or norBNI 
administration (F (3, 90) = 1.57, p > 0.05), with no significant interaction (F (3, 90) = 
1.34, p > 0.05).  As shown in Figure 22, weight change across recovery was virtually the 
same for morphine- and saline-treated subjects at all doses of norBNI. Subjects not 
treated with norBNI, however, showed significantly attenuated weight gain after injury if 
treated with morphine (F (1, 26) = 5.55, p < 0.05). This suggests that norBNI treatment, 
aside from blocking morphine-induced attenuation of locomotor recovery, also had 
protective effects on general health following SCI. 
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Figure 22: Effects of norBNI on weight change across recovery.  Weight loss was 
unaffected by morphine or norBNI treatment.  Results shown as Mean ± S.E.M. # p < 
0.05 for planned comparisons. 
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the entire experiment, only one rat had to be replaced due to mortality (treated with 0.02 
μmol norBNI and morphine).  Three rats exhibited mild autophagia, which resolved 
rapidly with treatment and did not require removal from the study (all were in the 0.02 
μmol group; one treated with vehicle, and two with morphine). Lastly, four rats 
developed spastic hypertonia during the recovery period (two in the 0.08 μmol group, 
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and one each in the 0 and 0.02 μmol groups, and all received morphine). No other 
complications were observed. 
Effects of norBNI on tissue sparing at the site of injury 
 To assess whether the effects of the high doses of norBNI on locomotor function 
were the result of increased neuroprotection, I assessed the amount of tissue sparing in 
the spinal cord at the end of the recovery period. Spinal tissue was subdivided into 
rostral (2400 – 600 μm), center (0 μm), and caudal (-600 – -2400 μm) segments.  Four 
measures were analyzed: relative lesion size (damage + missing tissue), tissue damage, 
residual gray matter, and residual white matter.  
 There were no significant main effects of norBNI or morphine treatment on 
relative lesion size across the extent of the spinal cord (Figure 23). Planned comparisons, 
however, revealed a significant difference between vehicle and morphine-treated rats 
without norBNI pre-treatment at the center of the lesion (p < 0.05). Morphine-treated 
rats had increased damage at the injury center, with a mean lesion size (± S.E.M.) of 
3.12 ± 0.26 mm
2
 compared to 2.39 ± 0.23 μm2 for vehicle controls. Similarly, no main 
effects on damage were observed, although rostral to the injury planned comparisons 
showed that a difference between vehicle and morphine rats at the 0 μmol dose of 
norBNI approached significance (p = 0.066).  
 None of the groups differed on the percentage of residual gray matter at any level 
of the spinal cord. However, for residual white matter, the treatment groups showed 
extensive differences in the center and rostral segments. I found a significant main effect 
of morphine treatment at the center of the lesion (F (1, 56) = 3.94, p < 0.05), with 
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morphine-treated rats showing less residual white matter than their vehicle-treated 
counterparts, irrespective of norBNI.  Planned comparisons also uncovered a significant 
difference between vehicle and morphine controls (0 μmol norBNI) at this level (2.48 ± 
0.12 mm
2 
and 1.86 ± 0.12 mm
2
 respectively). Rostral to the injury site, the effects on 
residual white matter appeared to be the result of a significant interaction between 
norBNI and morphine treatment (F (3, 56) = 3.75, p < 0.05). At the lower doses of 
norBNI (0 and 0.02 μmol), morphine-treated rats lost more white matter than vehicle-
treated rats, and these differences reached statistical significance (p < 0.05). At the 0 
μmol dose, residual white matter was 3.39 ± 0.10 mm2 for the vehicle group, and 3.02 ± 
0.21 mm
2
 for the morphine group. At 0.02 μmol, 3.21 ± 0.20 mm2 for vehicle, and 2.84 
± 0.25 mm
2 for morphine. Lastly, at the 0.08 μmol dose, a difference between morphine 
and vehicle groups approached, but did not reach significance (p = 0.073), and no 
differences were found at the 0.32 μmol dose (p = 0.98).   
 
 
 
 
 
 
 
Figure 23: Effects of norBNI on tissue sparing at the site of injury.  As found in previous 
studies, morphine increased the percent relative lesion at the injury center (0 μm) relative 
to vehicle treated controls. This effect was not present in morphine-treated subjects that 
were pre-treated with norBNI. There were no main effects of morphine or norBNI on 
relative lesion size (A), tissue damage (B), or residual gray matter (C). However, 
residual white matter was significantly affected by morphine treatment at the center of 
the lesion, and there was a significant interaction between norBNI and morphine 
treatment rostral to the injury site (D). Morphine decreased the residual white matter at 
the center of the lesion, but in the rostral segment, norBNI pre-treatment at higher doses 
blocked the adverse effects of morphine on white matter sparing. Results shown as Mean 
± S.E.M. # p < 0.05 for planned comparisons; M = significant main effect of morphine. 
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Discussion 
The experiments presented here evaluated the contributions of the MOR and 
KOR systems to the morphine-induced attenuation of function following SCI. First, I 
assessed the contribution of the MOR system using the selective agonist DAMGO. At 
doses commensurate with an effective dose of morphine, DAMGO produced robust 
analgesia in tests of thermal and mechanical reactivity, without producing any adverse 
effects on recovery (Experiment 1.A). To further explore the role of the MOR following 
SCI, I challenged morphine treatment with the highly-selective antagonist CTOP 
(Experiment 1.B). At 10 times the inhibitory constant, 10 μg of CTOP reduced, but did 
not completely block, the analgesic effects of morphine. Similarly, CTOP did not 
effectively block the adverse effects of morphine. Instead of improving recovery for 
morphine-treated subjects, CTOP alone appeared to impair recovery of function.  
 Next, I used a similar approach to assess the contribution of the KOR system 
following SCI. Despite its analgesic efficacy, treatment with the selective KOR-agonist 
GR89696 significantly undermined recovery of locomotor function, increased 
mechanical reactivity, and decreased gray matter sparing after SCI (Experiment 2.A). In 
fact, the lowest dose of GR89696 replicated the negative side effects associated with 
morphine treatment in our previous studies (Hook et al., 2009; Hook et al., 2011)-  even 
at a dose 32 times lower than the 0.32 μmol (90 μg) dose of morphine. Further 
supporting a role of KOR activation in the morphine-induced attenuation of function, 
pretreatment with the KOR-antagonist norBNI significantly reduced the adverse effects 
of morphine treatment (Experiment 2.B). In the absence of norBNI, morphine-treated 
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rats showed decreased locomotor recovery relative to vehicle-treated controls, 
replicating our previous studies (Hook et al., 2009; Hook et al., 2011). However, 
moderate to high doses of norBNI (0.08 and 0.32 μmol respectively), blocked the 
adverse effects of morphine on locomotor recovery, improved overall health, and 
increased white matter sparing at the lesion site, while maintaining moderate analgesia.   
Based on the data presented here, I propose that the analgesic efficacy of 
intrathecal morphine in the SCI model is mediated by binding to MORs and KORs. 
While studies on opioid receptor distribution in the spinal cord support the significant 
contribution of the MOR to the antinociceptive effects of morphine (Arvidsson et al., 
1995; Mansour et al., 1995b), the results of selective activation of the KOR were 
unexpected.  Studies have long disputed the role of the KOR in spinal analgesia. For 
example, in a study by Leighton and colleagues (1988), intrathecal administration of 
three different KOR agonists (PD1 17302, U50488, U69593) failed to increase 
antinociception to noxious mechanical and thermal stimuli, even at doses up to 100 µg.  
Others have suggested that KOR-mediated analgesia is intensity- and stimulus-
dependent, with intrathecally applied KOR ligands showing potency on tests of 
chemical-visceral pain but not cutaneous-thermal or electrical sensory input (Millan, 
1989; Schmauss, 1987; Schmauss & Yaksh, 1984). Furthermore, intrathecal 
administration of exogenous and endogenous KOR ligands has also been associated with 
paralysis and flaccidity of the tail and hind limbs, effects which complicate the 
interpretation of analgesic tests requiring a motor response (Herman & Goldstein, 1985; 
Leighton et al., 1988).  
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In contrast to these studies, however, others have shown that KOR agonists can 
produce significant spinal analgesia (Lahti et al., 1982; Piercey et al., 1982). Indeed, 
using knockout mice, Yamada et al. (2006) found that intrathecal administration of 
morphine produced analgesia in the absence of MORs by acting through spinal KORs. 
In our studies, this could explain why morphine- the prototypical MOR agonist- 
produced moderate analgesia following treatment with CTOP, a potent and selective 
MOR antagonist. Further, Yamada’s findings could also explain why the selective KOR 
agonist, GR89696, exhibited an analgesic profile comparable to morphine and DAMGO. 
Acute intrathecal administration of GR89696 increased subjects’ thermal and 
mechanical thresholds. Notably, I verified that the decreased motor responses in these 
tests were not simply due to paralysis by recording vocal responses to stimulation. 
Subjects treated with GR89696 displayed increased vocal response thresholds with 
mechanical stimulation, indicative of analgesia. Overall, these findings point to an 
important role for the spinal KOR system in intrinsic pain modulation after SCI. 
Regarding the effects on recovery of function, as discussed in the introduction to 
this chapter, the literature strongly implicates the KOR system in the pathophysiology of 
SCI. There is controversy, however, regarding the opioid-receptor mediated (classic) and 
non-opioid (non-classic) actions of KOR ligands. Supporting a KOR-mediated 
mechanism, previous studies have shown that administration of norBNI limits the 
paralytic effects of dynorphin (Faden, 1990), and has been shown to improve functional 
outcomes in rodent models of spinal (Faden, 1990; Faden et al., 1987) and brain (Vink et 
al., 1991) injury. Conversely, although showing decreased potency, administration of 
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Dyn A-(2-17), a prodynorphin product inactive at opioid receptors, replicates 
dynorphin’s adverse effects on locomotor function (Faden, 1990). It has been posited 
that these pathophysiological effects may result from NMDA-mediated excitotoxicity. 
NMDA antagonists limit dynorphin-induced behavioral effects (Bakshi & Faden, 1990a, 
1990b; Caudle & Isaac, 1988). Moreover, dynorphin administration increases 
extracellular levels of excitatory amino acids, including glutamate and aspartate, through 
a non-classic mechanism (Faden, 1992). These studies suggest that while KOR 
activation may contribute to decreased locomotor function after SCI, endogenous and 
exogenous opioids may also engage alternative mechanisms that compromise recovery. 
Although our findings strongly support a KOR-mediated mechanism of action, the non-
classic effects of morphine and other opioids should be further evaluated.  
In conclusion, I have shown that KOR activation with GR89696 is sufficient to 
undermine locomotor recovery following SCI. I have also shown that blocking this 
opioid receptor system using norBNI prevents morphine’s adverse effects. In contrast, 
DAMGO did not affect recovery, and CTOP did not effectively block the negative side-
effects of morphine. Based on these data, I hypothesize that the adverse effects of 
morphine on recovery of locomotor function are mediated by the KOR system. 
Importantly, given that frequently prescribed analgesics like oxycodone act through the 
KOR receptor system, it is paramount that I identify the mechanisms mediating the 
adverse effects of KOR activation after SCI.  Indeed, our data demonstrate that even 
very low doses of KOR ligands may undermine recovery, as shown by the attenuation of 
function observed at a dose 32-fold lower than an effective dose of morphine. Lastly, the 
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role of the MOR should not be discounted. Although I did not observe any effects of 
DAMGO after a single intrathecal injection, it is possible that detrimental effects may 
emerge with prolonged administration (Mao et al., 1995). Alternative mechanisms, 
including non-classic opioid receptor signaling, also need to be further explored. 
Ultimately, elucidating the molecular mechanisms underlying the effects of morphine, 
and other opioids, is imperative in order to develop pharmacological interventions that 
are both safe and efficacious in a clinical setting. 
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CHAPTER IV  
EVALUATION OF THE NON-CLASSIC OPIOID RECEPTORS
*
 
 
Introduction  
 In the previous chapter, I evaluated the contribution of the classic opioid 
receptors to the morphine-induced attenuation of function following SCI. Using selective 
agonists and antagonists, I assessed the differential effects of the MOR and KOR spinal 
systems. The results of these experiments support a role for the KOR, but not the MOR, 
in the adverse effects of morphine administration following SCI. However, as already 
discussed in Chapter 1, although morphine binds to the classic opioid receptors with 
high affinity, it may also bind to other receptors in non-classic fashion (Kristensen et al., 
1994; Wang et al., 2012). In this chapter, I will assess the role of non-classic opioid 
receptor activation in the attenuation of recovery observed when morphine is 
administered following trauma. 
 Non-classic opioid receptors are sites that can bind opioids in a non-
stereoselective fashion (Goldstein et al., 1971). As opposed to the classic opioid 
receptors, these sites accept natural and unnatural opioids (opioid enantiomers) and do 
not result in analgesia. The extant literature suggests that the toll-like receptors (TLRs) 
are the primary sites of non-classic opioid binding (Hutchinson et al., 2010a; Hutchinson 
                                                 
*
 Part of the data reported in this chapter is reprinted from Aceves, M., Mathai, B.B., & 
Hook, M.A. (2016). Evaluation of the effects of specific opioid receptor agonists in a 
rodent model of spinal cord injury. Spinal Cord, 54(10), 767-777 (Copyright 2016 by the 
authors). 
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et al., 2008b; Hutchinson et al., 2010b; Kigerl et al., 2007; Lewis et al., 2010). The toll-
like receptors (TLRs) are important components of the innate immune system (Kawasaki 
& Kawai, 2014). These receptors form part of a wide class of pattern recognition 
receptors (PRRs) that detect danger signals in the cellular environment, including 
pathogen-associated microbial patterns (PAMPs) and danger-associated molecular 
patterns (DAMPs) released from dying cells. Ultimately, TLR binding triggers signaling 
cascades that activate kinases and transcription factors, and eventually result in the 
production and release of pro-inflammatory cytokines, chemokines, and other molecules. 
 I hypothesize that morphine may exert its negative effects through activation of 
these non-classic opioid receptors found on immune-competent cells (Hutchinson et al., 
2007; 2008b; Tawfik et al., 2005; Watkins et al., 2009).  Indeed, research suggests that 
opioid ligands can bind to TLR4 (the receptor that recognizes lipopolysaccharide) and its 
accessory molecules in a non-stereoselective manner, leading to glial activation and 
initiating the inflammatory response (Hutchinson et al., 2010a; Hutchinson et al., 2010b; 
Lewis et al., 2010; Wang et al., 2012). The subsequent release of pro-inflammatory 
cytokines in the spinal cord has been shown to oppose opioid analgesia and facilitate 
pain (Hutchinson et al., 2008a; Johnston et al., 2004). Importantly, in our SCI model, we 
have shown that morphine administration results in increased pro-inflammatory cytokine 
expression at the injury site, and that blocking the interleukin-1 (IL-1) receptor during 
treatment with this analgesic prevents the morphine-induced attenuation of locomotor 
recovery (Hook et al., 2011). These data suggest that by binding to non-classic opioid 
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receptors, morphine may alter the normal immune response following SCI, resulting in 
the adverse long-term consequences typically observed in this model. 
 To address this, the following experiments evaluated the contribution of non-
classic opioid receptor activation to the morphine-induced attenuation of function 
following SCI. Since the extant literature strongly supports a role of TRL4 in the non-
classic effects of morphine administration, I first assessed the role of this receptor using 
the selective agonist LPS and selective antagonist LPS-RS. Next, for a more thorough 
investigation of non-classic opioid receptor binding, I used the unnatural enantiomer of 
morphine ([+]- morphine). This compound cannot bind to the stereoselective classic 
opioid receptors, but may bind to other non-classic receptor sites (including the TLRs). 
Finally, since I hypothesized that binding to non-classic receptors ultimately leads to 
glial activation, I challenged morphine treatment with minocycline, a glial inhibitor. Our 
results showed that neither administration of LPS or [+]- morphine replicated the 
adverse effects of morphine. However, inhibiting the innate immune response with LPS-
RS or minocycline blocked the adverse effects of morphine administration, without 
disrupting the analgesic efficacy of the drug. This suggests that following injury, opioid-
immune interactions mediate the analgesic and pathological responses to morphine.  
Methods and results 
The role of the toll-like receptor 4 
Exp. 3A Sufficiency of TLR4 activation 
In this experiment I used the natural TLR4 agonist LPS (Lipopolysaccharide 
from Escherichia coli; Sigma-Aldrich, St. Louis, MO, USA) to assess the contribution of 
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this non-classic opioid receptor to the morphine-induced attenuation of function after 
SCI. To test whether increased activation of TLR4 following SCI is sufficient to 
reproduce the adverse effects of morphine, LPS was dissolved in endotoxin-free water. 
The solution was then administered via an intrathecal catheter, as described in Chapter II 
General Methodology. Based on previous literature, a high dose of LPS was tested (100 
μg) along with a vehicle control (0 μg). With an n=9 per group, this experimental design 
used a total of 18 rats. 
Analgesic efficacy of LPS 
Sensory function was evaluated using the tail-flick test to establish baseline 
thermal reactivity thresholds. Prior to treatment, tail-flick scores (± S.E.M.) were 4.00 ± 
0.17 s and 3.75 ± 0.34 s for the vehicle and LPS groups, respectively. Statistical analyses 
showed that there were no significant differences between the groups at this time point 
(F (1, 16) = 0.40, p > 0.05; data not shown). As expected, selective activation of TLR4 
using LPS did not result in analgesia (F (1, 16) = 2.36, p > 0.05; Figure 24).  
Although analgesia was not expected following LPS administration, hyperalgesia 
has been reported in the literature (Reeve et al., 2000). Hyperalgesia was not observed in 
the injured subjects receiving 100 μg LPS. This could have been due to a masking effect 
by the injury itself, or could indicate that our LPS batch was defective.  To ascertain that 
the LPS was working properly, I ran an acute analgesia study using sham subjects. Sham 
subjects were administered 100 μg LPS or vehicle. An hour later, all subjects were  
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Figure 24: Analgesic efficacy of LPS.  The results of the tail-flick test of thermal 
reactivity are depicted. Administration of LPS to the spinal cord did not produce 
analgesia. Results shown as Mean ± S.E.M.  
 
 
 
 
 
Figure 25: Analgesic efficacy of morphine with LPS.  Sham subjects were treated with 
vehicle or LPS, followed by morphine treatment. Vehicle controls showed robust 
analgesia at all testing points following morphine administration. LPS-treated subjects 
did not reach full analgesia, and efficacy began to decrease at 2 hr post-morphine. 
Results shown as Mean ± S.E.M. *p < 0.05   
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treated with 90 μg morphine, and analgesic efficacy was measured for the next 4 hours 
using the tail-flick test.As shown in Figure 25, both groups showed increased tail-flick 
latency following morphine administration. However, as opposed to the vehicle-treated 
subjects, subjects treated with LPS and morphine did not display signs of robust 
analgesia (did not reach an 8 s tail-flick latency). Moreover, although I did not observe 
decreases in analgesic efficacy at 4 hrs in the vehicle controls, LPS-treated subjects also 
showed decreases in analgesia starting at 2 hrs, and significant behavioral differences by 
4 hrs (p < 0.05). These results indicate that the LPS was working properly. 
Effects of LPS on locomotor recovery 
Surprisingly, LPS did not have a significant effect on recovery of locomotor 
function (Figure 26). Mean converted BBB scores (± S.E.M.) collected before treatment 
on day 1 were 2.39 ± 0.46 for vehicle-treated controls and 2.22 ± 0.44 for LPS-treated 
subjects, and did not differ statistically (F (1, 16) = 0.06, p > 0.05). Using day 1 scores 
as a covariate, a mixed-design ANOVA revealed no group differences in locomotor 
function across the recovery period (F (1, 15) = 0.77, p > 0.05). Furthermore, as shown 
in Figure 27, there were no significant differences between the groups after day 21 on 
either the beam (F (1, 16) = 1.01, p > 0.05) or ladder (F (1, 16) = 0.08, p > 0.05) tests. 
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Figure 26: Effect of LPS on locomotor recovery.  Subjects were monitored for 21 days 
following a moderate contusion SCI. Intrathecal administration of LPS, on day 1 post-
injury, did not affect locomotor recovery assessed with the BBB scale. Results shown as 
Mean ± S.E.M.  
 
 
 
 
Figure 27: Effects of LPS on beam and ladder walk performance.  At the end of the 21-
day recovery period, locomotor recovery was further assessed using the tapered beam 
(A) and ladder walk (B) tests. Administration of LPS following SCI did not affect 
performance on either task. Results shown as Mean ± S.E.M.  
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Effects of LPS on sensory reactivity 
Sensory function was re-assessed at the end of the 21-day recovery period using 
the tail-flick, von Frey, and girdle tests (Figure 28).  As observed with locomotor 
recovery, treatment with LPS did not affect sensory reactivity after day 21 post-injury.  
The groups did not show any differences in thermal reactivity assessed with the tail-flick 
test (F (1, 16) = 0.13, p > 0.05). Furthermore, no differences were observed on motor (F 
(1, 16) = 0.10, p > 0.05) or vocal reactivity (F (1, 16) = 0.30, p > 0.05) to a mechanical 
stimulus applied to the hindpaws. Finally, administration of LPS did not affect at-level 
allodynia assessed with the girdle test (F (1, 14) = 0.23, p > 0.05). 
 
 
Figure 28: Effects of LPS on sensory reactivity.  At the end of the 21-day recovery 
period, sensory reactivity was assessed using the tail-flick (A), girdle (B), and von Frey 
(C, D) tests. LPS administration did not result in the development of paradoxical pain. 
Results shown as Mean ± S.E.M.  
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Effects of LPS on general health 
Weight was monitored as an index of general health. Weight immediately before 
injury did not differ across groups (F (1, 16) = 0.002, p < 0.05; data not shown). To 
assess changes in weight across recovery, the daily % weight loss was calculated by 
subtracting the starting weight (weight at the day of surgery) from daily weight.  A 
repeated-measures ANOVA on daily % weight loss values showed that there were no 
significant differences between the groups (F (1, 16) = 0.32, p > 0.05; Figure 29).  
 
 
Figure 29: Effect of LPS on weight change across recovery.  This graph depicts the daily 
% weight loss across the 21-day recovery period, calculated by subtracting starting 
weight from daily weight. LPS did not affect weight change, or other signs of general 
health, following SCI. Results shown as Mean ± S.E.M.  
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did not observe any significant effects of drug treatment on bladder control (F (1, 16) = 
0.82, p < 0.05; data not shown). Lastly, treatment did not exacerbate autophagia.  Only 
two subjects showed signs of self-harm, one in each of the groups. 
Exp. 3B Necessity of TLR4 activation 
While LPS administration did not replicate the morphine effect observed in our 
previous studies, I hypothesized that the downstream effects of TLR4, such as the 
release of pro-inflammatory factors, contribute to the adverse effects of morphine. To 
address this, in this experiment I used the selective TLR4 antagonist LPS-RS 
(Lipopolysaccharide from Rhodobacter sphaeroides; InvivoGen, San Diego, CA, USA). 
To test whether inhibition of the TLR4 signaling cascade blocks the adverse effects of 
morphine following SCI, subjects were pretreated with intrathecal LPS-RS (0, 20, or 40 
μg dissolved in endotoxin-free water). Thirty minutes later, half of the subjects in each 
dose group were treated with 90 μg of morphine and the remaining subjects were treated 
with vehicle (0.09% saline). This 3 X 2 experimental design (6 groups) used a total of 60 
rats (n=10).  
Effects of LPS-RS on the analgesic efficacy of morphine 
 Sensory function was evaluated using the tail-flick test to establish baseline 
thermal reactivity thresholds. There were no significant differences between the groups 
prior to treatment (F (5, 50) = 1.24, p > 0.05; data not shown). A two-factor ANOVA on 
post-treatment scores, however, revealed significant main effects of morphine (F (1, 50) 
= 2390.94, p < 0.001) and LPS-RS treatment (F (2, 50) = 8.64, p < 0.05), and a 
significant interaction (F (2, 50) = 8.64, p < 0.05). As shown in Figure 30, across all  
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Figure 30: Effects of LPS-RS on the analgesic efficacy of morphine.  The analgesic 
efficacy of morphine following LPS-RS pre-treatment is depicted for the test of thermal 
reactivity. All groups that received morphine had significantly increased tail-flick 
latencies relative to vehicle-treated controls. Analgesia was also higher for subjects 
treated with the highest dose of LPS-RS alone. Results shown as Mean ± S.E.M. *p < 
0.05 or post-hoc tests; # p < 0.05 for planned comparisons; M = significant main effect 
of morphine. 
 
 
LPS-RS doses, subjects that received morphine showed significantly increased tail-flick 
latencies relative to their saline-treated counterparts. Moreover, subjects pre-treated with 
40 μg of LPS-RS alone showed increased analgesia in comparison to those in the 0 or 20 
μg groups. The test was automatically terminated at 8 seconds to prevent tissue injury. 
Effects of LPS-RS on locomotor recovery 
 Locomotor recovery was monitored for 21 days post-injury (Figure 31). 
Locomotor scores collected before treatment on day 1 did not differ significantly across 
groups (F (5, 50) = 0.25, p > 0.05). Mean converted BBB scores (± S.E.M.) on day 1  
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Figure 31: Effects of LPS-RS on locomotor recovery.  LPS-RS pretreatment blocked the 
adverse effects of morphine on long-term recovery of locomotor function. Morphine 
undermined recovery of locomotor function in the absence of LPS-RS (A). Pretreatment 
with 20 (B) or 40 (C) μg LPS-RS, however, prevented the morphine-induced attenuation 
of locomotor recovery. Results shown as Mean ± S.E.M.  # p < 0.05 for planned 
comparisons. 
 
 
 
 
Figure 32: Effects of LPS-RS on beam and ladder walk performance.  There were no 
significant effects of morphine or LPS-RS treatment on tapered beam (A) or ladder walk 
(B) performance 21-days post-injury. Results shown as Mean ± S.E.M.  
 
 
ranged from 1.40 ± 0.23 to 1.78 ± 0.47. A mixed-design ANCOVA using day 1 scores as 
a covariate did not uncover significant main effects of morphine (F (1, 49) = 3.02, p > 
0.05) or LPS-RS treatment (F (2, 49) = 0.94, p > 0.05), and no significant interaction (F 
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(2, 49) = 2.54, p > 0.05). Replicating our previous studies (Hook et al., 2009; Hook et 
al., 2011), planned comparisons revealed that control subjects (0 μg of LPS-RS) treated 
with morphine had significantly reduced locomotor recovery when compared to their 
saline-treated counterparts (p < 0.05). In contrast, there were no differences between 
morphine- and saline-treated subjects receiving 20 μg (p > 0.05) or 40 μg (p > 0.05) of 
LPS-RS.  
 Motor recovery was further evaluated at the end of the 21-day recovery period 
using the tapered beam and ladder walk tests (Figure 32). Using a two-factor ANOVA, I 
did not find significant main effects of morphine (F (1, 49) = 2.49, p > 0.05), LPS-RS (F 
(2, 49) = 0.04, p > 0.05), or an interaction between treatments (F (2, 49) = 0.31, p > 
0.05), on tapered beam performance. Similarly, I did not find any significant effects on 
ladder walk performance [morphine (F (1, 49) = 0.09, p > 0.05), LPS-RS (F (2, 49) = 
0.21, p > 0.05), morphine X LPS-RS interaction (F (2, 49) = 0.50, p > 0.05)].  
Effects of LPS-RS on sensory reactivity 
Long-term effects on sensory function were assessed at the end of the 21-day 
recovery period using the tail-flick, von Frey, and girdle tests (Figure 33). In the tail-
flick test, mean latencies (± S.E.M.) ranged from 2.74 ± 0.15 to 4.42 ± 0.66 seconds. 
Statistical analyses showed no significant main effect of morphine (F (1, 49) = 2.17, p > 
0.05), LPS-RS (F (2, 49) = 1.93, p > 0.05), or an interaction between the two (F (2, 49) 
= 2.10, p > 0.05), on thermal reactivity after day 21. In the von Frey test of mechanical 
reactivity, a two-factor ANOVA revealed significant main effects of morphine (F (1, 49) 
= 7.07, p < 0.05) and LPS-RS (F (2, 49) = 3.20, p < 0.05) on motor responses, but no 
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significant interaction (F (2, 49) = 0.07, p > 0.05). On vocal responses, analyses revealed 
a significant main effect of morphine (F (1, 49) = 7.51, p < 0.05), but no effect of LPS-
RS (F (2, 49) = 1.09, p < 0.05) or an interaction between morphine and LPS-RS (F (2, 
49) = 0.35, p < 0.05). Overall, morphine administration at all doses appeared to lower 
the threshold for mechanical reactivity at the spinal and supraspinal level. Lastly, I did 
not find any significant effects of morphine (F (1, 50) = 0.54, p > 0.05), LPS-RS (F (2, 
50) = 1.67, p > 0.05), or their interaction (F (2, 50) = 0.27, p > 0.05), in the girdle test of 
at-level allodynia.  
 
 
Figure 33: Effects of LPS-RS on sensory reactivity.  There were no significant main 
effects of morphine or LPS-RS treatment on thermal hyperalgesia (A) or at-level 
allodynia (B) tested at 21-days post-injury. However, both treatments affected motor 
responses to mechanical stimulation of the hindpaws (C). Morphine treatment also 
lowered the threshold for vocal responses in the von Frey test (D). Results shown as 
Mean ± S.E.M. *p < 0.05 for post-hoc tests; # p < 0.05 for planned comparisons; M = 
significant main effect of morphine. 
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Effects of LPS-RS on general health 
 Weight immediately before injury did not differ across groups (F (5, 50) = 1.90, 
p > 0.05; data not shown). Commensurate with all other experiments, all groups lost 
weight following SCI (Figure 34). However, I did not find any significant effects of 
morphine (F (1, 50) = 1.08, p > 0.05), LPS-RS (F (2, 50) = 0.11, p > 0.05), or an 
interaction (F (2, 50) = 0.57, p > 0.05), on weight change across recovery.  
 
 
Figure 34: Effects of LPS-RS on weight change across recovery.  Weight loss was 
unaffected by morphine or LPS-RS treatment. Results shown as Mean ± S.E.M.  
 
Mortality, autophagia, spastic hypertonia, and bladder control were also 
monitored throughout the 21-day recovery period. Mortality was not affected by drug 
treatment. Only 1 subject died in the entire experiment (originally in the 0 μg LPS-RS + 
morphine group; subject was replaced). Similarly, only 1 case of mild autophagia was 
observed (in the 0 μg LPS-RS + saline group), but this subject did not need to be 
replaced. Three subjects displayed signs of spastic hypertonia in this experiment (1 each 
in the 0 μg LPS-RS + saline and 0 μg LPS-RS + morphine groups, and 1 in the 20 μg 
LPS-RS + morphine group). Lastly, I found a significant main effect of LPS-RS (F (2, 
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50) = 3.25, p > 0.05) on recovery of bladder control, but no effect of morphine (F (1, 50) 
= 0.16, p > 0.05) or any interaction (F (2, 50) = 0.37, p > 0.05; data not shown). On 
average, subjects treated with 40 μg of LPS-RS showed slower recovery of bladder 
control than their vehicle-treated counterparts (20.78 days versus 18.70 days, 
respectively). 
Non-classic opioid receptor activation 
Exp. 4A Sufficiency of non-classic opioid receptor activation 
In this experiment I used the unnatural [+]- enantiomer of morphine to assess the 
contribution of non-classic opioid receptor activation to the morphine-induced 
attenuation of function after SCI. To test whether activation of non-classic opioid 
receptors in the spinal cord following injury is sufficient to reproduce the adverse effects 
of morphine, [+]- morphine was dissolved in 10 N hydrochloric acid and titrated with 1N 
sodium hydroxide to pH 5–6, then diluted to the intended concentration with 0.9 % 
saline. The solution was then administered via an intrathecal route, as described in 
Chapter II General Methodology. A single dose of [+]- morphine was tested (0.32 
μmol), equivalent to the effective dose of morphine seen in previous studies, along with 
a vehicle control (0 μmol). With an n=8 per group, this experimental design used a total 
of 16 rats. 
Analgesic efficacy of [+]- morphine 
 Sensory function was evaluated using the tail-flick test to establish baseline 
thermal reactivity thresholds. Prior to treatment, tail-flick scores (± S.E.M.) were 3.98 ±  
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Figure 35: Analgesic efficacy of [+]- morphine.  Administration of [+]- morphine did 
not produce analgesia. Results shown as Mean ± S.E.M. 
  
 
0.17 s and 3.68 ± 0.19 s for the vehicle and [+]- morphine groups, respectively. 
Statistical analyses showed that there were no significant differences between the groups 
at this time point (F (1, 14) = 1.23, p > 0.05; data not shown). As expected, selective 
activation of non-classic opioid receptors, using the unnatural [+]- enantiomer of 
morphine, did not result in analgesia (F (1, 14) = 1.30, p > 0.05; Figure 35). Since [+]- 
morphine failed to produce analgesia at the high dose of 0.32 μmol, lower doses were 
not tested.  
Effects of [+]- morphine on locomotor recovery 
 Administration of the unnatural [+]- enantiomer of morphine did not have any 
significant effects on recovery of locomotor function (Figure 36), despite administering 
a dose equivalent to the natural [-]- enantiomer of morphine previously shown to 
undermine recovery (Hook et al., 2009; Hook et al., 2011). Mean converted BBB scores 
(± S.E.M.) collected before treatment on day 1 were 1.88 ± 0.33 for vehicle-treated  
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Figure 36: Effects of [+]- morphine on locomotor recovery.  Subjects were monitored 
for 21 days following a moderate contusion SCI. Intrathecal administration of [+]- 
morphine, on day 1 post-injury, did not affect locomotor recovery as assessed using the 
BBB scale. Results shown as Mean ± S.E.M.  
 
 
 
 
 
Figure 37: Effects of [+]- morphine on beam and ladder walk performance.  At the end 
of the 21-day recovery period, locomotor recovery was further assessed using the 
tapered beam (A) and ladder walk (B) tests. [+]- Morphine had no effect on performance 
of these tests. Results shown as Mean ± S.E.M.  
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controls and 1.81 ± 0.35 for [+]- morphine-treated subjects, and did not differ 
statistically (F (1, 14) = 0.02, p > 0.05). Using day 1 scores as a covariate, a mixed-
design ANOVA revealed no differences in locomotor recovery between the groups 
across the 21 days post-injury (F (1, 14) = 0.20, p > 0.05). Further, as shown in Figure 
37, there were no significant differences between treatment groups after day 21 on either 
the beam (F (1, 14) = 1.25, p > 0.05) or ladder (F (1, 14) = 0.02, p > 0.05) tests. 
Effects of [+]- morphine on sensory reactivity 
Sensory function was assessed at the end of the 21-day recovery period using the 
tail-flick, von Frey, and girdle tests (Figure 38).  As observed with locomotor recovery, 
treatment with the unnatural morphine enantiomer did not affect sensory reactivity at 
day 21 post-injury.  The groups did not show any differences in thermal reactivity 
assessed with the tail-flick test (F (1, 14) = 0.86, p > 0.05). Similarly, no differences 
were observed for motor (F (1, 14) = 0.28, p > 0.05) or vocal reactivity (F (1, 14) = 1.18, 
p > 0.05) to a mechanical stimulus applied to the hindpaws. Finally, administration of 
[+]- morphine did not affect at-level allodynia assessed with the girdle test (F (1, 14) = 
1.16, p > 0.05). 
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Figure 38: Effects of [+]- morphine on sensory reactivity.  At the end of the 21-day 
recovery period, sensory reactivity was assessed using the tail-flick (A), girdle (B), and 
von Frey (C, D) tests. [+]- Morphine administration did not affect long-term pain 
reactivity. Results shown as Mean ± S.E.M.  
 
 
Effects of [+]- morphine on general health 
Weight was monitored as an index of general health. Weight immediately before 
injury differed across groups (F (1, 14) = 11.54, p < 0.05; data not shown). Mean weight 
immediately before injury (± S.E.M.) was 372.50 ± 3.04 g for subjects treated with [+]- 
morphine and 347.13 ± 6.29 for controls. To assess changes in weight across recovery 
taking into account initial differences, the daily % weight loss was calculated by 
subtracting the starting weight (weight at the day of surgery) from daily weight.  A 
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repeated-measures ANOVA on daily % weight loss values showed that there were no 
significant differences between the groups (F (1, 14) = 0.40, p > 0.05; Figure 39).  
In addition to weight, mortalities, autophagia, spastic hypertonia, and recovery of 
bladder control were also recorded to assess general health. I did not observe any 
significant effects of drug treatment on mortality (a single subject died in the vehicle 
group). None of the subjects recovered bladder control, and no spastic hypertonia was 
recorded throughout the duration of the experiment. Administration of [+]- morphine 
appeared to exacerbate autophagia, with 37.5% of [+]- morphine subjects demonstrating 
signs of self-harm, compared to 0% of vehicle-treated controls. This effect approached, 
but did not reach statistical significance (χ2= 3.69, p = 0.055). 
 
 
 
Figure 39: Effects of [+]- morphine on weight change across recovery.  This graph 
depicts the daily % weight loss across the 21-day recovery period, calculated by 
subtracting starting weight from daily weight. [+]- morphine did not affect weight 
change, or other signs of general health, following SCI. Results shown as Mean ± 
S.E.M.  
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Exp. 4B Necessity of non-classic opioid receptor activation 
Since treatment with LPS-RS appeared to decrease the adverse effects of 
morphine, I hypothesized that the attenuation of function results from opioid-mediated 
increases in the innate inflammatory response following SCI. I posited that morphine 
increases glial activation, increasing the release of pro-inflammatory factors, and leading 
to neurotoxicity. To test whether glial inhibition prevents the adverse effects of 
morphine following SCI, subjects were pretreated with intrathecal minocycline (0, 50, or 
100 μg dissolved in distilled water). Fifteen minutes later, half of the subjects in each 
dose were treated with 90 μg of morphine and the remaining subjects were treated with 
vehicle (0.09% saline). This 3 X 2 experimental design (6 groups) used a total of 60 rats 
(n=10).  
Effects of minocycline on the analgesic efficacy of morphine 
Sensory function was evaluated using the tail-flick test to establish baseline 
thermal reactivity thresholds. There were no significant differences between the groups 
prior to treatment (F (5, 54) = 1.58, p > 0.05; data not shown). A two-factor ANOVA on 
post-treatment scores, however, revealed a significant main effect of morphine (F (1, 54) 
= 372.38, p < 0.001), but no effect of minocycline treatment (F (2, 54) = 1.10, p > 0.05) 
and no interaction (F (2, 54) = 0.21, p > 0.05). As shown in Figure 40, across all doses, 
subjects that received morphine, irrespective of minocycline treatment, showed 
significantly increased tail-flick latencies relative to their saline-treated counterparts (p < 
0.05). The test was automatically terminated at 8 seconds to prevent tissue injury.  
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Figure 40: Effects of minocycline on the analgesic efficacy of morphine.  The analgesic 
efficacy of morphine challenged with minocycline pre-treatment is depicted for the test 
of thermal reactivity. At all doses (0, 50, and 100 μg), subjects that received morphine 
had significantly increased tail-flick latencies relative to saline controls. Results shown 
as Mean ± S.E.M. # p < 0.05 for planned comparisons; M = significant main effect of 
morphine. 
 
 
 
Effects of minocycline on locomotor recovery 
 Locomotor recovery was monitored for 21 days post-injury (Figure 41). 
Locomotor scores collected before treatment on day 1 did not differ significantly across 
groups (F (5, 54) = 0.70, p > 0.05). Mean converted BBB scores (± S.E.M.) on day 1 
ranged from 2.50 ± 0.50 to 3.70 ± 0.64. A mixed-design ANCOVA using day 1 scores as 
a covariate did not uncover significant main effects of morphine (F (1, 53) = 0.86, p > 
0.05) or minocycline treatment (F (2, 53) = 0.55, p > 0.05). Their interaction, however, 
reached significance (F (2, 53) = 3.26, p < 0.05). Replicating our previous studies (Hook 
et al., 2009; Hook et al., 2011), planned comparisons revealed that control subjects (0 μg 
of minocycline) treated with morphine showed significantly reduced locomotor recovery  
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Figure 41: Effects of minocycline on locomotor recovery.  Morphine significantly 
undermined locomotor function following SCI in subjects not treated with minocycline 
(A). However, minocycline pre-treatment at a 50 μg (B) or 100 μg dose (C) effectively 
blocked the adverse effects of morphine. Results shown as Mean ± S.E.M.  # p < 0.05 
for planned comparisons. 
 
 
 
 
 
 
Figure 42: Effects of minocycline on beam and ladder walk performance.  At the end of 
the 21-day recovery period, locomotor recovery was further assessed using the tapered 
beam (A) and ladder walk (B) tests. Morphine administration significantly undermined 
tapered beam performance in the absence of minocycline. No effects of morphine or 
minocycline were observed in ladder walk performance. Results shown as Mean ± 
S.E.M. # p < 0.05 for planned comparisons. 
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when compared to their saline-treated counterparts (p < 0.05). In contrast, there were no 
differences between morphine- and saline-treated subjects receiving 50 μg (p > 0.05) or 
100 μg (p > 0.05) of minocycline.  
Motor recovery was further evaluated at the end of the 21-day recovery period 
using the tapered beam and ladder walk tests. A two-factor ANOVA uncovered a 
significant main effect of minocycline (F (2, 54) = 3.66, p < 0.05) on the tapered beam 
test, but no effect of morphine (F (1, 54) = 1.77, p > 0.05) or interaction (F (2, 54) = 
2.45, p > 0.05). As shown in Figure 42, there was a tendency for improved performance 
on the beam with minocycline administration. Additionally, morphine-treated subjects 
that did not receive minocycline showed the worst performance of all groups (unable to 
travel beyond an average width of 9.73 cm) and significantly differed from their saline-
treated counterparts (p < 0.05).  I did not find any significant effects of morphine (F (1, 
54) = 0.41, p > 0.05) or minocycline (F (2, 54) = 2.51, p > 0.05) treatment on ladder 
walk performance, and no interaction (F (2, 54) = 0.16, p > 0.05). 
Effects of minocycline on sensory reactivity 
 Long-term effects on sensory function were assessed at the end of the 21-day 
recovery period using the tail-flick, von Frey, and girdle tests. In the tail-flick test, mean 
latencies (± S.E.M.) ranged from 3.74 ± 0.25 to 4.70 ± 0.42 seconds. Statistical analyses 
revealed a significant main effect of minocycline treatment on thermal reactivity after 
day 21 (F (2, 54) = 3.41, p < 0.05), but no effect of morphine (F (1, 54) = 0.004, p > 
0.05) or interaction (F (2, 54) = 0.11, p > 0.05). As shown in Figure 43, controls (0 μg  
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Figure 43: Effects of minocycline on sensory reactivity.  Minocycline treatment 
decreased the development of thermal hyperalgesia (A), however, no effects of morphine 
or minocycline were observed on at-level allodynia (B) or mechanical reactivity of the 
hindpaws (C, D). Results shown as Mean ± S.E.M. *p < 0.05 for post-hoc tests. 
 
 
minocycline) showed lower thresholds than minocycline-treated subjects, regardless of 
morphine administration.   
In the von Frey test of mechanical reactivity, although morphine-treated subjects 
showed lower motor thresholds than saline-treated animals, I did not find any significant 
effects of morphine (F (1, 52) = 1.67, p > 0.05) or minocycline (F (2, 52) = 0.94, p > 
0.05), and no interaction (F (2, 52) = 0.12, p > 0.05), on motor responses. On vocal 
responses to tactile stimulation, a main effect of morphine approached, but did not reach, 
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statistical significance (F (1, 52) = 3.07, p = 0.08). Furthermore, no effect of 
minocycline (F (2, 52) = 0.56, p > 0.05) or interaction (F (2, 52) = 0.31, p > 0.05) was 
observed.  Similarly, I did not find any significant effects of morphine (F (1, 54) = 2.72, 
p > 0.05) or minocycline (F (2, 54) = 2.24, p > 0.05), and no interaction (F (2, 54) = 
0.004, p > 0.05), on the girdle test of at-level allodynia.  
Effects of minocycline on general health 
Weight, monitored as an index of general health, did not differ across groups 
immediately before injury (F (5, 51) = 0.69, p > 0.05; data not shown). To assess 
changes in weight across recovery, the daily % weight loss was calculated by subtracting 
the starting weight (weight at the day of surgery) from current weight. These scores were 
analyzed using a repeated-measures ANOVA, which revealed a significant main effect 
of minocycline (F (2, 51) = 5.17, p < 0.05), but no effect of morphine (F (1, 51) = 2.08, 
p > 0.05) and no interaction (F (2, 51) = 0.14, p > 0.05). As shown in Figure 44, all 
groups lost weight following SCI. Treatment with minocycline, however, attenuated 
weight loss irrespective of morphine treatment. In fact, by the end of the recovery 
period, every group that received minocycline returned to their pre-injury weight, but 
this was not the case for controls (0 μg minocycline).  
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Figure 44: Effects of minocycline on weight change across recovery.  The average daily 
% weight loss is depicted for the 21-day recovery period. Treatment with minocycline 
attenuated weight loss following SCI, irrespective of morphine treatment. Results shown 
as Mean ± S.E.M. *p < 0.05 for post-hoc tests (in comparison to 0 μg controls). 
 
 
I also recorded mortality, autophagia, spastic hypertonia, and bladder control 
throughout the 21-day recovery period. There were no mortalities, and very few 
instances of autophagia and spastic hypertonia. Overall, there were only two cases of 
autophagia (both treated with 50 μg minocycline, 1 each in the morphine and saline 
groups), and four subjects showing signs of spastic hypertonia (all treated with 
morphine, 2 each pretreated with 0 or 100 μg minocycline). Lastly, neither morphine (F 
(5, 51) = 0.69, p > 0.05) nor minocycline (F (5, 51) = 0.69, p > 0.05) affected recovery 
of bladder control (data not shown).  
Effects of minocycline on tissue sparing at the site of injury 
To assess whether the effects of minocycline on locomotor function were the 
result of increased neuroprotection, I quantified the amount of tissue sparing in the 
spinal cord at the end of the recovery period (Figure 45). Spinal tissue was subdivided 
into rostral (2400 – 1200 μm), center (600 – -600 μm), and caudal (-1200 – -2400 μm) 
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segments.  Four measures were analyzed: relative lesion size (damage + missing tissue), 
tissue damage, residual gray matter, and residual white matter. Across the rostral-caudal 
extent of the spinal cord, there were no significant main effects on any of these four 
measures (for all, p > 0.05). Planned comparisons between saline and morphine-treated 
subjects, however, showed differences in residual white matter across the rostral-caudal 
extent of the lesion, only in subjects that were not pretreated with minocycline. It 
appears that minocycline treatment protected residual white matter in morphine-treated 
subjects commensurate to that of their saline-treated counterparts. 
 
 
 
 
 
 
 
 
 
 
Figure 45: Effects of minocycline on tissue sparing at the site of injury.  At the end of 
the experiment, subjects were perfused and tissue was collected for histological 
assessment. The were no significant effects of minocycline on lesion size (A), damage 
(B), residual gray matter (C), or residual white matter (D). However, differences in white 
matter sparing were found at every segment between saline and morphine-treated 
subjects without minocycline. Results shown as Mean ± S.E.M. #p < 0.05 for planned 
comparisons.  
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Discussion 
 In these experiments I evaluated the contribution of non-classic opioid receptor 
activation to the morphine-induced attenuation of function following SCI. First, I 
assessed the role of TLR4 using the selective agonist LPS.  At a high dose of 100 μg, 
LPS significantly decreased the analgesic efficacy of morphine in sham subjects, but did 
not result in adverse consequences in contused subjects (Experiment 3.A). To further 
explore the role of TLR4 in morphine’s effects following SCI, I challenged morphine 
treatment with the highly-selective antagonist LPS-RS (Experiment 3.B). Pre-treatment 
with LPS-RS, at 20 and 40 μg, did not disrupt morphine’s analgesic efficacy.  However, 
at both doses, LPS-RS appeared to reduce the adverse effects of morphine on recovery 
of function. This suggests that it is possible that I did not see an effect of TLR4 
activation with LPS due to the immune response innate to SCI (ceiling effect).  
 Since selective activation of TLR4 did not replicate morphine’s adverse effects, 
next I evaluated the contribution of overall non-classic opioid receptor activation using 
the unnatural enantiomer of morphine (Experiment 4.A). As expected, I found that [+]- 
morphine does not produce analgesia, confirming that the classic opioid receptors were 
not activated by the treatment. At a dose commensurate with an effective dose of 
morphine, I found that [+]- morphine does not have any adverse effects on recovery 
following SCI. However, as observed with LPS-RS, reducing glial activation with 
minocycline blocked the adverse effects of morphine on locomotor recovery, prevented 
the development of thermal hyperalgesia and increased tissue sparing at the injury site. 
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 The data presented here support previous findings from our laboratory (Hook et 
al., 2007; Hook et al., 2009; Hook et al., 2011). In our rodent SCI model, we have shown 
that morphine administration significantly increases the levels of pro-inflammatory 
cytokines as early as 30 minutes post-injection (Hook et al., 2011). Notably, we have 
also shown that blocking the interleukin-1 (IL-1) receptor prior to morphine treatment 
prevents the attenuation of locomotor function and reduces symptoms of at-level 
neurophatic pain (Hook et al., 2011). In the current studies I showed that blocking TLR4 
activation with LPS-RS, or using minocycline to inhibit glia at the site of injury, also 
prevents morphine-induced attenuation of function. Altogether, our findings suggest that 
opioids interact with the immune system to undermine recovery following SCI. The 
mechanisms leading to these adverse effects, however, remain unclear and should be 
further investigated.  
 While few studies have looked at the immunomodulatory effects of opioids 
following SCI, opioid-immune interactions have been extensively documented in other 
injury models (Hutchinson et al., 2007; Hutchinson et al., 2011; Watkins et al., 2007a; 
Watkins et al., 2007b; Watkins et al., 2009). Research in pre-clinical pain models, for 
instance, have characterized a TLR4-mediated mechanism through which morphine 
contributes to the initiation and maintenance of paradoxical pain (Grace et al., 2016; 
Hutchinson et al., 2011; Hutchinson et al., 2010b). Briefly, this mechanism posits that 
morphine forms a complex with TLR4 and MD2, which then activates intracellular 
signaling cascades via the recruitment of adaptor proteins. These proteins engage 
downstream signaling pathways, such as the phosphatidylinositol 3-kinase (PI3K)/Akt 
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pathway, involved in cell motility, survival, and apoptosis, or the NF-κB and MAPK 
pathways, responsible for the production and release of pro-inflammatory cytokines and 
chemokines (Hutchinson et al., 2011).  
 Surprisingly, in the studies presented here, selective activation of TLR4 using 
LPS and of other non-classic opioid receptors with [+]- morphine did not did not 
replicate the adverse effects of morphine previously observed in our SCI model (Hook et 
al., 2007; Hook et al., 2009; Hook et al., 2011). It is possible that the effect of these 
agonists was masked by the immune response innate to SCI. In comparison to the nerve 
injury models, which have provided the majority of evidence supporting an opioid-TLR4 
relationship, SCI results in a more robust pro-inflammatory response. Indeed, within 
hours, SCI leads to an extensive upregulation of TLRs and their downstream regulators 
in the injured spinal cord (Kigerl et al., 2007). Specifically, studies have shown 
increased mRNA levels for TLR1, 2, 4, 5, and 7, as well as the adaptor protein MyD88, 
and the transcription factor NF-κB. To further contrast the role of TLR signaling in 
nerve injury and SCI models, genetic knockout of TLR2 and TLR4 in a mouse model of 
SCI resulted in increased inflammation, increased gliosis, and decreased recovery of 
locomotor function (Kigerl et al., 2007). This suggests that following SCI, TLR 
activation may approach a ceiling effect, masking any other effects of LPS or [+]- 
morphine. I posit that opioids engage additional molecular pathways- for example, via 
KOR signaling- to augment the inflammatory response and undermine recovery of 
function. 
  
 
109 
 The data presented here also suggest that, although activation of TLR4 and other 
non-classic opioid receptors is not sufficient to replicate morphine’s effects, the immune 
system plays a critical role in the attenuation of recovery. Pharmacological modulation 
of the immune response appears to prevent morphine’s adverse consequences without 
compromising the innate immune response necessary for recovery of function. Indeed, 
our findings suggest that anti-inflammatories should be further investigated as adjuvants 
to improve the safety and efficacy of opioids in the clinical setting. In animal models of 
nerve injury, for example, treatment with glial inhibitors like minocycline and 
pentoxifylline significantly potentiates morphine analgesia (Mika et al., 2007) and 
decreases tolerance (Cui et al., 2008; Mika et al., 2009). Blocking glial activation also 
has other benefits, such as attenuating the development of allodynia and hyperalgesia 
after injury to the nervous system (Chang & Waxman, 2010; Ledeboer et al., 2005; Mika 
et al., 2007). Further corroborating our results, research in other laboratories also suggest 
that glial inhibitors can be powerful tools for neuroprotection in models of traumatic 
brain and spinal cord injury (Mejia et al., 2001; Stirling et al., 2004). Notably, 
minocycline and other FDA-approved anti-inflammatories are currently under 
investigation in a variety of clinical trials as treatments for neurodegenerative conditions 
like Huntington disease and Parkinson disease (Kim & Suh, 2009; Plane et al., 2010). 
Overall, these drugs appear to be promising clinical tools, and warrant further 
investigation as adjuvants to opioid regimens for spinally-injured patients. 
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CHAPTER V 
CELLULAR MECHANISMS: EFFECTS OF MORPHINE ADMINISTRATION AT 
THE SITE OF INJURY 
  
Introduction 
 The analyses of classic and non-classic receptor binding, presented in Chapters 3 
and 4, suggest that both KOR signaling and glial activation contribute to the adverse 
effects of morphine administration following SCI.  While the literature strongly supports 
a role of TLR signaling in the immunomodulatory effects of opioids, LPS and [+]- 
morphine failed to replicate the adverse effects of morphine consistently shown in our 
SCI model.  Altogether, the findings presented here point to a classically-mediated 
mechanism of action underlying morphine’s unwanted side effects. I posit that morphine 
undermines recovery following SCI by binding to KORs on microglia/macrophages, and 
biasing these cells toward a pro-inflammatory profile. Indeed, evidence suggests that 
following trauma to the nervous system, responding microglia/macrophages adopt either 
an M1 phenotype, which is pro-inflammatory and neurotoxic, or an M2 phenotype, 
which is anti-inflammatory and promotes repair (Kigerl et al., 2009). In the already 
highly inflammatory context of a SCI, KOR signaling may induce a positive-feedback 
loop through which aberrant glial activation results in secondary damage to residual 
tissue. 
 Supporting an interaction between the classic opioid receptors and immune 
system, studies have demonstrated that cells involved in host defense, including 
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peripheral blood mononuclear cells (T-cells and B-cells), granulocytes, and peritoneal 
macrophages, also express classic opioid receptor mRNA (Bidlack et al., 2006; Chuang 
et al., 1995; Sharp, 2006). Even within the nervous system, opioid receptor expression is 
not restricted to neurons. Astrocytes, oligodendrocytes, and microglia have been shown 
to express classic opioid receptors (Belcheva et al., 2005; Bruchas et al., 2006; Chao et 
al., 1996; Chao et al., 1997; Eriksson et al., 1993; Gurwell et al., 1996; Hauser et al., 
1996; McLennan et al., 2008; Ruzicka et al., 1995; Stiene-Martin & Hauser, 1991; 
Stiene-Martin et al., 2001; Stiene-Martin et al., 1993; Stiene-Martin et al., 1998; Xu et 
al., 2007). Importantly, research shows that some of these cells can exhibit altered opioid 
receptor expression in response to inflammation or injury.  
 Evidence suggests that cytokines and chemokines present in the cellular 
environment can trigger changes in opioid receptor expression on immune cells and glia. 
For example, IL-1β can regulate opioid peptide production and opioid receptor 
expression in astrocyte-enriched cultures, but its effects differ depending on the opioid 
receptor subtype and brain regions under investigation (Ruzicka & Akil, 1997; Ruzicka 
et al., 1996). In these studies, treatment with IL-1β for 24 hours increased the level of 
MOR mRNA by 55-75% in cultures from rat striatum, cerebellum, and hippocampus, 
but not in those derived from the cortex or hypothalamus. Conversely, the same 
treatment reduced KOR mRNA in all cultures, but had no effect on DOR mRNA. 
Simultaneous treatment with IL-1α and IL-1β has also been shown to increase MOR 
expression in neural microvascular endothelial cell cultures (Vidal et al., 1998). These 
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data suggest that opioid-immune interactions may be dramatically altered by the 
pathophysiological context in which they are applied. 
 I hypothesize that in the acute phase of SCI morphine binds to KORs expressed 
on glial cells, leading to increased activation, and subsequently increased cell death at 
the site of lesion. In order to test this, in the following experiments I used 
immunohistochemistry and flow cytometry to characterize the cellular environment at 
the site of lesion, with and without morphine treatment. Our results show that at 48 hours 
following injury, morphine administration does not significantly change the number of 
neurons or astrocytes present. However, morphine treatment results in a robust increase 
in the number of microglia/macrophages regardless of injury. Injury alone also 
significantly increases the number of microglia/macrophages with MOR and KOR 
expression. Furthermore, as opposed to their saline-treated counterparts, contused 
subjects that receive morphine had significantly more KOR+ microglia at the site of 
injury. This supports our pharmacological studies, and underscores the need to further 
investigate the use of opioids in the context of trauma. 
Methods and results 
Cellular effects assessed with immunohistochemistry 
In this experiment I used immunohistochemistry (IHC) to assess the effects of 
morphine administration at the site of a spinal cord injury. I hypothesized that sub-acute 
morphine treatment alters spinal cellular populations that play a key role in secondary 
injury, leading to attenuation of function in the chronic stages of recovery. To test this, I 
quantified neurons, astrocytes, and macrophages at the injury epicenter.  Briefly, 
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subjects received a sham or contusion surgery. Twenty-four hours after injury, morphine 
(90 μg) or vehicle (filtered 0.9% saline) were administered via an intrathecal catheter. 
Twenty-four hours after drug treatment (48 hr post-injury), subjects were humanely 
euthanized, and tissue was collected for immunohistochemical analyses as described in 
Chapter II General Methodology. With an n=4 per group, this 2 (surgery) X 2 (drug) 
experimental design used a total of 16 subjects.  
Exp. 5A Histological assessment of lesion size in the acute phase of contusion injury 
First, I assessed the lesion size using histology (Figure 46). Spinal tissue was 
subdivided into rostral (2400 – 1200 μm), center (600 – -600 μm), and caudal (-1200 – -
2400 μm) segments.  Four measures were analyzed: relative lesion size (damage + 
missing tissue), tissue damage, residual gray matter, and residual white matter.  For 
relative lesion size, no significant effects were observed in the rostral and caudal 
segments (for all, p > 0.05). However, in the center segment, I found a significant main 
effect of surgery (F (1, 12) = 68.52, p < 0.05), but no effect of drug treatment (F (1, 12) 
= 0.02, p > 0.05) or surgery X drug treatment interaction (F (1, 12) = 0.09, p > 0.05). 
Surgery also significantly affected the amount of damage at the rostral (F (1, 12) = 6.60, 
p < 0.05), center (F (1, 12) = 186.75, p < 0.05), and caudal (F (1, 12) = 19.54, p < 0.05) 
segments of the spinal cord. However, no effects of drug treatment or interactions on 
damage to the spinal cord were observed throughout the rostral-caudal extent of the 
lesion (for all, p > 0.05) at this early time point. Not surprisingly, contused subjects had  
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Figure 46: Tissue sparing at the site of injury.  Two days post-SCI, subjects were 
perfused and tissue was collected for histological assessment. There was a significant 
main effect of surgery at the center spinal segment for relative lesion (A), residual gray 
matter (C), and residual white matter (D). Surgery also affected damage throughout the 
rostral-caudal spinal cord, with no effect of drug treatment or interaction (B). Results 
shown as Mean ± S.E.M.  
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a bigger lesion and more damage than their sham counterparts, regardless of drug 
treatment.  
 For residual gray matter, there were no significant effects of surgery or drug 
treatment in the rostral and caudal segments (for all, p > 0.05). However, in the center 
segment, I found a significant main effect of surgery (F (1, 12) = 129.11, p < 0.05), but 
no effect of drug treatment (F (1, 12) = 0.16, p > 0.05) or surgery x drug treatment 
interaction (F (1, 12) = 1.30, p > 0.05). Similarly, for residual white matter, no 
significant effects were found in the rostral and caudal segments (for all, p > 0.05), but in 
the center segment, there was a significant main effect of surgery (F (1, 12) = 14.28, p < 
0.05), with no effect of drug treatment (F (1, 12) = 0.30, p > 0.05) or significant 
interaction (F (1, 12) = 0.21, p > 0.05). Overall, although contused subjects lost more 
gray and white matter than their sham counterparts, there was no significant effect of 
morphine treatment on residual tissue at this early time point.  
Exp. 5B Neurons, astrocytes, and microglia/macrophages at the lesion epicenter 
 Following the histological assessment of the lesion area, I used 
immunohistochemistry (IHC) to investigate whether morphine treatment alters key 
cellular populations following SCI. Spinal tissue was prepared for IHC and images were 
analyzed using ImageJ software as described in Chapter II General Methodology. First I 
quantified the number of neurons (NeuN+ cells; Figure 47) present across the rostral-
caudal extent of the lesion. In the rostral segment (1200 – 2400 μm), a mixed-design 
ANOVA uncovered a significant main effect of surgery (F (1, 12) = 16.19, p < 0.05), but  
  
 
116 
 
 
 
 
 
Figure 47: Visualizing neurons using immunohistochemistry.  Neurons in the spinal cord 
were visualized using NeuN antibodies. These sections were taken from the center of the 
injury at 4X magnification. 
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Figure 48: Quantification of neurons at the injury epicenter.  Quantification of NeuN+ 
cells at the rostral, center, and caudal spinal segments are shown in this graph. There was 
a significant main effect of surgery across all segments, with contused subjects losing 
more neurons than sham subjects. Morphine treatment also significantly decreased 
neuron number, but only in the caudal segment. There were no significant interactions 
between surgery and drug treatment at any spinal level. Results shown as Mean ± S.E.M. 
*p < 0.05 or post-hoc tests; M = significant main effect of morphine. 
 
no effect of drug treatment (F (1, 12) = 0.08, p > 0.05) or interaction (F (1, 12) = 0.14, p 
> 0.05; Figure 48). At 48 hrs post injury, there were significantly more neurons present 
in sham tissue than contused tissue, regardless of drug treatment. Similarly, in the center 
segment (-600 – 600 μm), there was an effect of surgery (F (1, 12) = 56.17, p < 0.05), 
but no effect of drug treatment (F (1, 12) = 0.01, p > 0.05) or interaction (F (1, 12) = 
1.36, p > 0.05). Caudally (-2400 – -1200 μm), however, there were significant main 
effects of both surgery (F (1, 12) = 9.14, p < 0.05), and drug treatment (F (1, 12) = 4.57, 
p < 0.05), although the two did not interact (F (1, 12) = 0.19, p > 0.05). At this level, 
contused subjects and morphine-treated subjects had less neurons than their sham and 
saline-treated counterparts, respectively. 
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Figure 49: Visualizing astrocytes using immunohistochemistry.  Astrocytes in the spinal 
cord were visualized using GFAP antibodies. These sections were taken from the center 
of the injury at 4X magnification. 
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Figure 50: Quantification of astrocytes at the injury epicenter.  Quantification of GFAP 
expression at the rostral, center, and caudal spinal segments is shown in this graph. 
There were no significant effects of surgery or drug treatment at any level of the spinal 
cord. Results shown as Mean ± S.E.M. *p < 0.05 or post-hoc tests; M = significant main 
effect of morphine. 
 
 
Next I assessed astrogliosis across the rostral-caudal extent of the lesion by 
quantifying the expression of GFAP (Figure 49). As previously described, I used mixed-
design ANOVAs to assess the effects of surgery and morphine treatment in the rostral, 
center, and caudal spinal segments. In the rostral segment, there was no effect of drug 
treatment (F (1, 11) = 0.03, p > 0.05) or interaction (F (1, 11) = 0.05, p > 0.05), and a 
main effect of surgery approached but did not reach significance (F (1, 11) = 3.35, p = 
0.09: Figure 50). Similarly, I did not find any significant effects in the center or caudal 
segments (for all, p > 0.05). The data suggest that neither surgery nor morphine 
significantly affect astrogliosis across the rostral-caudal extent of the lesion at 48 hour 
post-injury.  
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I also quantified CD11b (Ox42) expression, a marker of microglia and other 
macrophages, to assess inflammation across the rostral-caudal extent of the lesion 
(Figure 51). Mixed-design ANOVAs showed that in the rostral segment, there was a 
significant main effect of surgery (F (1, 12) = 43.49, p < 0.05), but no effect of drug 
treatment (F (1, 12) = 0.99, p > 0.05) or interaction (F (1, 12) = 1.20, p > 0.05; Figure 
52). Contused subjects showed a robust increase in CD11b expression compared with 
their sham counterparts. I also found similar results in the center [main effect of surgery 
(F (1, 12) = 46.52, p < 0.05), no effect of drug treatment (F (1, 12) = 0.002, p > 0.05) or 
interaction (F (1, 12) = 0.00, p > 0.05)] and caudal [main effect of surgery (F (1, 12) = 
94.25, p < 0.05), no effect of drug treatment (F (1, 12) = 0.32, p > 0.05) or interaction (F 
(1, 12) = 0.93, p > 0.05)] segments. As expected, injury increases the presence and/or 
activation of immune cells across the rostral-caudal extent of the lesion. 
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Figure 51: Visualizing microglia/macrophages using immunohistochemistry.  Microglia 
and macrophages in the spinal cord were visualized using CD11b antibodies. These 
sections were taken from the center of the injury at 4X magnification. 
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Figure 52: Quantification of microglia / macrophages at the injury epicenter.  
Quantification of CD11b (Ox42) expression at the rostral, center, and caudal spinal 
segments is shown in this graph. There was a significant main effect of surgery across all 
segments, with contused subjects showing higher CD11b expression than sham subjects. 
Morphine treatment did not significantly affect CD11b expression, and there were no 
significant surgery X drug treatment interactions at any spinal level. Results shown as 
Mean ± S.E.M. *p < 0.05 or post-hoc tests; M = significant main effect of morphine. 
 
 
 
Changes in the inflammatory response assessed with flow cytometry 
In this experiment I used flow cytometry to further assess opioid-immune 
interactions following spinal cord injury. I decided to use flow cytometry because, it 
allows for the rapid and reliable characterization and quantification of individual cells. 
This would have been difficult to perform using immunohistochemistry due to the high 
density of immune cells in spinal cord sections following injury. Based on the protective 
effects of minocycline (Chapter 4), I hypothesized that morphine exacerbates the innate 
immune response following SCI, increasing the neurotoxic environment, and producing 
the attenuated recovery of locomotor function observed in our model. To test this, I 
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quantified immune cells (resident and infiltrating macrophages) at the injury epicenter 
and their expression of opioid receptors.  As in the previous experiment, subjects 
received a sham or contusion surgery. Twenty-four hours after injury, morphine (90 μg) 
or vehicle (filtered 0.9% saline) were administered via an intrathecal route. Twenty-four 
hours after drug treatment (48 hr post-injury), subjects were humanely euthanized, and 
tissue was collected for flow cytometry as described in Chapter II General Methodology. 
With an n=6 per group, this 2 (surgery) X 2 (drug) design used a total of 24 subjects. 
Exp. 6A Infiltrating macrophages and microglia 
To assess opioid-immune interactions that could lead to decreased recovery of 
function in our model, I began by characterizing the infiltrating and resident response 
following injury and drug treatment. First, I used forward and side scatter to select live 
cells in our heterogeneous samples. There were no significant differences in the number 
of total live cells across the groups (for all, p > 0.05). Next, I used markers for CD11b 
and IBA1 to quantify the total number of microglia and macrophages present in our 
samples (Figure 53). As expected, I found a significant main effect of surgery (F (1, 20) 
= 18.76, p < 0.05) on the total number of microglia/macrophages, with increased 
numbers due to injury alone. Statistical analyses also showed that there was a significant 
main effect of drug treatment (F (1, 20) = 4.85, p < 0.05). Regardless of injury, 
morphine administration increased the total number of microglia/macrophages at the site 
of the lesion. Finally, although there was no significant interaction between surgery and 
drug treatment (F (1, 20) = 0.22, p > 0.05), their effects may be cumulative, since 
subjects that received morphine after a contusion had the highest levels of 
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microglia/macrophages at the injury site. 
To further evaluate the local and peripheral immune response, the cells identified 
as microglia/macrophages were further classified into infiltrating macrophages (high 
CD45 expression) or resident microglia (low CD45 expression) as shown in Figure 54. 
Not surprisingly, I found that injury significantly increased the number of infiltrating 
macrophages (F (1, 20) = 20.17, p < 0.05; Figure 55). However, there was no significant 
main effect of drug treatment (F (1, 20) = 0.68, p > 0.05) or interaction (F (1, 20) = 0.26, 
p > 0.05) on infiltrating macrophages. Alternatively, drug treatment significantly 
increased the number of microglia present at the site of injury (F (1, 20) = 5.31, p < 
0.05), but there was no significant main effect of surgery (F (1, 20) = 1.00, p > 0.05) or a 
surgery X drug treatment interaction (F (1, 20) = 0.01, p > 0.05). 
Figure 53: Live cells and microglia / macrophages at the injury epicenter.  Microglia 
and macrophages were quantified using CD11b and IBA1 antibodies. Surgery alone and 
drug treatment alone significantly affected the total number of microglia/macrophages at 
the site of injury, with no significant interaction. Results shown as Mean ± S.E.M. *p < 
0.05 for post-hoc tests; M = significant main effect of morphine. Total number of cells in 
sham + saline group indicated in the first bar. 
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Figure 54: Pseudocolor plot of macrophages and microglia at the injury epicenter.  
Cells positive for CD11b and IBA1 markers are displayed here using a pseudocolor plot 
(warmer colors indicate higher cell density). The cells were further subdivided according 
to CD45 expression, as shown by the boxes. The number in the boxes indicates the 
percentage of cells encompassed by the gate out of the total CD11b+ and IBA1+ parent 
population.  
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Figure 55: Infiltrating macrophages and microglia at the injury epicenter.  The local 
and peripheral immune response was characterized using CD45 expression. Injury 
increased the number of infiltrating macrophages with no effect of drug treatment (A). 
On the other hand, morphine increased the number of resident microglia with no effect 
of surgery (B). No significant interactions were observed. Results shown as Mean ± 
S.E.M. *p < 0.05 for post-hoc tests; M = significant main effect of morphine. Total 
number of cells in sham + saline group indicated in the first bar. 
  
 To further characterize whether the infiltrating macrophages and resident 
microglia were also M1 polarized, I used markers for CD68 and CD86. Although not all 
previously identified infiltrating macrophages expressed CD68 and CD86, the overall 
effects remained (Figure 56). Injury significantly increased the number of M1 infiltrating 
macrophages (F (1, 20) = 27.39, p < 0.05), with no effect of drug treatment (F (1, 20) = 
0.93, p > 0.05) or interaction (F (1, 20) = 0.35, p > 0.05). On the other hand, there was 
no significant effect of surgery (F (1, 20) = 0.004, p > 0.05), drug treatment (F (1, 20) = 
2.73, p > 0.05), or interaction (F (1, 20) = 0.24, p > 0.05) on M1 microglia, although 
slight elevations after morphine treatment were observed. 
 
 
A. Infiltrating Macrophages
Sham Contusion
0
5
10
15
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
ls
254
*
B. Microglia
Sham Contusion
0
1
2
3
Saline
Morphine
545
M
M
  
 
127 
 
 
Figure 56: M1 polarization of macrophages and microglia at the injury epicenter.  M1 
polarization was assessed using markers for CD68 and CD86. Injury increased the 
number of M1 infiltrating macrophages with no effect of drug treatment (A). No 
significant main effects were observed on M1 microglia (B). Results shown as Mean ± 
S.E.M. *p < 0.05 for post-hoc tests. Total number of cells in sham + saline group 
indicated in the first bar. 
 
Exp. 6B MOR co-localization 
 I hypothesized that the adverse effects of opioids in our model could also be 
related to changes in opioid receptor expression following injury. To investigate this, I 
assessed overall MOR expression and its co-localization on immune cells following SCI 
and morphine treatment (Figure 57). As done previously, first I assessed the total 
number of live cells in the heterogeneous samples using forward and side scatter. There 
were no significant main effects of surgery (F (1, 20) = 1.55, p > 0.05) or drug treatment 
(F (1, 20) = 3.07, p > 0.05), but a planned comparisons test showed that there were more 
live cells in the sham-morphine versus the sham-saline group. Next, I quantified the total 
number of MOR-expressing cells at the injury center (this includes immune cells, as well  
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Figure 57: MOR+ cells at the injury epicenter.  There were no significant main effects 
of surgery or drug treatment on total MOR+ cells at the site of injury. Total number of 
cells in sham + saline group indicated in the first bar. 
 
 
 
as other cell types such as neurons and astrocytes). I did not find any significant effects 
of surgery (F (1, 20) = 0.49, p > 0.05), drug treatment (F (1, 20) = 3.58, p > 0.05), or an 
interaction (F (1, 20) = 0.38, p > 0.05) on total MOR+ cells.  
 Although I did not find any effects on total MOR+ cells, I also wanted to explore 
MOR expression specifically on immune-competent cells. To do this, once again I 
identified microglia/macrophages using CD11b and IBA1 markers (Figure 58). Our 
results in this experiment paralleled those obtained in Exp. 6A. I found a significant 
main effect of surgery (F (1, 20) = 7.62, p < 0.05) on the number of 
microglia/macrophages. Drug treatment approached, but did not reach significance (F (1, 
20) = 3.30, p > 0.05), and there was no significant interaction (F (1, 20) = 0.38, p > 
0.05). Next, I looked at microglia/macrophages that also expressed MOR and CD206. I 
found a significant main effect of surgery (F (1, 20) = 4.86, p < 0.05) on the number of 
MOR+ microglia/macrophages, but no effect of drug treatment (F (1, 20) = 2.79, p >  
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Figure 58: Microglia / macrophages and co-localization with MOR and CD206.  
Surgery significantly affected the total number of microglia/macrophages (A), the 
number of MOR+ microglia/macrophages (B), and the number MOR+ & CD206+ 
microglia/macrophages (D) at the site of injury, with no significant effect of drug 
treatment or interaction. Drug treatment significantly affected CD206+ 
microglia/macrophages at the site of injury, with no effect of surgery or interaction (C).  
Results shown as Mean ± S.E.M. *p < 0.05 for post-hoc tests; # p < 0.05 for planned 
comparisons; M = significant main effect of morphine. Total number of cells in sham + 
saline group indicated in the first bar. 
 
 
 
0.05) or interaction (F (1, 20) = 0.84, p > 0.05). On the other hand, when I looked at 
CD206 expression, I found a significant main effect of drug treatment (F (1, 20) = 4.37, 
p < 0.05) on the number of CD206+ microglia/macrophages, but no effect of surgery (F 
(1, 20) = 2.19, p > 0.05) or interaction (F (1, 20) = 0.14, p > 0.05). Finally, when I 
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looked at the number of microglia/macrophages expressing both, MOR and CD206, 
statistical analyses uncovered a significant main effect of surgery (F (1, 20) = 23.08, p < 
0.05), but no effect of drug treatment (F (1, 20) = 1.52, p > 0.05) or interaction (F (1, 20) 
= 0.17, p > 0.05).  
Exp. 6C KOR co-localization 
 As with the MOR, I assessed overall KOR expression and its co-localization on 
immune cells following SCI and morphine treatment. First, I used forward and side 
scatter to select live cells in our heterogeneous samples. There were no significant 
differences in the number of total live cells across the groups (for all, p > 0.05; Figure 
59). 
 
  
Figure 59: KOR+ cells at the injury epicenter.  Injury significantly increased the number 
of total KOR+ cells at the site of lesion, with no effect of drug administration or 
interaction. Results shown as Mean ± S.E.M. *p < 0.05 for post-hoc tests. Total number 
of cells in sham + saline group indicated in the first bar. 
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 Next, I quantified the total number of KOR-expressing cells at the injury center 
(this includes immune cells, as well as other cell types such as neurons and astrocytes). 
Statistical analyses showed a significant increase in total KOR+ cells following injury (F 
(1, 20) = 12.81, p < 0.05), but no effect of drug treatment (F (1, 20) = 0.02, p > 0.05) or 
significant interaction (F (1, 20) = 0.14, p > 0.05).  
As in the previous experiment, to evaluate KOR expression specifically on 
immune-competent cells, once again I identified microglia/macrophages using CD11b 
and IBA1 markers. Corroborating our previous findings (Exp. 6A and Exp. 6B), I found 
a significant main effect of surgery (F (1, 20) = 12.40, p < 0.05) on the number of 
microglia/macrophages (Figure 60). Drug treatment approached, but did not reach 
significance (F (1, 20) = 2.30, p > 0.05), and there was no significant interaction (F (1, 
20) = 0.39, p > 0.05). Next, I looked at microglia/macrophages that also expressed KOR 
and CD206. I found a significant main effect of surgery (F (1, 20) = 8.06, p < 0.05) on 
the number of KOR+ microglia/macrophages, but no effect of drug treatment (F (1, 20) 
= 0.00, p > 0.05) or interaction (F (1, 20) = 0.05, p > 0.05). Similarly, when I looked at 
CD206 expression, I found a significant main effect of surgery (F (1, 20) = 31.68, p < 
0.05) on the number of CD206+ microglia/macrophages, but no effect of drug treatment 
(F (1, 20) = 2.19, p > 0.05) or interaction (F (1, 20) = 0.14, p > 0.05). Finally, when I 
looked at the number of microglia/macrophages expressing both, KOR and CD206, 
statistical analyses uncovered a significant main effect of surgery (F (1, 20) = 31.57, p < 
0.05), but no effect of drug treatment (F (1, 20) = 0.002, p > 0.05) or interaction (F (1, 
20) = 0.029, p > 0.05). 
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Figure 60: Microglia / macrophages and co-localization with KOR and CD206.  
Surgery significantly affected the total number of microglia/macrophages (A), KOR+ 
microglia/macrophages (B), CD206+ microglia/macrophages (C), and KOR+ & 
CD206+ microglia/macrophages (D) at the site of injury, with no significant effect of 
drug treatment or interaction.  Results shown as Mean ± S.E.M. *p < 0.05 for post-hoc 
tests. Total number of cells in sham + saline group indicated in the first bar. 
 
 
 
 As in experiment 6.A, in these samples I also evaluated the local and peripheral 
immune response using CD45 expression. The microglia/macrophages previously 
described were classified into infiltrating macrophages (high CD45 expression) or 
resident microglia (low CD45 expression), and I assessed their KOR and CD206 
expression (Figure 61). I found a significant main effect of surgery (F (1, 20) = 32.96, p  
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Figure 61: Infiltrating macrophages and co-localization with KOR and CD206.  Surgery 
significantly affected the total number of infiltrating macrophages (A), KOR+ 
macrophages (B), CD206+ macrophages (C), and KOR+ & CD206+ macrophages (D) at 
the site of injury, with no significant effect of drug treatment or interaction. Results 
shown as Mean ± S.E.M. *p < 0.05 for post-hoc tests; #p < 0.05 for planned 
comparisons. Total number of cells in sham + saline group indicated in the first bar. 
 
 
 
< 0.05) on the number of infiltrating macrophages, but no effect of drug treatment (F (1, 
20) = 0.28, p > 0.05) or interaction (F (1, 20) = 0.12, p > 0.05). Next, I looked at 
infiltrating macrophages that also expressed KOR. I found a significant main effect of 
surgery (F (1, 20) = 20.86, p < 0.05) on the number of KOR+ infiltrating macrophages, 
but no effect of drug treatment (F (1, 20) = 0.05, p > 0.05) or interaction (F (1, 20) = 
0.005, p > 0.05). Similarly, when I looked at CD206 expression, I found a significant 
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main effect of surgery (F (1, 20) = 45.27, p < 0.05) on the number of CD206+ 
infiltrating macrophages, but no effect of drug treatment (F (1, 20) = 0.32, p > 0.05) or 
interaction (F (1, 20) = 0.17, p > 0.05). Finally, when I looked at the number of 
infiltrating macrophages expressing both, KOR and CD206, statistical analyses 
uncovered a significant main effect of surgery (F (1, 20) = 20.25, p < 0.05), but no effect 
of drug treatment (F (1, 20) = 0.002, p > 0.06) or interaction (F (1, 20) = 0.12, p > 0.05). 
 The resident immune cells of the CNS, microglia (low CD45 expression), were 
also quantified and assessed for their KOR and CD206 expression (Figure 62). As 
opposed to what I observed with infiltrating macrophages, I found a significant main 
effect of drug treatment (F (1, 20) = 5.24, p < 0.05) on the total number of microglia, but 
no effect of surgery (F (1, 20) = 0.07, p > 0.05) or interaction (F (1, 20) = 0.37, p > 
0.05). Next, I looked at microglia that also expressed KOR. I found no effect of surgery 
(F (1, 20) = 1.31, p > 0.05) or interaction (F (1, 20) = 0.39, p > 0.05), and the effect of 
drug treatment on the number of KOR+ microglia approached, but did not reach 
significance (F (1, 20) = 3.33, p > 0.05). However, it is important to highlight that 
planned comparisons showed that our contused subjects treated with morphine had 
significantly more KOR+ microglia than their saline-treated counterparts. When I looked 
at CD206 expression, I found a significant main effect of surgery (F (1, 20) = 5.86, p < 
0.05) on the number of CD206+ microglia, but no effect of drug treatment (F (1, 20) = 
0.25, p > 0.05) or interaction (F (1, 20) = 0.22, p > 0.05). Finally, when I looked at the 
number of microglia expressing both, KOR and CD206, statistical analyses uncovered a 
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significant main effect of surgery (F (1, 20) = 7.03, p < 0.05), but no effect of drug 
treatment (F (1, 20) = 0.02, p > 0.06) or interaction (F (1, 20) = 0.02, p > 0.05). 
 
 
 
Figure 62: Microglia and co-localization with KOR and CD206.  Drug treatment 
significantly affected the total number of microglia (A). There were no significant 
effects of surgery or drug treatment on the number of KOR+ microglia (B).  Surgery 
significantly affected the number CD206+ (C) and KOR+ & CD206+ microglia (D) at 
the site of injury, with no significant effect of drug treatment or interaction. Results 
shown as Mean ± S.E.M. *p < 0.05 for post-hoc tests; #p < 0.05 for planned 
comparisons; M = significant main effect of morphine. Total number of cells in sham + 
saline group indicated in the first bar. 
 
 
 
 
 
A. Microglia
Sham Contusion
0.0
0.5
1.0
1.5
2.0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
ls
992
MM
C. CD206+ Expression
Sham Contusion
0.0
0.5
1.0
1.5
2.0
2.5
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
ls
134
*
B. KOR+ Expression
Sham Contusion
0.0
0.5
1.0
1.5
2.0
102
#
Saline
Morphine
D. KOR+ & CD206+ Expression
Sham Contusion
0
1
2
3
4
28
*
  
 
136 
Discussion  
 In these experiments, I used immunohistochemistry and flow cytometry to 
characterize the cellular environment at the site of lesion 24 hours following morphine 
administration. First, I conducted a histological assessment of tissue sparing in contused 
subjects and uninjured controls, treated with morphine or saline (Experiment 5.A). I 
found that SCI significantly affected lesion size, tissue damage, residual gray matter, and 
residual white matter, with no added effect of morphine. Next, I used 
immunohistochemistry to quantify three key cell populations at the lesion site: neurons, 
astrocytes, and microglia/macrophages (Experiment 5.B). As expected, I found that SCI 
significantly decreased the number of remaining neurons (NeuN+) and increased the 
number of microglia/macrophages (CD11b+) across the rostral-caudal extent of the 
spinal cord. Morphine further decreased the number of remaining neurons, but only 
caudal to the injury. At this time point, astrocyte (GFAP+) expression was not affected 
at any level of the spinal cord by either injury or morphine treatment.  
 For a more in-depth investigation of the opioid-immune interactions that could 
underlie the adverse effects of morphine, I assessed the role of infiltrating macrophages 
and microglia, and their expression of MOR and KOR, using flow cytometry. I found 
that SCI significantly increased the number of infiltrating macrophages, while morphine 
significantly increased the number of microglia regardless of injury (Experiment 6.A). 
The number of microglia/macrophages expressing the MOR was also significantly 
increased by SCI (Experiment 6.B), as was the total number of KOR+ cells and KOR+ 
microglia/macrophages (Experiment 6.C). Interestingly, contused subjects treated with 
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morphine also showed significantly higher numbers of KOR+ microglia than their 
saline-treated counterparts. 
 As expected, our results showed that microglia/macrophages are increased at the 
site of lesion following SCI. More interesting, however, was the significant effect of 
morphine on these cells types, increasing their presence in the spinal cord regardless of 
injury. Furthermore, when assessing immune polarization, I also observed trends 
suggesting that morphine may bias microglia toward an M1 phenotype. Although this 
was effect did not reach significance,  extensive in vitro and in vivo evidence suggests 
that opioid administration results in glial activation and the release of pro-inflammatory 
cytokines (Cui et al., 2006; Hutchinson et al., 2008a; Johnston et al., 2004; Raghavendra 
et al., 2002; Raghavendra et al., 2004; Song & Zhao, 2001). For instance, lumbar dorsal 
spinal cord sections show significant increases in the release of IL-1β, IL-6, fractalkine, 
GRO/KC, MIP-1α, MCP-1 and TNF-α following 180 minutes of incubation with 100 
µM morphine compared to media alone (Hutchinson et al., 2008a). In vivo, increases in 
IL-1α, IL-1β, IL-6 and TNF-α have also been demonstrated after 7 days of intrathecal 
morphine (Hutchinson et al., 2008a). It is clear that opioids can modulate the immune 
response from an anti-inflammatory (M2) to a pro-inflammatory and neurotoxic (M1) 
phenotype.  
 Supporting an immunomodulatory role of the classic opioid receptors, here I 
presented evidence of MOR and KOR expression on immune cells, a finding that is 
supported by the literature (Bidlack et al., 2006; McCarthy et al., 2001; Rogers & 
Peterson, 2003; Sharp, 2006). I also showed that following SCI, the total number of 
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KOR+ cells, but not MOR+ cells, is increased at the lesion site. This is also consistent 
with the literature. For instance, a study using selective radioligands for the classic 
opioid receptors showed a significant increase in KOR binding, but not the other 
receptor types, on spinal tissue collected 2 hours, 24 hours, and 1 week after a T10 
contusion (Krumins & Faden, 1986). Surprisingly, I also observed a significant increase 
in KOR+ microglia at the lesion site of contused subjects treated with morphine, when 
compared to their saline-treated counterparts. Notably, this may increase the 
vulnerability of these cells to dynorphin, an endogenous KOR ligand that is significantly 
elevated in the spinal cord following trauma, and which has been implicated in the 
pathophysiology of SCI (Cox et al., 1985; Faden et al., 1985a; Faden et al., 1985b; 
Przewłocki et al., 1988; Tachibana et al., 1998). 
 Aside from the immune cells investigated in this study, the significant increase in 
total KOR+ cells following SCI suggests that other cell populations are also vulnerable 
to the effects of endogenous and exogenous KOR ligands. For instance, Adjan et al. 
(2007) measured caspase-3 activity at the injury site in wild-type and prodynorphin 
knockout mice following an experimental spinal contusion. They found that not only 
was caspase-3 significantly decreased in tissue homogenates from prodynorphin 
knockout mice, but astrocytes and oligodendrocytes in these subjects also expressed 
significantly lower levels of active caspase-3 hours after injury (Adjan et al., 2007). 
Aside from directly engaging apoptotic mechanisms following SCI, KOR signaling may 
also contribute to secondary injury through aberrant glial activation. A role for the KOR 
in glial activation and proliferation following trauma is supported by evidence from 
  
 
139 
other injury models. Following partial sciatic nerve ligation, KOR immunoreactivity is 
significantly increased in dorsal horn GABAergic neurons and astrocytes, ipsilateral and 
contralateral to the injury (Xu et al., 2004).  Importantly, KOR activation appears to play 
a direct role in the astrocytic response to injury. As reported by Xu et al. (2007), mice 
with a dynorphin knockout, a KOR knockout, or pretreated with norBNI, lacked the 
marked increase in GFAP immunoreactivity observed 1-week post-nerve injury in wild-
type controls. In vitro, cultured astrocytes treated with the KOR agonist U50,488 showed 
a significantly increased proliferation rate, and this effect was blocked by norBNI (Xu et 
al., 2007). Altogether, the release of pro-inflammatory factors from immune and glial 
cells vulnerable to KOR ligands could contribute to the neurotoxic environment 
following SCI. This could explain the significant decrease in neurons observed caudal to 
the injury in contused subjects treated with morphine, when compared to saline-treated 
controls (Experiment 5.B).  
In sum, the KOR also appears to play an important role in the mechanisms 
leading to the adverse effects of morphine administration following SCI. I hypothesize 
that these effects are the result of an opioid-induced exacerbation of the inflammatory 
response intrinsic to SCI.  In vitro and in vivo evidence suggests that opioid 
administration results in the activation of glial cells and the release of pro-inflammatory 
cytokines (Cui et al., 2006; Hutchinson et al., 2008a; Johnston et al., 2004; Raghavendra 
et al., 2002; Raghavendra et al., 2004; Song & Zhao, 2001). While non-classic opioid 
receptor signaling has been implicated in these opioid-immune interactions (Hutchinson 
et al., 2010b; Wang et al., 2012), our findings point to a previously overlooked role of 
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the KOR. Based on the results of this study, I posit that morphine’s adverse effects may 
result from activation of KORs on glial cells. The synergistic effects of immune cell 
activation and KOR-mediated gliopathy could explain the decreased locomotor 
recovery, increased nociceptive reactivity, and decreased tissue sparing observed in our 
rodent model when morphine is administered following SCI (Hook et al., 2007; Hook et 
al., 2009; Hook et al., 2011). These results underscore the need for further studies 
targeting the cell-specific effects of opioid administration, and other medications, 
following SCI.  Overall, however, these data suggest that KOR antagonists and glial 
inhibitors may be viable adjuvants to morphine, reducing the adverse long-term 
consequences of opioid administration in the acute phase of SCI.  
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CHAPTER VI 
GENERAL DISCUSSION AND CONCLUSIONS 
 
 The experiments presented here investigated the mechanisms underlying the 
adverse effects of morphine, the prototypical opioid, in a rodent model of SCI. 
Commensurate with our previous studies, I found that morphine administered in the 
acute phase of SCI decreased locomotor recovery and increased the size of the spinal 
lesion. After an evaluation of the classic and non-classic opioid receptors, I found that 
the κ-opioid receptor (KOR) system plays a significant role in the morphine-induced 
attenuation of function. I also found that glial activation is critical to morphine’s adverse 
effects. Lastly, I observed that morphine significantly increases the microglial response 
following SCI, and that this mechanism may be mediated by co-localization with KORs. 
Our data suggests that SCI increases the expression of classic opioid receptor subtypes 
on immune cells. In the following sections I will discuss the effects of selective opioid 
receptor activation on recovery after SCI, and show that injury-induced changes in 
opioid-immune interactions may significantly change the consequences of exogenous 
opioids administered for pain management after injury. 
Contribution of the opioid receptors 
 In these experiments, I used selective opioid receptor agonists and antagonists to 
assess the contribution of the classic and non-classic opioid receptors to the adverse 
effects of morphine following SCI. Our main finding was that the KOR significantly 
contributes to morphine’s adverse effects. The selective KOR-agonist GR89696 
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significantly undermined recovery of locomotor function, increased mechanical 
reactivity, and decreased gray matter sparing after SCI. This was observed at a dose 32 
times lower than the 0.32 μmol (90 μg) dose of morphine previously used in our studies 
(Hook et al., 2009; Hook et al., 2011). The powerful effects of selective KOR activation 
are consistent with previous literature. In fact, it has been reported that dynorphin and 
dynorphin-related peptides can  induce paraplegia even when administered to the intact 
spinal cord (Faden & Jacobs, 1983; Herman & Goldstein, 1985). Further supporting a 
KOR-mediated mechanism, pretreatment with the KOR-antagonist norBNI significantly 
reduced morphine’s adverse effects. Others have also shown that norBNI limits the 
paralytic effects of dynorphin (Faden, 1990), and can improve functional outcomes in 
rodent models of spinal and brain injury (Faden, 1990; Faden et al., 1987; Vink et al., 
1991). Although I did not find a therapeutic effect of norBNI per se, our data suggests 
that KOR activation is sufficient and necessary for the morphine-induced attenuation of 
function following SCI. 
 Contrary to our expectations, however, I found that selective μ-opioid receptor 
(MOR) activation using DAMGO does not replicate morphine’s adverse effects on 
locomotor function. Although the literature suggests that MOR activation may be linked 
to excitotoxicity (L. Chen & Huang, 1992; L. Chen & Marine, 1991; Mao et al., 1995; 
Mayer et al., 1995), I did not observe behavioral changes suggesting increased cell death 
at the lesion site. Opioid-induced excitotoxicity, however, has been primarily reported 
following prolonged morphine treatment (Mao et al., 1994; Mao et al., 1995; Mao et al., 
2002a, 2002b; Marek et al., 1991; Mayer et al., 1995; Trujillo & Akil, 1991; L. Yang et 
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al., 2008). In our studies, only a single opioid administration was given; therefore, it is 
possible that this did not induce the changes in MOR activity necessary to produce 
excitotoxicity. Alternatively, the null effects of MOR activation in our studies could also 
reflect differences in the rate of elimination between DAMGO and morphine. Indeed, 
the half-life of DAMGO is approximately 30 minutes (Szeto et al., 2001), while the half-
life of morphine is between 1.5 – 4.5 hours (Paul, 2015).  To address this, I challenged 
morphine with CTOP, a MOR antagonist. Surprisingly, I found that CTOP did not block 
morphine’s adverse effects, but instead promoted the development of paradoxical pain in 
the chronic stage of SCI. In comparison to controls treated with saline only, subjects 
treated with CTOP showed increased mechanical allodynia (vocal reactivity to von Frey 
stimulation) 21 days post-injury. This may reflect a role of MOR activation in 
endogenous pain control following neurotrauma. This finding also underscores the 
necessity for mitigation of pain in the early phase of injury. As suggested by others (J. 
Katz et al., 1992; Møiniche et al., 2002; Pergolizzi et al., 2014; Woolf & Chong, 1993), 
effective management of acute pain appears to be necessary to prevent the chronification 
of SCI-related pain. 
 Aside from the MOR and KOR, I also hypothesized that morphine may exert its 
negative effects through activation of non-classic opioid receptors found on immune-
competent cells, such as TLR4 (Wang et al., 2012). Binding to these receptors leads to 
glial activation, and the subsequent release of pro-inflammatory cytokines in the spinal 
cord, which is associated with decreased opioid analgesia and pain facilitation 
(Hutchinson et al., 2007; Hutchinson et al., 2008a; Hutchinson et al., 2011). However, 
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treatment with the TLR4 agonist LPS or [+]- morphine did not replicate morphine’s 
adverse effects on recovery of function. This was not due to defective LPS, as the 
functionality of the drug was verified in a separate experiment. Instead, it is possible that 
following SCI, TLR activation may approach a ceiling effect, due to the highly 
inflammatory nature of the injury per se. Indeed, although there were no effects of LPS 
treatment, pre-treatment with the TLR4 antagonist LPS-RS blocked the adverse effects 
of morphine. Similarly, in a previous study, pre-treatment with an IL-1 receptor 
antagonist also prevented morphine’s adverse effects (Hook et al., 2011). The IL-1 and 
TLR4 receptors engage highly congruent signaling pathways: upon binding, adaptor 
proteins are recruited that activate downstream kinases and transcription factors, such as 
NF-κB, ultimately leading to the production of pro-inflammatory cytokines and 
chemokines (Cohen, 2014). Importantly, in our study, treatment with minocycline also 
protected against morphine’s unwanted side effects.  Minocycline is a tetracycline 
antibiotic shown to promote neuroprotection by inhibiting glial activation and 
proliferation, and reducing inflammation (Ledeboer et al., 2005; Plane et al., 2010; Tikka 
et al., 2001). Together, the data presented here suggest that the immune response 
following SCI is intimately involved in morphine’s adverse effects.  
Opioid-immune interactions 
SCI alters opioid receptor expression 
 SCI not only increases the number of immune cells present in the spinal cord, it 
also appears to increase the expression of the classic opioid receptors on these cells. 
Using flow cytometry, I found that SCI significantly increased the number of infiltrating 
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macrophages at the lesion site by day 3 post-injury. This coincides with the time course 
of infiltration previously described in the literature (Beck et al., 2010; Popovich et al., 
1997). Interestingly, I also found that injury significantly upregulates total KOR 
expression, but not MOR expression, in the spinal cord. The total number of KOR+ cells 
was approximately three times higher in SCI subjects compared to uninjured controls. 
Others have also found increased expression of KOR, but not the other receptor types, 
on spinal tissue collected 2 hours, 24 hours, and 1 week after a T10 contusion (Krumins 
& Faden, 1986).  Unfortunately, in our experiments, I further pursued KOR co-
localization only in microglia and macrophages. However, I suspect that increased KOR 
expression also occurred in other cell types following SCI. Indeed, the literature shows 
that aside from neurons and microglia, other cells such as astrocytes, oligodendrocytes, 
and peripheral immune cells also express classic opioid receptors (Belcheva et al., 2005; 
Bidlack et al., 2006; Bruchas et al., 2006; Chao et al., 1997; Eriksson et al., 1993; 
Gurwell et al., 1996; Hauser et al., 1996; McLennan et al., 2008; Ruzicka et al., 1995; 
Sharp, 2006; Stiene-Martin et al., 2001; Stiene-Martin et al., 1998; Xu et al., 2007).  
 I hypothesize that the increased opioid receptor expression may be associated 
with cytokines and chemokines present in the acutely injured cellular environment.  
Indeed, co-administration of IL-1α and IL-1β has been shown to increase MOR 
expression in neural microvascular endothelial cell cultures (Vidal et al., 1998). 
Similarly, treatment with IL-1β for 24 hours can alter MOR and KOR mRNA expression 
in tissue cultures from the rat striatum, cerebellum, hippocampus, hypothalamus, and 
cortex (Ruzicka & Akil, 1997; Ruzicka et al., 1996). Cytokines appear to induce 
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upregulation of opioid receptors in immune and glial cells through the activation of 
transcription factors. For instance, IL-6-mediated upregulation of MOP-R expression is 
dependent on STAT (signal transducer and activator of transcription) 1 and STAT3 
binding to the promoter region of the opioid receptor gene (Börner et al., 2004). This 
may explain the reduced opioid analgesia and decreased MOR expression observed in 
IL-6 knockout mice (Bianchi et al., 1999). Stimulation with TNF-α has also been shown 
to induce MOR gene transcription in primary human T lymphocytes, Raji B cells, U937 
monocytes, primary human polymorphonuclear leukocytes and mature dendritic cells 
through activation of NF-κB (Kraus et al., 2003). Altogether, this suggests that pro-
inflammatory cytokines play an important role in opioid receptor regulation following 
SCI, which may significantly alter the effects of opioid analgesics when administered in 
a pathophysiological context. 
Morphine increases microglia at the injury site 
 Further supporting an immunomodulatory role of opioids, I found that morphine 
significantly increased the number of microglia present in the spinal cord regardless of 
injury.  This may result from opioid-induced increases in cell recruitment. For example, 
in microglia cultures, morphine treatment promotes morphological changes, activation, 
and chemotaxis- effects that are blocked by naloxone (Horvath & DeLeo, 2009; 
Takayama & Ueda, 2005; Tsai et al., 2015). Studies suggest that morphine may induce 
microglial migration via a mechanism involving the ionotropic purinergic receptor 
P2X4, which has also been implicated in aberrant glial activation and pathological pain 
(Biber et al., 2011; Horvath & DeLeo, 2009; Inoue et al., 2004; Tsuda et al., 2003). 
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Furthermore, opioid-induced proliferation has been observed in hippocampal neural 
progenitors, vascular endothelial cells, and peripheral blood mononuclear cells 
(Hutchinson et al., 2004; Leo et al., 2009; Persson et al., 2003). Therefore, it is possible 
that the increase in microglia that I observed could also be due to increased proliferation 
stimulated by morphine treatment. Irrespective of whether the increase in microglia 
resulted from increased recruitment or proliferation, the overall effect could lead to an 
elevation in the production and release of pro-inflammatory cytokines. Indeed, increases 
in IL-1α, IL-1β, IL-6 and TNF-α have been demonstrated after 7 days of intrathecal 
morphine (Hutchinson et al., 2008a). In the context of SCI, opioids could act 
synergistically with the innate immune response to exacerbate inflammation, increasing 
the neurotoxic environment at the lesion site. 
 Our experiments also showed that microglia and macrophages express classic 
opioid receptors after SCI. Contused subjects showed 5 times the number of MOR+ and 
KOR+ microglia/microphages at the lesion compared to sham controls. Additionally, 
contused subjects treated with morphine showed significantly more KOR+ microglia 
than their saline-treated counterparts.  This finding supports the immunomodulatory role 
of opioids that has been previously described in the literature (Bidlack et al., 2006; 
McCarthy et al., 2001; Rogers & Peterson, 2003; Sharp, 2006). More importantly, 
however, this may also provide a mechanism of action for morphine’s adverse effects. 
As shown in our pharmacological studies, KOR signaling and glial activation are 
necessary for morphine-induced attenuation of locomotor recovery. Increased KOR 
expression may leave microglia more vulnerable to dynorphin, an endogenous KOR 
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ligand that is significantly elevated in the spinal cord following trauma, and which has 
been implicated in the pathophysiology of SCI (Cox et al., 1985; Faden et al., 1985a; 
Faden et al., 1985b; Przewłocki et al., 1988; Tachibana et al., 1998). Furthermore, the 
significant increase in total KOR+ cells following SCI suggests that other cell 
populations are also vulnerable to the effects of endogenous and exogenous KOR 
ligands. For instance, KOR signaling has been implicated in spinal astrocyte activation 
and proliferation following nerve injury via a p38 MAPK-mediated mechanism (Xu et 
al., 2007; Xu et al., 2004). KOR signaling may also be associated with Caspase-3 
activation, since dynorphin knockout decreases astrocytes and oligodendrocyte apoptosis 
in a mouse model of SCI (Adjan et al., 2007). Overall, the evidence presented here 
suggests that neurotrauma may significantly alter the effects of exogenous opioids by 
changing the cellular expression of the opioid receptor subtypes.   
Clinical significance 
Locomotor recovery 
Studies from our laboratory have consistently shown that opioids are 
contraindicated following SCI (Hook et al., 2007; Hook et al., 2009; Hook et al., 2011; 
Hook et al., 2016). In our model, morphine administered in the acute phase of SCI leads 
to significant attenuation of functional recovery. These effects appear to be the result of 
opioid-induced cell death. Indeed, in the experiments presented here, even a single 
administration of 90 μg of intrathecal morphine, or an equivalent dose of a KOR agonist, 
decreased residual tissue at the site of lesion 21 days post-injury in comparison to 
vehicle-treated controls. Using immunohistochemistry, I also found that as early as 24 
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hours following morphine treatment, contused subjects treated with morphine show 
decreased neuron expression caudal to the injury epicenter than their saline-treated 
counterparts. Although at this time point I did not find any additional effects of 
morphine on astrocytes or macrophages, I know from our previous work that 7 days of 
morphine treatment completely depletes neurons and astrocytes at the lesion center and 
increases markers of neurodegeneration (Hook et al., 2016). Understanding the 
molecular mechanisms underlying morphine’s adverse effects is essential to improve the 
safety and efficacy of clinically-used opioids. I propose that morphine attenuates 
recovery of function by exacerbating the immune response following SCI via a KOR-
mediated mechanism (described in Figure 63). 
 The mechanism is initiated by SCI, as damage resulting from the primary injury 
triggers the innate immune response, leading to neutrophil and macrophage infiltration 
and activation of immune-competent glial cells in the spinal cord. In microglia, TLRs 
and purinergic receptors engage intracellular signaling mechanisms that activate 
transcription factors like the MAPKs and NF-κB. This leads to the production and 
release of pro-inflammatory cytokines and chemokines, including IL-1β, IL-6, 
fractalkine, GRO/KC, MIP-1α, MCP-1 and TNF-α, along with other excitatory factors. 
Subsequently, the release of pro-inflammatory cytokines and chemokines from microglia 
promotes the recruitment of other immune cells, as well as glial activation and 
proliferation. The release of pro-inflammatory cytokines may also lead to upregulated 
opioid receptor expression in microglia, astrocytes, and other cells, making them 
vulnerable to endogenous dynorphin and exogenous opioids.  
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Figure 63: Proposed mechanism of morphine-induced cell death following SCI.  Injury 
to the spinal cord initiates an innate immune response leading to microglia/macrophage 
activation, pro-inflammatory cytokine release, and a subsequent increase in KOR 
expression. Upon administration, morphine binds to KORs on immune-competent cells, 
further increasing glial activation, chemotaxis, and proliferation. This exacerbates the 
neurotoxic environment, increasing cell death, and attenuating recovery of function. 
 
 
Under these conditions, morphine can act synergistically with the immune 
response to exacerbate secondary damage. Upon administration, morphine binds to 
KORs expressed on microglia and other immune-competent cells. Subsequently, the 
KOR can signal through its G-protein, ultimately activating the MAPKs, which then 
regulate cell proliferation and cytokine release.  This activates a positive feedback loop, 
further activating immune-competent cells and prolonging cytokine release. The 
sustained release of pro-inflammatory cytokines from immune competent cells, in 
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combination with other SCI mechanisms, including excitatory neurotransmitter release 
and downregulation of glutamate transporters, exacerbates the neurotoxic environment.  
Pain management 
 While our focus has been on the morphine-induced attenuation of locomotor 
recovery after SCI, changes in opioid receptor expression will also affect the clinical 
management of other conditions associated with SCI, including pain, addiction, and 
depression. It is well-established that injury and inflammation decrease the analgesic 
efficacy of opioids. As previously discussed, the inflammatory response produces an 
excitatory cellular environment that sensitizes neurons, diminishing the net inhibitory 
function of opioid analgesics. Additionally, opioids per se can increase glial activation 
and the production of pro-inflammatory cytokines, counteracting their own 
antinociceptive effects (Hutchinson et al., 2008a; Hutchinson et al., 2010b; Lewis et al., 
2010). Changes in MOR expression following injury may significantly contribute to 
these effects. In our studies, although I observed no change in the total number of MOR+ 
cells, there was a significant increase in MOR+ microglia/macrophages after SCI. This 
suggests that, following injury, more MORs may be located on immune-competent cells 
than remaining neurons. Importantly, this could induce a shift in the overall effect of 
opioid administration, from anti-nociceptive to pro-inflammatory and even neurotoxic. 
Based on this, it might appear that opioids are not suitable analgesics for the 
treatment of neuropathic or inflammatory pain. However, our findings suggest that anti-
inflammatories may be used as adjuvants to opioid administration, to improve the safety 
and analgesic efficacy of these drugs. In animal models of nerve injury, for example, 
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treatment with glial inhibitors like minocycline and pentoxifylline significantly 
potentiates morphine analgesia (Mika et al., 2007) and decreases tolerance (Cui et al., 
2008; Mika et al., 2009). Interestingly, blocking glial activation alone also attenuates the 
development of allodynia and hyperalgesia after injury (Chang & Waxman, 2010; 
Ledeboer et al., 2005; Mika et al., 2007), suggesting that the combination of opioids and 
glial inhibitors may be used to manage and treat neuropathic pain in the clinic. 
Furthermore, evidence also suggests that glial inhibitors, such as minocycline, may even 
provide neuroprotection (Mejia et al., 2001; Stirling et al., 2004). Our current research 
suggests that minocycline effectively blocks the adverse effects of morphine following 
SCI. Indeed, minocycline and similar drugs are currently being evaluated in a variety of 
clinical trials as treatments for neurodegenerative conditions like Huntington disease and 
Parkinson disease (Kim & Suh, 2009; Plane et al., 2010). Although still under 
investigation, our studies and those of others, suggest that glial inhibitors are promising 
therapeutic strategies for neurotrauma and neurodegenerative disease. 
Addiction 
 Concerns regarding the possibility for addiction greatly complicate pain 
treatment in the clinic. It is well-known that under physiological conditions, opioids act 
as strong reinforcers, often leading to drug abuse. Chronic pain patients may be 
particularly vulnerable to developing addiction since the repeated administration of 
opioid drugs often leads to tolerance and a need for escalating doses. The mechanisms 
underlying opioid addiction, however, appear to be altered under conditions leading to 
the development of chronic pain.  For example, it appears that following neurotrauma, 
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the rewarding and addictive properties of opioids are decreased. In a study published in 
2013 by Wade and colleagues (Wade et al., 2013), fentanyl self-administration in mice 
was investigated under three different pain models: CFA-induced inflammation, spinal 
nerve ligation, and chronic chemotherapeutic-induced neuropathy. In all conditions, 
fentanyl reduced or failed to support self-administration compared to controls, although 
lever-pressing for a food reinforcer was unaffected (Wade et al., 2013). This suggests 
that the decreased operant behavior during pathological pain was probably due to 
decreases in the rewarding property of the opioid, and not due to motor or learning 
deficits. Others have shown that rats undergoing formalin or carrageenan-induced 
inflammation do not develop a preference for a morphine-paired context (Suzuki et al., 
1996). Similarly, mice undergoing experimental cancer pain do not develop morphine-
induced place preference (Betourne et al., 2008), and spinally-injured rats self-
administer significantly less morphine than their sham-counterparts early after SCI 
(Woller et al., 2014; Woller et al., 2012). 
 As discussed for pain and locomotor recovery, these changes may reflect altered 
opioid receptor expression following injury to the nervous system. Converging lines of 
evidence suggest that inflammation and injury may reduce the rewarding properties of 
opioids by changing opioid receptor expression and function. Normally, opioids exert 
their rewarding properties by activating cells in the ventral tegmental area (VTA), which 
send dopaminergic signals to the nucleus accumbens. Decreased opioid receptor 
expression in these areas due to inflammation and injury, however, may inhibit the 
opioid-induced activity in this reward center observed under physiological conditions. 
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Indeed, sciatic nerve ligation suppresses increased dopamine release in the nucleus 
accumbens normally observed after morphine administration in rodents (Niikura et al., 
2008; Ozaki et al., 2002). Furthermore, opioid-facilitation of the rewarding effects of 
VTA electrical stimulation is also suppressed in rats after a spinal nerve ligation (Ewan 
& Martin, 2011).   
 Increased expression of specific opioid receptor subtypes due to the release of 
pro-inflammatory cytokines may also play a role in decreased reward. The KOR system 
appears to be a particularly important player in these effects. For example, treatment 
with KOR agonists results in decreased morphine and cocaine intake in a model of 
rodent self-administration (Glick et al., 1995; Schenk et al., 1999). KOR activation may 
produce this effect by reducing extracellular dopamine in the nucleus accumbens 
(Maisonneuve et al., 1994). Conversely, nor-BNI treatment has been shown to reverse 
the attenuation of morphine-induced place preference in rats injected with formalin 
(Suzuki et al., 1998), probably by countering KOR-driven inhibition of dopamine 
turnover in limbic regions (Narita et al., 2005). Similar mechanisms might underlie 
decreased morphine self-administration observed early after SCI in rodents (Woller et 
al., 2014; Woller et al., 2012). By binding to upregulated supraspinal KORs, morphine 
may counteractively decrease, rather than increase, opioid reward. However, as 
inflammation subsides, KOR expression may return to baseline levels, no longer 
suppressing addiction. This might explain why, although contused rodents self-
administer significantly less morphine than their sham-counterparts in the first 7 days 
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after injury, the differences between injured subjects and sham controls disappear if self-
administration is started on days 14 or 35 after SCI. 
 Altogether, these findings have many important implications for the addictive 
potential of opioid drugs used after damage to the nervous system. Mainly, they suggest 
that altered opioid receptor expression in supraspinal regions may decrease the 
rewarding properties of opioids after injury. Nevertheless, this does not mean that the 
potential for addiction is completely abolished under neuropathic pain conditions. 
Increased dosage, for example, may overcome KOR-mediated suppression of dopamine 
turnover. Additionally, opiates that have partial KOR antagonist properties, like 
buprenorphine, may even increase reward. Ultimately, a better understanding of altered 
opioid receptor expression after injury to the nervous system will inform clinicians on 
the addictive potential of specific opioid analgesics, improving the safe use of these 
powerful drugs. 
Depression 
 Not surprisingly, psychological well-being is also significantly affected 
following neurotrauma. Within the spinally-injured alone, the prevalence of major 
depression has been estimated to be within 15-23% (Bombardier et al., 2004), compared 
to 6.6% in the general U.S. population (Kessler et al., 2003). Importantly, decreased 
psychological health in injured patients has been associated with numerous negative 
consequences, including decreased quality of life, decreased health, and even increased 
mortality (Krause et al., 2009; Krause et al., 2008). This underscores the importance of 
ensuring the mental, as well as the physical, well-being of patients following injury. 
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Increasing research suggests that targeting the immune system may be a viable strategy 
for the treatment of depression following injury to the nervous system. The 
inflammatory response has been strongly linked with the development of depression and 
other psychological disorders (Dantzer et al., 2008; Miller et al., 2009). For instance, 
elevated levels of pro-inflammatory cytokines, chemokines, and other factors have been 
observed in the peripheral blood circulation and in the cerebrospinal fluid of both 
healthy and sick patients exhibiting symptoms of depression (Dowlati et al., 2010; 
Howren et al., 2009; Lanquillon et al., 2000; Levine et al., 1999; Owen et al., 2001). 
Cytokine-induced depression has also been observed in patients undergoing 
immunotherapy with interferon (IFN)-α for the treatment of cancer and other diseases 
(Capuron & Ravaud, 1999; H. Miyaoka et al., 1999; Valentine et al., 1998). In animal 
models of spinal cord and traumatic brain injury, aberrant glial activation resulting from 
the injury may also potentiate depressive-like behaviors (Fenn et al., 2014; Luedtke et 
al., 2014; Wu et al., 2014). Furthermore, there is also data suggesting that anti-
inflammatory drugs possess anti-depressive qualities, and should be used as adjuncts to 
traditional therapies for mood disorders (Akhondzadeh et al., 2009; Guo et al., 2009; T. 
Miyaoka et al., 2012; Molina-Hernández et al., 2008; Müller et al., 2006). 
 Cytokines may influence the expression of depressive-like behaviors through a 
variety of pathophysiological mechanisms. For instance, cytokines may target the 
monoamines (C. L. Raison et al., 2009; C. L. Raison et al., 2010b). Indeed, altered 
synthesis, release, and re-uptake of neurotransmitters like serotonin, norepinephrine, and 
dopamine is a well-known underlying cause of depression in many patients. Cytokines 
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can also interact with the hypothalamic-pituitary-adrenal (HPA) axis, dysregulating the 
secretion of hormones that play an important role in the response to stress (Capuron et 
al., 2003; Kaestner et al., 2005; C. Raison et al., 2010a). Lastly, inflammation may also 
influence the emergence of depression and other mood disorders by modulating neural 
plasticity in the brain. Neurodegeneration has been linked with depression in some 
disorders of the nervous system, like Parkinson’s and Alzheimer’s (Förstl et al., 1992; 
Pålhagen et al., 2008; Zubenko & Moossy, 1988). Similarly, cytokines may increase 
neuronal loss through increased excitotoxicity and apoptosis. 
 Additionally, cytokines may also play a role in the development of depression by 
altering opioid receptor expression in the brain after injury. As previously discussed, 
cytokines can modulate opioid receptor expression. Opioids are well-known mood 
regulators, causing both euphoric and dysphoric effects. This suggests that opioid 
receptor activity may play a critical role in affective disorders. Indeed, experimental data 
suggests that this is the case. For example, mice with a genetic knockout for the MOR or 
DOR show anxiogenic and depressive-like profiles, although this phenotype is not 
observed after deletion of the KOR gene (Filliol et al., 2000). The DOR appears to have 
a particularly strong therapeutic potential. Endogenous activation of DOR, or 
administration of selective agonists, results in anxiolytic and anti-depressant effects in 
preclinical models (Jutkiewicz, 2006; Nieto et al., 2005; Perrine et al., 2006; Saitoh et 
al., 2004). On the other hand, KOR signaling appears to induce negative emotional 
states. Administration of salvinorin A, a KOR agonist, induces depressive-like behavior 
in rats (Carlezon et al., 2006), while administration of antagonists, like nor-BNI, have 
  
 
158 
been shown to decrease immobility time in the forced swim test in a dose-dependent 
fashion (Mague et al., 2003).  
 Importantly, opioid treatment alone may significantly affect psychological well-
being. Retrospective studies have found that the duration and dose of prescription 
opioids is strongly correlated with increased risk of depression, even after controlling for 
pain and other confounding variables (Scherrer et al., 2016; Scherrer et al., 2015; 
Scherrer et al., 2014). In the context of altered opioid receptor expression following 
injury, the effects of exogenous opioids on mood may be greatly increased. Research 
suggests that the ultimate depressant or anti-depressant effects of the analgesic 
prescribed will be largely driven by actions at specific opioid receptor subtypes (Lutz & 
Kieffer, 2013b). For example, as with addiction, opioid treatment after SCI may 
potentiate depression by activating upregulated KORs. This suggests that, for SCI 
patients about to begin an opioid regimen, treatment with a drug that has known 
antagonistic properties at the KOR would prevent affective dysregulation. Alternatively, 
a KOR agonist may produce dysphoria and even exacerbate anxiety and stress. Once 
again, the significant effects of opioids on psychological wellbeing underscore the 
importance of understanding the changes in opioid receptor expression after injury to the 
nervous system. 
Conclusions 
 Opioids, long considered the golden standard of analgesic efficacy, remain one of 
the most powerful tools available to clinicians for the treatment of acute and chronic 
pain. This is reflected in the steep increase in opioid use that has been observed in recent 
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years. For instance, opioid prescriptions in the United States nearly tripled in the past 25 
years,  skyrocketing from approximately 76 million in 1991, to nearly 207 million in 
2013 (National Institute of Drug Abuse (NIDA), 2014). Importantly, this alarming 
increase in opioid consumption has also lead to rising concerns over the safety of these 
medications. As I have already discussed, neurotrauma patients may be particularly 
vulnerable to the negative side effects of these drugs. 
 Here, I proposed one central idea: the pathophysiological context of an injury 
alters the function of opioids, decreasing their analgesic efficacy and safety. I reviewed 
evidence from the literature suggesting that opioids and SCI may act synergistically to 
exacerbate excitoxicity, apoptosis, and inflammation. I also presented data from our own 
studies showing that opioid-immune interactions via a KOR-mediated mechanism may 
underlie the adverse effects of morphine on recovery of function following SCI. Lastly, I 
discussed the clinical implications of opioids in a system with altered opioid receptor 
expression, focusing specifically on locomotor recovery, pain management, addiction, 
and depression.  
 Ultimately, evidence from the literature and our findings point to a crucial fact: 
we need to increase our understanding of opioid receptor expression and function in the 
injured nervous system in order to improve the safety and efficacy of opioid analgesics. 
Studies rarely differentiate among the variety of cell types that may show altered opioid 
receptor expression, usually limiting their assessment to a macroscopic approach. Our 
data suggest that in order to properly predict how opioid function will change after 
injury, we need to know how receptor expression will be altered in specific cell 
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populations. For example, upregulated opioid receptor expression on microglia versus 
neurons would be expected to affect opioid-induced analgesia in significantly different 
ways. The time course of altered expression also needs to be further explored, as this 
will inform clinicians on windows of vulnerability when opioids should be avoided. In 
SCI, for example, opioid-induced attenuated recovery is only observed if morphine is 
administered in the acute phase of injury. This may reflect opioid receptor changes that 
parallel the inflammatory response, and that should be taken into account before 
beginning an opioid regimen. 
  Similarly, our understanding of the molecular mechanisms underlying opioid 
receptor signaling must also expand to improve our use of opiates in the clinic. The 
evidence suggests that opioid receptors show type-specific, agonist-specific, and 
oligomerization differences, and all of these factors contribute to opioid signaling. 
Moreover, ligand-dependent conformational changes can also affect the formation of 
intracellular signaling complexes, which can drastically change important cell functions 
depending on the cascade activated. Finally, receptor-receptor interactions (also known 
as receptor oligomerization) also greatly affect opioid signaling. The MOR and DOR, 
for instance, can form heterodimers that exhibit synergistic effects upon activation 
(Gomes et al., 2000).  
Clearly, preventing the unwanted effects of opioid administration following 
neurotrauma is not as easy as blocking one opioid receptor subtype. Thus, one might be 
tempted to remove opioids from the list of analgesics currently used for the treatment of 
pain following injury to the nervous system. However, denying patients suffering from 
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debilitating chronic pain conditions a medication that could relieve their pain, and 
significantly improve their quality of life, is simply not an option. Instead, functional 
selectivity of opioids could be achieved by targeting all of the different factors that 
influence opioid signaling described here. Alternatively, neuroprotective drugs could 
also be used as adjuncts to inhibit opioid-induced secondary damage. Overall, the 
experiments presented here underscore the need for further evaluation of opioid-receptor 
signaling in the pathophysiological context in which they are applied. 
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